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Abstract

Mycoplasma hyopneumoniae is the etiological agent of porcine enzootic pneumonia, a
commercially expensive respiratory disease of swine. Currently there are no easily
administered, cost effective vaccines against this pathogen. The development of
efficacious recombinant subunit vaccines would aid greatly in ameliorating economic
losses incurred in the pig meat industry as a consequence of enzootic pneumonia. As
part of a program aimed at identifying protective antigens of Mycoplasma
hyopneumoniae, a random pEX library was constructed and screened with antisera
from hyperimmunised pigs. One clone (pSD9), identified by Dr S.P. Djordjevic,
contained a 0.8 kb M. hyopneumoniae DNA fragment which encodes an
immunoreactive antigen of that pathogen. This antigen was expressed as an 11 kDa M.
hyopneumoniae component fused to the carboxy-terminus of the 117 kDa pgalactosidase protein to produce a 128 kDa fusion protein. Antibodies generated in
rabbits against the 128 kDa fusion protein reacted in immunoblots against a 42 kDa
protein of M hyopneumoniae. The vaccine potential of purified fusion protein was
assessed in pig vaccine trials by delivery of the antigen emulsified in different
adjuvant formulations.

Following experimental challenge with virulent M.

hyopneumoniae, the mean Goodwin lung score of all vaccinated animals, irrespective
of the adjuvant treatment, was significantly reduced compared to control unvaccinated
pigs (P < 0.05) (performed by staff at the Elizabeth Macarthur Agricultural Institute).

In order to thoroughly evaluate the impact of the 11 kDa M. hyopneumoniae antigen
the p-galactosidase component was removed. The 0.8 kb M. hyopneumoniae DNA
fragment was cloned from pSD9 into pHSG398 to produce the plasmid pKFl. This
plasmid expressed the 11 kDa M hyopneumoniae antigen as a component of a much
smaller 15 kDa recombinant protein in Escherichia coli. For simple one-step large
scale purification of the 11 kDa M hyopneumoniae antigen, the 0.8 kb DNA insert
was cloned into pQE9 to produce plasmid pETEl. This plasmid expressed the 11 kDa
XX

antigen with an N-terminal 6x histidine tag which allowed for simple affinity
purification of the protein.

Southern hybridisation and polymerase chain reaction analyses demonstrated that the
cloned 0.8 kb M hyopneumoniae DNA fragment did not cross-react with Mycoplasma
hyorhinis chromosomal DNA but did so with Mycoplasma flocculare DNA The
plasmid pKFl was used as a template to sequence the 0.8 kb M hyopneumoniae DNA
fragment. Sequence analysis revealed the presence of three open reading frames, two
of which had amino acid sequence homology to the prokaryotic class I nrdF
ribonucleotide reductase and an associated gene. In both the 128 kDa fusion protein
and the 15 kDa protein, the recombinant M hyopneumoniae antigen consisted of the
carboxy terminal 11 kDa of a 42 kDa M hyopneumoniae protein thought to be the
NrdF ribonucleotide reductase R2 subunit protein.

Antibodies raised in rabbits against the 11 kDa portion of the recombinant proteins
reacted against the wild type protein in all M hyopneumoniae strains isolated from a
number of regions throughout the world. These antibodies were able to react against
the wild type protein in whole cell ELISA, demonstrating the surface accessibility of
the 42 kDa protein. Furthermore, in-vitro growth inhibition studies using antibodies
specific for the 15 kDa NrdF antigen demonstrated the vulnerability of viable M.
hyopneumoniae to neutralising antibodies.

Salmonella typhimurium aroA SL3261 was used as a live carrier of the plasmids
pSD9 and pKFl, which expressed the respective 128 kDa and 15 kDa recombinant
proteins. When used as live oral vaccines, S. typhimurium SL3261(pSD9) and S.
typhimurium SL3261(pKFl) induced a significant secretory IgA immune response in
the lungs of orally immunised mice against the M. hyopneumoniae antigen. The S.
typhimurium SL3261 (pSD9) also elicited significant NrdF serum IgG, a response
which was not seen in mice immunised with S. typhimurium SL3261(pKFl).
XXI

The efficacy of the S. typhimurium aroA SL3261 (pKFl) vaccine strain was evaluated
in a pig trial. Pigs were split into 4 immunisation groups; NrdF intraperitoneal, PBS
negative control, oral salmonella vector and oral salmonella vaccine and immunised
twice prior to experimental challenge. Pigs parenterally immunised with the 15 kDa
NrdF antigen had a significantly higher (P < 0.05) serum IgG response after the
second vaccination and before challenge compared with all other groups. Oral
immunisation with the Salmonella vaccine strain did not elicit any antibody response
against the recombinant NrdF antigen after vaccination but prior to challenge.
However, after challenge the oral salmonella vaccine elicited a significant (P < 0.05)
secretory IgA response in the lungs of pigs against the 15 kDa NrdF antigen compared
to all other immunisation groups. Immunised swine in the NrdF intraperitoneal and
oral salmonella vaccine groups, which received the recombinant NrdF antigen,
showed higher average daily weight gains and reduced lung pathology compared to
the control groups.

Utilisation of live oral vaccines expressing potentially protective M. hyopneumoniae
proteins, such as the NrdF antigen, which can stimulate a lung mucosal response
against surface accessible proteins may provide a cost affective alternative to the
present control strategies used for porcine enzootic pneumonia.

XXII

Chapter 1

Review of the literature

C hapter 1
Review of literature

1.1

Biology of the mycoplasmas

Mycoplasma hyopneumoniae is the causative agent of porcine enzootic pneumonia
(PEP), a chronic non-fatal respiratory disease of pigs (Simecka et al, 1992) which
incurs severe economic losses on pig meat producers throughout the world due to
reduced growth rate, ongoing management costs and antibiotic supplements (Leman et
al, 1982). Worldwide estimated losses due to the disease are approaching $1 billion
per year, with approximately $

(Aust)

20 million per annum being lost in Australia

(Eamens, 1992). M. hyopneumoniae colonises porcine ciliated epithelial cells of the
trachea, bronchi and bronchioles (Blanchard et al, 1992), subsequently damaging and
eventually causing the loss of cilia (DeBey et al, 1994). Ciliostasis compromises
mucosal clearance and, coupled with characteristic PEP lung lesions, predisposes
infected pigs to potentially fatal secondary invaders such as Pasteurella multocida
(Ciprian et al, 1988) and Actinobacillus pleuropneumoniae (Yagihashi et al, 1984).
Presently, in Australia, there are no cost effective vaccines available for the control of
PEP. This thesis describes work involved in vaccine development using a live
Salmonella typhimurium aroA mutant as a carrier of recombinant M. hyopneumoniae
antigens. Previous studies by other groups using attenuated mutants of S. typhimurium
aroA (Hoiseth and Stocker, 1981) have demonstrated the strains to be invasive yet
non-virulent and capable of eliciting immune responses (Cardenas and Clements,
1992; Lumsden and Wilkie, 1992; Mukkur, 1992). Furthermore, other studies have
determined the usefulness of using attenuated S. typhimurium aroA strains expressing
heterologous mucosal pathogen antigens as live oral vaccine vectors that are capable
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of stimulating a secretory immune response ( Fairweather et al, 1990; Guzman et al,
1991, Cardenas and Clements, 1992). It is the aim of this study to target the mucosal
immune system of swine using attenuated S. typhimurium aroA strains expressing an
immunogenic and protective M. hyopneumoniae antigen.

1-1-1

The mollicutes

The Mollicutes are a genetically diverse group characterised by their lack of cell wall,
morphologically small size, very low G.C content and small genome size. Analysis of
5S rRNA sequences and a number of evolutionary conserved proteins indicate that the
Mollicutes evolved by a degenerative evolutionary process from larger ancestral
eubacteria closely related to the Genera of Bacillus and Lactobacillus (Ferrell et al,
1989; Razin, 1992a). The largest of the Mollicutes, the Acholeoplasma, have a
genome of approximately 1700 kb. Divergence from this branch led to the sterolrequiring Spiroplasma and further genomic reduction led to the 620-1140 kb
Mycoplasma and Ureaplasma lineages (Weisburg et al, 1989).

M. hyopneumoniae belongs to the Genus Mycoplasma within the Mollicute Class. The
Mollicutes are classified according to cell morphology, genome size and nutritional
requirements.

Genera

within

this

Class

are

Mycoplasma, Acholeoplasma,

Anaeroplasma, Asteroleplasma, Spiroplasma and Ureaplasma (Weisburg et al, 1989).
Recently, the two Genera Entomoplasma and Mesoplasma, also referred to as
mycoplasma-like organisms (for review see Lee and Davis, 1992) were also included
into the Class Mollicutes within the order Entomoplasmatales (Tully et al, 1993).
Organisms within the Mollicutes can also be phylogenically grouped as determined by
parsimony analysis of the full 16S rRNA gene sequence (Gundersen et al, 1994). This
type of grouping identifies a number of closely related groups. Under this scheme M.
hyopneumoniae is grouped into the M. hominis clade that contains only the genus
Mycoplasma. Other groupings include the Mycoplasma pneumoniae clade containing
organisms from both the genera Mycoplasma and Ureaplasma. The Spiroplasma clade
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contains Aiycoplasynas and Spiroplaswias\ the Anaeroplastna clade contains the
mycoplasma-like organisms, Acholeplasmas and Anaeroplasmas, and the final
grouping the Asteroleplasma (Gundersen et al, 1994). In the future, these
phylogenetic groupings will be combined with the present phenotypic groupings to
form a new integrated Mollicute classification scheme (Gundersen et al, 1994).

1-1-2

The Mycoplasmas

Mycoplasmas, like all Mollicutes, lack a cell wall and many biosynthetic pathways in
response to adopting a symbiotic/parasitic mode of existence (Razin, 1992a; Razin
1992b; Razin, 1978). These organisms rely on the host for a maintained environment
providing saccharides, amino acids, lipids, nucleic acid precursors, vitamins and
certain co-enzymes (Miles, 1992). Although the nutritional requirements of only a
limited number of mycoplasmas have been determined, it is apparent that
mycoplasmas lack major energy producing pathways such as the tricarboxylic acid
cycle (Manolukas et al, 1988). The mode of ATP synthesis is varied between
mycoplasma species, and is through a number of different aerobic and anaerobic
processes utilising transported primary energy sources. The predominant pathways are
glycolysis, oxidation of pyruvate and the hydrolysis of arginine (Miles, 1992; Razin,
1992b).

There are a number of essential “housekeeping” genes that mycoplasmas, being a
minimal cell, must conserve. These genes include those encoding ATPase, DNA
gyrase, DNA polymerase, RNA polymerase, rRNA, tRNA, adhesin and attachment
proteins and a number of other proteins associated with nucleotide salvage and the
synthesis of ribonucleotides (Razin, 1992b). In all mycoplasma species characterised
there is always a single DNA polymerase (Labarere, 1992) compared to three in
Escherichia coli. Similarly, mycoplasmas contain one or two ribosomal gene copies
compared to between seven and ten copies in eubacteria (Razin, 1992b). Furthermore,
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in Mycoplasma capricolum there are 30 tRNA genes for 29 tRNA species compared
to 78 tRNA genes for 45 tRNA species in E. coli (Razin, 1992b).

Perhaps the most significant of losses due to reductive evolution is the loss of uracilDNA glycosylase. This enzyme is responsible for the excision of uracil from genomic
DNA. Cytosine in DNA may become deaminated to form uracil and consequently a
C.G pair will be converted to a U.G pair. After a subsequent round of replication an
A.T pair is yielded. Thus the absence of the uracil-DNA glycosylase will result in A.T
bias transition mutations, leading to an A.T accumulation and the characteristic low
G.C composition of mycoplasmal genomic DNA (Labarere, 1992). Only a single
mycoplasma, Mycoplasma lactucae, is the exception. This organism is reported to
contain a uracil-DNA glycosylase. However, this enzyme is extremely inefficient and
its action is not sufficient to prevent an accumulation of A.T and subsequently the G.C
content of its genome falls within the characteristic mycoplasma range of 24-33%
(Williams and Pollack, 1990).

The structural organisation of mycoplasma genomes is essentially similar to that
found in eubacteria such as E. coli and Bacillus subtilis (Muto et al, 1992), with
exceptions being due to the effect of the differing G.C content rather than structural
differences (Taschke et al, 1987). Conserved -10 and -35 consensus sequences that
can also function in E. coli have been reported for M capricolum rRNA and tRNA
genes (Gafny et al, 1988). Similarly Shine-Dalgamo sequences from Mycoplasma
genitalium that function in E. coli have also been reported (Loechel et al, 1991).
However, in M. hyopneumoniae the reported transcription initiation sites and
promotor-like consensus sequences do not function within other bacterial systems
(Taschke et al, 1987). This difference is assigned to significant sequence divergence
in M hyopneumoniae, however, the underlying basis for gene expression is thought to
be similar (Taschke et al, 1987). Regulation and termination of transcription in the
my coplasmas has been extensively researched for M capricolum and Mycoplasma
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hyorhinis, however the large genetic diversity between mycoplasma species precludes
any speculation on these processes in M. hyopneumoniae.

Another effect of A.T accumulation in the mycoplasma genome is the usage of the
UGA codon to encode tryptophan rather than the bacterial stop. Transition mutation
bias towards A.T accumulation would have led the UGA stop codon to become UAA,
leaving UGA unassigned, and allowing mutation from the tryptophan UGG codon to
the UGA tryptophan codon found in M hyopneumoniae (Futo et al, 1995) and other
mycoplasma species (Jukes, 1985; Yamoa et al, 1985; Inamine et al, 1988).

1.1.3

Mycoplasma pathogenesis

Evidence indicates that most mycoplasmas are genetically predetermined to be
commensals (Simecka et al, 1992), with some species being considered low level
parasites. Mechanisms of mycoplasma pathogenicity have not been elucidated and it
is considered that pathogenicity is largely due to a bystander effect where the hosts
immune response plays a major role in the development of the disease (Simecka et al,
1992). In all cases the mycoplasma colonises a specific mucosal surface of the host.
The mycoplasmas Mycoplasma penetrans, M. pneumoniae and M. genitalium have
been shown to actively invade the hosts epithelial surface (Razin, 1992b; Baseman et
al, 1995); all other species studied remain associated with the external mucosal
surface. Toxins have been identified and linked to the pathogenicity of some
mycoplasmal diseases. Viable Mycoplasma mycoides produces a diffusable toxin
which can induce tissue necrosis in rabbits and cattle (Simecka et al, 1992),
Mycoplasma arthriditis produces a 15 kDa protein that induces a damaging localised
inflammatory response (Fleischer, 1994). Mycoplasma gallisepticum produces a
neurotoxin which is capable of producing encephalitis in turkeys (Simecka et al,
1992). Presently, a single non-diffusable 54 kDa protein purified from M.
hyopneumoniae has been identified as a potential toxin. This factor is a membrane
associated cytosolic protein which after purification can induce cellular rounding,
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lysis and detachment of cultured human lung fibroblast cells in vitro (Geary and
Walczak, 1985). However, the actual role of the native protein in pathogenesis of PEP
is not understood. Studies on the effects of this cytopathic protein, purified from high
passage number M hyopneumoniae indicate that its toxicity does not diminish after
high passage. This observation is contrary to results obtained from ciliostasis studies
which indicate that cellular damage and loss of cilia, by unknown factors, is
diminished in high passage number M. hyopneumoniae strains (DeBey and Ross,
1994). This discrepancy between passage number and toxin activity indicates that the
54 kDa cytotoxic factor may not be directly involved in initial cellular damage of
ciliated epithelial cells of swine caused during colonisation. Rather, it is feasible that
the 54 kDa protein is a cytosolic metabolic enzyme, possibly a nuclease or protease,
with the observed toxicity being due to the tracheal culture cells being exposed to the
active purified enzyme.

1.2

Pathogenesis of Mycoplasma hyopneumoniae

Historically PEP has always been recognised as an economically important swine
disease. During the 1920s and 1930s an all encompassing description of “hog flu” was
used to describe bacterial, viral and mycoplasmal respiratory diseases (Betts, 1953).
Research in the mid 1930s identified that Haemophilus influenzae suis and
Pasteurella multocida were frequently cultured from pneumonic lungs, yet at times
the lung lesions were found to be bacteriologically sterile (Betts, 1953). Researchers
at the time agreed that pneumonia of swine was due to viral infection, distinct from
swine influenza, and frequently complicated by secondary bacterial infections. The
mycoplasmal etiological agent of PEP was isolated and characterised in both America
(Mare and Switzer, 1966) and England (Goodwin et al, 1967) at approximately the
same time. Recent studies (Morrison et al, 1986; Wilson et al, 1986; Straw, 1991)
have demonstrated that producers with herds infected with M. hyopneumoniae will
only lose money if compounding factors such as secondary invaders, environmental
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conditions, strain variation and poor animal husbandry practices are not addressed.
However, it is also feasible that by addressing the compounding factors and
introducing an efficacious vaccination program M. hyopneumoniae could be
eradicated from herds.

1.2.1

Mycoplasma colonisation

Most mycoplasmas utilise more than one mechanism to bind host cells. The most
characterised adherence mechanism studied is that of M pneumoniae. This pathogen
has two characterised adhesins, PI and P30 (Dallo et al, 1989), as well as mycoplasma
A, B, C, HMW1-HMW5, P65, P41 and P24 proteins. These proteins interact to form
an attachment organelle which allows for host specific cytadherence (Krause, 1996).
Other mycoplasmas, such as Mycoplasma iowae utilize a “fuzzy” layer of interlocking
fimbrils which interact with host cell microvilli, allowing attachment but not intimate
association with the epithelial surface (Kahane and Harowitz, 1993).

In M. hyopneumoniae, adherence can be abrogated by trypsin and periodate treatment
of the pathogen, indicating attachment is facilitated by proteins and polysaccharides
(Zeilinski et al, 1990 and 1993). The presence of a “fuzzy” layer on M.
hyopneumoniae cells has been reported and interaction between this layer and porcine
cilia has been demonstrated (Tajima and Yagihashi, 1982).

A single M. hyopneumoniae adhesin, designated P97 has been identified and is
associated with the external fuzzy layer. This protein has an uncharacterised porcine
epithelial target (Zhang et al, 1995). However, DNA sequence analysis of the gene has
revealed predicted proline rich repeat sequences (Wilton et al, 1997). The presence of
these repeats in other organisms has been associated with receptor-ligand binding
(Williamson, 1994).
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The P97 adhesin displays size variation between M. hyopneumoniae strains (Wilton et
al, 1997; Hsu et al, 1997). Similar antigenic variation has been demonstrated in M
hyorhinis (Rosengarten and Wise, 1990; Yogev et al, 1991; Rosengarten et al, 1993),
M pulmonis, Ureaplasma urealyticum and M. hominis virulence antigens (Kahane
and Horowitz, 1993). In M hyopneumoniae, the mechanism responsible for antigenic
variability has yet to be experimentally proven. However, the presence of copy
number variations of the proline rich P97 repeat sequences, AKPE(V)A and
GA(E,S)PN(S)QGKKAE

implicates

genetic

rearrangements

by

homologous

recombination as one possible mechanism (Wilton, 1996).

N-terminal amino acid sequence comparisons have revealed no P97 protein homology
to any other characterised mycoplasma adhesins, indicating this adhesin may be a
novel antigen specific for M hyopneumoniae (Zhang et al, 1995). Monoclonal
antibody blockage of the P97 adhesin, or preincubation of M. hyopneumoniae with
high concentrations of hyperimmune sera, does not completely inhibit attachment to
porcine ciliated cells (Zielinski and Ross, 1993; Zhang et al, 1995), indicating that
there are other adhesins or nonspecific mechanisms of attachment present.
Furthermore, reduction of IgM or removal of tetrameric IgM molecules from the
hyperimmune sera restores M. hyopneumoniae adherence, indicating inhibition is
attributable to the agglutinating activity of various anti-M hyopneumoniae epitopes
rather than specific adhesin blockage (Zielinski and Ross, 1993).

Three porcine glycolipids found on ciliated tracheal epithelial cells, designated La, Lb
and Lc, have been identified as major binding targets for M hyopneumoniae (Zhang et
al, 1994). Colonisation of ciliated tracheal cells can be inhibited by the addition of
laminin, a basement membrane component which competes for these porcine
glycoproteins. However, the M. hyopneumoniae receptors responsible for recognising
and binding to the porcine glycolipids have yet to be identified (Zhang et al, 1994).
Nonspecific hydrophobic interaction also plays a role in M. hyopneumoniae
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attachment and colonisation. Adherence to glass surfaces is a characteristic of the
normally extremely fastidious M. hyopneumoniae and has been demonstrated to be
due to hydrophobic interactions (Zielinski and Ross, 1993). Colonisation of inert glass
surfaces by mycoplasmas is energy dependent and any inhibition of energy
metabolism significantly reduces attachment (Bredt et al, 1982). However, the exact
role and mechanism of this phenomenon is unknown. In summary, the adherence of
M hyopneumoniae in vivo to porcine tracheal cells is essential for PEP pathogenesis
and involves a complex relationship between specific and nonspecific mechanisms.

1.2.2

Lesion development

Characteristic lung lesions symptomatic of PEP in swine occur in the ventral regions
of the apical and cardiac lobes (Ross, 1986). The severity of the disease can be
determined at slaughter by identifiable areas of plum coloured discolouration (Fig
1.1). The progression of characteristic PEP induced lung lesions corresponds to
morphological sequential changes which are due to nonspecific host immune
inflammatory responses. The onset of PEP after exposure to M. hyopneumoniae will
usually occur within six months of exposure (Ross, 1986). Disease progression is
dependent upon a number of factors related to the conditions under which livestock
are housed. Initially the disease was thought to have an incubation period after
exposure to the pathogen of two to seven days with disease onset being sudden and
occurring “simultaneously amongst all the pigs in the herd” (Betts, 1953). This onset
is now understood to be due to a number of compounding factors (discussed in
Section 1.3). Evidence of lesion development can be seen in slaughtered pigs lungs in
as few as three days after PEP infection (Baskerville, 1972). Initial host response to
infection consists of accumulation of polymorphonuclear cells (Ross, 1986) and
isolated
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Fig 1.1.

Pig lungs removed at slaughter. Characteristic plum coloured

lesions are indicated by arrow. Ear tag disc can be seen in the intermediate
lobe region.

mononuclear cells (Baskerville, 1972) in the lumina of the bronchioli and small
bronchi. This response is compounded approximately five days post infection by the
accumulation of lymphocytes in the peribronchial space and lamina propria of the
alveoli. Significant lymphoid hyperplasia is visible around the affected airways by day
7-10; this lymphoid tissue accumulation continues causing stenosis of the bronchioli
and peribronchiolar alveoli. Hypersecretion of mucus is also detectable during this
period, and predominantly there is an increased level of sulfation of mucosubstance
(DeBey et al, 1992). By day 15 post infection there is extensive alveolar oedema,
regional alveolar collapse and irregularities in the bronchioli epithelium (Baskerville,
1972; Ross, 1986). Mucopurulent exudate is predominant in the small airways at this
time. Build up of exudate is due to hypersecretion compounded by ciliostasis (DeBey
et al, 1992) brought about by extensive damage due to lesion progression.

1-2.3

Cell mediated immune responses to M. hyopneumoniae
infection

In both natural and experimental M. hyopneumoniae infection, bronchial lymphocytes
are sensitised to M. hyopneumoniae antigens as early as one week post exposure
(Kristensen et al, 1981). Other studies observed that sensitised lymphocytes appear to
marginate in the lymph nodes, particularly in the bronchial region. However, there are
no reports of sensitised lymphocytes in the systemic population until late in infection
and during the period corresponding to recovery 15 to 44 weeks post infection (Suter
et al, 1985; Messier and Ross, 1991). The lack of responsiveness of systemic blood
lymphocytes corresponds to the lack of a M. hyopneumoniae specific DTH response
and has been used as evidence to demonstrate immunosuppression of CMI by the
pathogen (Adegboye 1978a and 1978b). However, this may also be due to
compartmentalisation of the immune system, particularly within the bronchial
associated lymphoid tissue (BALT), and margination of sensitised immune cells in
regions associated with this lymphatic tissue such as the bronchial lymph nodes.
There are conflicting studies examining the regulation of nonspecific responses to
11
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mitogens such as phytohemagglutinin by M. hyopneumoniae infection (Adegboye,
1978a and 1978b; Messier et al, 1990; Messier and Ross, 1991). Clarification of these
studies would be useful to determine what regulation there is on the lymphocyte
populations.

Nonspecific mitogenic effects by mycoplasmal antigens on a range of naive
lymphocytes have been reported in a number of studies (Cole et al, 1982; Daynes et
al, 1982). The most studied mycoplasmal mitogen is a 15 kDa factor secreted by
Mycoplasma arthritidis which is shown to greatly exacerbate damage caused by
localised hyperplasie inflammation (Fleischer, 1994). The extent of the nonspecific
mitogenic effects caused by M. hyopneumoniae antigens is not well characterised. A
number of experimental trials have demonstrated a moderate mitogenic effect on
porcine blood lymphocytes (Adegboye, 1978; Kishima et al, 1985; Messier and Ross,
1990; Messier and Ross, 1991), however, the weak response is extremely variable and
the degree and extent of the effect varies with the pigs genetic lineage, age of the
swine at infection and the M. hyopneumoniae strain used.

1.2.4

Nonspecific activation of alveolar macrophages

As early as 2 weeks post-infection, M. hyopneumoniae stimulates increases in
phagocytosis of non-opsonised particles by

nonspecific activation of alveolar

macrophages (Caruso and Ross, 1990). This is a possible route of colonisation by a
low level invasion of secondary pathogens such as A. pleuropneumoniae (Nicolet,
1992). These bacteria secrete a cytocidal toxin that kills the phagocyte allowing the
internalised viable bacteria to evade host defences and colonise the host (Caruso and
Ross, 1990). Conversely, experimental challenge doses of secondary mucosal
invaders have been demonstrated to significantly decrease macrophage function that
could also increase the incidence of secondary infections (Caruso and Ross, 1990).
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1*2.5

Humoral immune responses

Colostrum derived neutralising antibodies against M. hyopneumoniae are responsible
for protection against PEP in suckling pigs. Antibodies can persist in the serum of
piglets for up to 51 days (Durisic et al, 1975), with the average half life of serum anti
M. hyopneumoniae IgG being 8-15 days (Morris et al, 1994). Swine are likely to
develop serum antibodies (seroconvert) after 3 months of age (Kobisch et al, 1993),
which corresponds to the period when pigs show clinical signs of disease and when
weaners are usually transferred into the growing population. Unvaccinated PEP
negative pigs will seroconvert within 3-4 weeks after experimental inoculation and 6
9 weeks after natural exposure to virulent M. hyopneumoniae (Djordjevic et al, 1994).
Serum antibody responses following seroconversion are of a low magnitude (Nicolet,
1987) and are predominantly IgG (Sheldrake et al, 1993). M. hyopneumoniae specific
antibodies detected in lung washes are predominantly IgA during the early stages with
IgG becoming predominant later in the infection (Messier et al, 1990). No correlation
in weaned pigs has been determined between the presence of serum or mucosal
antibodies and protection from PEP (Kishima et al, 1985; Djordjevic et al, 1997).
However, passive transfer of hyperimmune serum has been shown to protect swine
against the development of disease (Messier et al, 1990). Furthermore, acute infection
(Sheldrake et al, 1992) and resolution of disease has been correlated to marked
increases in serum immunoglobulin levels (Messier et al, 1990).

1.2.6

Resolution

Resolution of PEP in swine is dependent upon many factors, similar to those factors
involved in the onset and severity of disease. Resolution of disease can be affected by
secondary invaders, environmental conditions, strain variation and poor animal
husbandry practices. Recent studies which strictly control these factors demonstrated
that swine with PEP infection take more than 4 weeks but less than 13 weeks post
challenge to resolve lesions and clear viable M. hyopneumoniae from the lungs
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(Amass et al, 1994). More severe outbreaks which last in excess of 16 weeks post
inoculation without any recovery signs being detected have been reported (Underdahl
et al, 1980). However, it is possible that uncontrolled confounding factors in this
study may have combined to alter disease pathogenicity and epidemiology.

1.2.7

Growth performance changes due to PEP and complications

Uncomplicated PEP has an uncertain effect on average daily gains (ADG) and the
feed: gain ratio (F/G) of infected swine. Large variations of growth performance exist
between studies examining the association between these indicators and PEP; these
have been summarised in the comprehensive study by Morrison and colleagues
(1986). Of 23 studies examined in this review, 10 studies reported no significant
variations in growth performance, the remaining studies reported decreased ADG
between 5% and 25% and F/G increases between 4.6% to 25%. A study by Noyes et
al (1990) found no correlation between the incidence of lesions at slaughter and
weight gain, however, using radiological techniques they were able to show
correlation between lifetime complicated PEP burden and weight gain. In the herd
studied, for every 1% increase in lifetime burden there was a 1.46 kg decrease in body
weight at slaughter (180 days old). This radiological technique is cost prohibitive and
labour intensive yet this study is useful as an indicator to demonstrate that PEP results
in large economic losses. Large variations between growth rate and the extent of PEP
have been reported from many other researchers using various other diagnostic
methods (Pointon et al, 1985; Christensen and Mousing, 1992; Amass et al, 1994).
For all these studies the reported differences are due to a number of recognised
factors, and in particular environmental factors, secondary pathogens and animal
husbandry practices. However, assigning formula to describe the extent of causality
for all circumstances on all farms is not possible due to the compounding nature of
these interactions.
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1.2.8

Secondary invaders

Any PEP lesion damage to swine lungs in an intensive piggery situation can leave
affected pigs susceptible to opportunistic secondary invaders. The most common
economically important pathogens involved in the complication of PEP are P.
multocida (Ciprian et al, 1988; Ross, 1992), M. hyorhinis, M. flocculare (Christensen
and Mousing 1992), Bordetella bronchiseptica

(Christensen and Mousing, 1992;

Bernardo et al, 1990; Wilson et al, 1986; De Jong, 1992) and A. pleuropneumoniae
(Wilson et al, 1986; Straw, 1991). M. hyorhinis, M. flocculare, E. coli, non hemolytic
streptococci and staphylococci are routinely isolated from the respiratory tract of
healthy swine. Although some of these organisms are potentially pathogenic, the
presence of these organisms may not indicate any deviation from normal flora. B.
bronchiseptica, non-toxigenic P. multocida and less pathogenic strains of A.
pleuropneumoniae are also occasionally detected in healthy lung flora (Christensen
and Mousing, 1992). The pathogenic strains of A. pleuropneumoniae, like M.
hyopneumoniae, are never found in the respiratory tract of healthy swine, their
presence is always associated with disease at either a subclinical or acute level
(Christensen and Mousing, 1992).

1.2.8.1 Pasteurella multocida
P. multocida does not colonise pig lungs unless the lung epithelial surface is
compromised (Amass et al, 1994). This pathogen is the causative agent of progressive
atrophic rhinitis and is associated with pleuritis (Pijoan and Fuentes, 1987; Gardner et
al, 1994) Strains vary in toxigenicity and as a consequence the extent of complication
caused by P. multocida varies widely. The bacteria were detected in 7% of swine
herds in Australia in 1991 and 1992 (Christensen and Mousing, 1992). However, in
other nations it is the most frequently isolated secondary invader in PEP and is
considered to play a significant role in determining the severity of this disease
(Morrison et al, 1986). The bacteria complicate PEP and in severe cases the F/G ratio
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has been decreased up to 37.5% (Ciprian et al, 1988). Clearance of P. multocida from
non-compromised lungs is rapid and the best strategy for eradication of the pathogen
from a herd is to treat primary invaders such as B. bronchiseptica and M.
hyopneumoniae and allow the host respiratory defences to clear the other secondary
pathogens (Amass et al, 1994).

1.2.8.2 Bordetella bronchiseptica
B. bronchiseptica is a pathogenic bacterium which is a chronic infectious agent in
many mammals. In pigs, acute B. bronchiseptica infection causes catarrhal
inflammation of the nasal mucosa (Christensen and Mousing, 1992). The presence of
disease facilitates the colonisation of secondary invaders, particularly toxigenic P.
multocida strains. The pathogen may also be linked to the predisposition of pigs to the
development of acute PEP (Switzer et al, 1981).

1.2.8.3 Actinobacillus pleuropneumoniae
A. pleuropneumoniae causes pleuropneumonia with the resulting lesions occurring in
the cardiac, apical and diaphragmatic lobes, and is associated with the development of
fibrous pleuritis (Nicolet, 1992). Swine with PEP and other porcine respiratory
pathogens have a demonstrable reduction in resistance to A. pleuropneumoniae
resulting in more rapid onset and exacerbation of the severity of pleuropneumonia.
The acute condition is often fatal and results in large economic losses due to the cost
of treatment and mortality caused by acute outbreaks (Nicolet, 1992).

1.2.8.4 Mycoplasma flocculare and Mycoplasma hyorhinis
M. flocculare is considered non-pathogenic in swine (Hovind-Hougen and Friis,
1991). However, it is extremely widespread and is commonly isolated from the lungs
and nasal cavities of pigs, including specific pathogen free (SPF) pigs. Although this
mycoplasma is not considered pathogenic it can cause problems in the early detection
and identification of M. hyopneumoniae. Polyclonal antisera raised against M.
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hyopneumoniae antigens will cross react with M. flocculare

(Bolske et al, 1990;

Scarman et al, 1997) resulting in “false positives”. M. hyorhinis is another
mycoplasmal agent commonly isolated from porcine respiratory tracts (Baskerville,
1972). This pathogen has been implicated as an agent of polyserositis and arthritis
(Friis and Feenstra, 1994). M. hyorhinis has also been suggested to play a role in the
development of PEP (Simecka et al, 1992). This organism is a common tissue culture
contaminant which rapidly outgrows M. hyopneumoniae, making species-specific
identification by culture difficult (Ross 1986).

1.2.9

Transfer of pathogen

A lack of sensitive M. hyopneumoniae specific early detection diagnostic assays
coupled with low virulence and a long incubation period of the pathogen makes it
difficult to control chronic infections within a swine herd (Jericho, 1986). Because
routine detection within herds relies heavily upon necropsy to determine the extent of
the infection, the actual mode of transmission is not well understood. Sow-to-piglet
transfer prior to weaning has been implicated as a mode of transmission. Although
PEP is rarely seen in pigs younger than 3 months of age (Morris et al, 1995) early
reports indicated possible infections in pigs as young as 2 weeks (Holmgren, 1974)
where the only carrier could be the farrowing sow. However, this early study may
have detected passively acquired resistance to the pathogen via colostral antibodies
which were misinterpreted as a serological host response against the pathogen (Clark
et al, 1991; Morris et al, 1994). Most studies downplay the role of sow-to-piglet
transfer of M hyopneumoniae because animal husbandry practices may be utilised
which prevent mixing of weaned pigs with older acutely infected animals thereby
significantly reducing the extent of PEP within these pigs (Clark et al, 1991). The
predominant form of transmission of M. hyopneumoniae is direct contact between
acutely infected and uninfected swine (Ross, 1992; Morris et al, 1995). Repeated low
dose exposure in rapidly growing weaned pigs is optimal for the transmission and
colonisation of this fastidious pathogen (Jericho, 1986) and direct contact between
17

cohorts allows for this type of exposure. Aerosol exposure is another mode of transfer
which significantly affects transmission and is blamed for the less frequent
transmission between non-contiguous pens. Once infected, a single swine can then
transfer the pathogen to penmates and swine in adjacent stalls by direct contact.
Airborne transmission between M. hyopneumoniae free piggeries and infected
piggeries nearby is implicated in new outbreaks (Ross, 1992). This form of
transmission is particularly prevalent when piggeries are less than 3.2 kilometres apart
and the infected farm has more than 500 swine (Ross, 1992).

1.2.10

Diagnosis of PEP

The control of M. hyopneumoniae has been difficult due to a lack of a commercially
available, rapid, cost effective and simple diagnostic assay which can detect this
pathogen in low numbers in the respiratory tract of swine. Pig meat producers rely
heavily upon lung examination at slaughter to determine the extent and severity of
PEP in their herds. This method of detection is not optimal because it will only give
an indication of PEP severity at the point of slaughter due to lung lesions being
transitory and resolving over time. Furthermore, lung examination at necropsy gives
no indication of the chronic levels of infection in pigs where all visual respiratory
damage has been resolved.

1.2.10.1

Incidence of coughing

A dry unproductive cough in swine older than three months of age is an early
indicator of an established outbreak of PEP within a herd. Coughing can be correlated
to the presence of pneumonic lesions if the coughing is observed between 1 and 30
days prior to slaughter; if the period is longer no comparison can be made due to the
resolution of lesions (Morris et al, 1995). Coughing is a disease symptom but is not a
good indication of the severity of disease. Coughing is exacerbated by moderate
exercise, however, the area restrictions imposed by modem intensive piggeries often
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preclude exercise and subsequently coughing may not be observed in swine with
severe PEP (Eamens pers com).

1.2.10.2

Visual appraisal of porcine lungs at slaughter

The lungs of swine are divided into seven lobes. On both sides, left and right, there are
apical, cardiac and diaphragmatic lobes. A single intermediate lobe is also found
between the diaphragmatic lobes. Lobes found on the left side are smaller compared
to those on the right to accommodate the heart. PEP is detected at slaughter by
characteristic rose-coloured areas in the apical, cardiac and intermediate lobes (Fig
1.1). Uncomplicated PEP is seen in the upper areas of these lobes which represent
approximately 25-30% of the lung area. When PEP is complicated by secondary
invaders a further area of approximately of 15-20% may be affected (Fig 1.2). The
diaphragmatic regions of the lungs are not affected by PEP, with lesions detected in
these areas considered to be due to pleuropneumonia (Christensen and Mousing,
1992).

There is no universally applied standard for the visual appraisal of the severity of PEP
in the lungs of slaughtered swine. Most researchers who use gross lung morphology as
a diagnostic will observe the percentage of each lobe affected then calculate the
overall percentage by applying a weighted average determined for each of the lobes.
There is not a widespread consensus on the overall percentage value weighting that
each of the lung lobes should be given (Table 1.1), leading to a standardisation
problem between studies. Further problems may also arise due to variation being
introduced by different inspectors, however, a widespread education of scorers would
standardise this problem (Humik et al, 1993).
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Fig. 1.2: Schematic representation of swine lungs showing the region affected by
uncomplicated enzootic pneumonia (light grey), complicated pneumonia (dark grey)
and pleuropneumonia (stippled) (modified Christensen and Mousing 1992).
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Table 1.1: Table showing the differences between the percentage value area assigned
by various researchers to the relevant lobes.

Lung lobe

Reference
Morrison et al,
1985

Goodwin et al,
1969

Christensen and
Mousing, 1992

Straw et al,
1983

Right apical

11.9%

10%

11%

10%

Right cardiac

7.5%

10%

10%

10%

Right
diaphragmatic

30%

Leading edge
5%

34%

25%

Intermediate

4.6%

Leading edge
5%

5%

10%

Left apical

7.1%

10

5%

10%

Left cardiac

6.9%

10

6%

10%

Left
diaphragmatic

31.6%

Leading edge
5%

29%

25%

Total score:

100%

Max score 55

100%

100%

For the purposes of diagnosis of PEP within a herd, visual appraisal of the lungs at
slaughter is sufficiently accurate to give a good indication of the severity of disease
when large numbers of animals are scored and the average age of the animals is
approximately 6 months (Morrison et al, 1986). A more accurate method of diagnosis
for researchers would be to remove and weigh affected lung tissue and calculate the
percentage value of the total lung weight. To overcome variation due to the resolution
of disease sample, sizes must be large. This method is time consuming, labour
intensive and impractical for large scale screening of herds. However, for use in
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studies examining the correlation between ADG and feed conversion efficiency in
relation to PEP severity, this method overcomes standardisation problems.

Both visual appraisal and weighing affected lung tissue at necropsy also give
inspectors and researchers an indication of the severity of disease within a herd
(Goodwin, 1971) (Table 1.2).

Table 1.2: Table correlating the percentage of pigs within a herd to the severity of the
outbreak (Goodwin, 1971).

Percentage of herd detected with lesions

Severity of outbreak

0

Not affected

< 30%

Slightly affected

30 - 50%

Common prevalence

50 - 70%

Moderate

70 - 85%

Severe

> 85%

Very severe

1.2.10.3

Serological detection ofM, hyopneumoniae

M. hyopneumoniae is a nutritionally fastidious organism which is rapidly overgrown
in culture by less fastidious serologically cross-reactive mycoplasmas such as M.
flocculare and M. hyorhinis (Simecka et al, 1992). These organisms are commonly
isolated from porcine respiratory tracts and make culturing of M. hyopneumoniae
extremely difficult. Although M. hyopneumoniae can easily be distinguished from
other mycoplasmas either morphologically (Hovind-Hougen and Friis, 1991) or by
immunofluorescence, the less fastidious organisms can overgrow cultures and prevent
the subsequent detection of M. hyopneumoniae. The labour intensive nature of
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culturing M. hyopneumoniae often produces false negatives and requires long
incubation periods; as a consequence it is considered a poor screening technique.
Growth inhibition assays rely on the inhibition of M. hyopneumoniae growth by
porcine sera to indicate the presence of neutralising antibodies (Stanbridge and
Hayflick, 1967). This technique requires 3 to 7 days incubation of the assay plates
during which time contamination may overgrow the plate. Other techniques requiring
the culturing of M. hyopneumoniae include the indirect hemagglutination assay,
complement fixation and immunoflourescence. These assays do not have the problem
of co-isolation of other mycoplasmas leading to overgrowth, however, the cross
reactivity of contaminating mycoplasmas (Friis, 1971; Freeman et al, 1984; Scarman
et al, 1997), expense of culture and the long incubation periods prevent these
techniques being used as routine diagnostics. The indirect hemagglutination assay
gives a relative measure of the antibody binding capacity by serially diluting porcine
sera against M. hyopneumoniae until no further visible agglutination is detected
(Hudson and Hay, 1980). The test has a poor (41%) accuracy rate in the detection of
PEP when compared against necropsy lung scores (Freeman et al, 1984). Complement
fixation utilises cascade reactions thereby amplifying a small antibody-antigen
interaction to result in a large detectable assay response (Hudson and Hay, 1980). This
test is sensitive in the initial 38 days post exposure, however doubts have been raised
about the accuracy of the test after this early stage (Freeman et al, 1984).

1.2.10.4

Enzyme linked immunosorbant assay (ELISA) detection

A number of ELISA techniques have been developed to specifically detect M.
hyopneumoniae (Nicolet et al, 1980; Mori et al, 1987; Feld et al, 1992; Sheldrake and
Romalis, 1992; Djordjevic et al, 1994). ELISA detects antibody in seroconverted pig
samples, however, it is not useful in detecting subclinical infections of M.
hyopneumoniae. Results from ELISA are recorded as a ratio calculated by dividing
the obtained sample absorbance by a control negative sera. Ratios greater than 3 are
designated PEP positive, less than 2 are PEP negative and those sera between 2 and 3
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are inconclusive. This screening is 98.8% specific; no M. jlocculare or M. hyorhinis
infected pigs had ELISA readings outside the negative upper limit of 2 (Sheldrake and
Romalis, 1992). False negatives occurred in the Sheldrake study at a rate of only 1%
and was successful in detecting 95.6% of PEP positives when compared to gross lung
examination at necropsy. ELISA has been useful in a number of seroepidemiological
studies (Sheldrake et al, 1990; Morris et al, 1995); the method is rapid, relatively
inexpensive and can handle large numbers of samples. The problem that prevents the
commercialisation of the Sheldrake ELISA is that the antigen cannot be quality
controlled between batches. Furthermore, this method requires the animals to have
seroconverted which may take up to 10 weeks post natural exposure (Djordjevic et al,
1994) during which time the pathogen can spread further within the herd. Djordjevic
et al (1994) have developed a 43 kDa antigen M. hyopneumoniae specific ELISA
which overcomes the problems encountered by the Sheldrake method. The 43 kDa
ELISA is based upon a single preparative SDS-PAGE purified antigen which can be
quality controlled. This antigen is specific for M. hyopneumoniae and is present in all
strains tested (Scarman et al, 1997). This ELISA is more sensitive and can detect
seroconverted pigs 2-3 weeks earlier than the Sheldrake method (Djordjevic et al,
1994). As a research diagnostic assay this ELISA is specific, accurate and
reproducible.

1.2.10.5

Molecular biology techniques

Using the molecular techniques of PCR and DNA hybridisation allows investigators
to determine the presence of M. hyopneumoniae before the onset of clinical
symptoms. Both techniques utilise species specific DNA sequences, in which the
sequences of interest may not be a single gene; rather the sequences may span regions
covering a number of uniquely arranged open reading frames, which may have no
single function when expressed. Mycoplasmas have been shown to use gene
rearrangements to evade host defences by producing structurally variant forms of
surface components (Rosengarten and Wise, 1990; Yogev et al, 1991; Yogev et al,
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1993; Rosengarten et al, 1993). Consequently, a foreseeable problem with the
molecular techniques is that if the mycoplasmal DNA undergoes frequent
rearrangement, the unique random DNA fragments may only be present in a certain
strain at a specific point in time. This problem is further compounded by the presence
of repeated genetic elements resembling prokaryotic insertion sequences (Ferrell et al,
1989). These genetic elements are 1550 bp in length, show variation in their
chromosomal location and are present in various copy numbers in a majority of M.
hyopneumoniae strains studied (Ferrell et al, 1989). The size and random nature of
these elements can lead to false negatives if they have rearranged into a target DNA
sequence.

DNA probes are able to detect the organism by hybridising to M. hyopneumoniae
specific DNA sequences. A number of sequences unique to this pathogen have been
detected (Table 1.3). Only the DNA probe described in the Johansson study
(Johansson et al, 1992) uses a demonstrated essential gene, the 16S rRNA gene. These
genes are the most conserved genetic elements in all organisms due to their essential
role in protein synthesis (Olson et al, 1986; Woese, 1987). However, there is
sufficient variation in the DNA sequences between organisms to make these genes
species-specific and consequently useful target regions.

Molecular probes are a useful tool in research where only small numbers of samples
are being tested. Under these conditions the associated Southern blot or dot blot
hybridisation techniques may be routinely used. However, the polymerase chain
reaction (PCR) has superseded DNA hybridisation techniques, offering a safer, more
rapid and more sensitive M. hyopneumoniae detection system (Artiushin et al, 1993).
PCR is an expensive technique to establish in a laboratory due to the cost of
equipment and reagents. The training of research staff is vital to prevent
contamination due to the extreme sensitivity of the technique which will often result
in false positives (Razin, 1994). Once the technique is established in a laboratory, the
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PCR detection of M. hyopneumoniae is a simple and reproducible early detection
method (Narita, 1993).

Table 1.3: M. hyopneumoniae specific DNA probes

Probe

Detection method

Sensitivity

Reference

16S rRNA
(rDNA probe)

32p

Not determined

Johansson et al,
1992

1.3 kb DNA (f5)

35S

100 pg in culture

Aherns & Friis,
1991

2 kb £coRI DNA
fragment

32p

10 pg in culture

Stemke, 1989

1.65 kb DNA
fragment (1141)

32p

400 pg in lung
sample

Abiven et al, 1992

Studies by Artiushin and colleagues (Artiushin et al, 1993; Artiushin and Minion,
1996) have demonstrated that genetic variation within M. hyopneumoniae field
isolates can lead to false negatives and differing PCR banding patterns when arbitrary
DNA primers are used. However, as described previously, the amplification of 16S
rRNA genes overcomes this problem of genetic heterogeneity. Blanchard (Blanchard
et al, 1994) described the development of a 16S M. hyopneumoniae specific PCR
diagnostic sensitive enough to detect 1000 mycoplasmas seeded into porcine
tracheobronchial secretions. The sensitivity of amplification of DNA from such
biological samples is difficult due to the presence of PCR inhibitors which may also
lead to

false

negative

results

(Razin,

1994).

Furthermore,

collection

of

tracheobronchial washings is not viable for widespread herd screening due to the
labour costs and time involved. Immunomagnetic capture of the pathogen is a
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technique which removes inhibitors and subsequently increases sensitivity (Djordjevic
et al, 1995) to reproducibly detect fewer than 10 mycoplasmas per assay (Zalanardo,
1995), a level that would allow for routine screening of nasal secretions.

1.3

Prevention and treatment of PEP

Introduction of M. hyopneumoniae and subsequent outbreaks of PEP can be
minimised by both treatment and prevention. Effective control of the disease depends
predominantly on the provision of a stable healthy environment, sound hygiene
practices, low levels of bioaerosols, adequate ventilation, climatic control and
adequate floor space for animals (summarised in Table 1.4). Correct animal husbandry
practices must be adhered to because the buildings used for intensive pig production
may represent health risks not only to the swine being housed but also to pig meat
industry workers (Donham, 1995).

1.3.1

Selection of Swine

Sourcing of pigs from SPF herds for most producers is not a commercially viable
option. There are methods, however, which minimise the introduction and spread of
M. hyopneumoniae within a commercial piggery. Furthermore with correct animal
husbandry practices, PEP free herds may be obtained. Research has demonstrated that
pigs sired by Yorkshire boars have more extensive lung lesions and significantly
reduced market weights than pigs of other breeds (Morris et al, 1995); subsequently,
selection of less predisposed breeds such as Landrace pigs will reduce the impact of a
pneumonia outbreak (Done, 1991). The sex of swine does not have any predisposing
influence on the extent or severity of PEP (Done, 1991).

1.3.2

Antibiotic treatment

Antibiotics are used both for the treatment of outbreaks and for the prevention of
colonisation by the pathogen. Due to the problems of screening a swine herd for M.
hyopneumoniae, the symptoms of a dry unproductive cough and general poor
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condition will alert producers to a disease problem. Only when the cost of
pharmaceutical treatment is justified, such as in breeding stock, will antibiotics be
used to treat animals at an individual level. The most potent antimycoplasmal agent is
tiamulin (Dynamutalin), which is often used in conjunction with a tetracycline class
antibiotic such as oxytetracycline (tetramycin) or chlortetracycline (aureomycin,
aurofac) which act synergistically not only against M. hyopneumoniae but are also
very potent against the common secondary invaders P. multocida and B.
bronchiseptica (Eamens, 1992; Miller, 1995). The routine use of antibiotics in
piggeries is directed against the enzootic pathogen rather than against the subsequent
disease. Medicated early weaning involves treating the sow with antibiotics in the late
period of gestation. The sows offspring are subsequently weaned at a maximum of 14
days into an isolated nursery piggery (Tubbs, 1995). The 14 day limit is the period
after which the colostrum derived passive immunity against M. hyopneumoniae
begins to decline, leaving the piglets at risk of being infected by the pathogen from the
sow. Medicated early weaning when used in conjunction with the All-In All-Out (AIAO, see 1.3.3) batch production system has been shown in studies to minimise PEP
from experimental herds (Miller, 1995). Nurseries should be routinely disinfected
between batches and weaners should be isolated from other pigs. During the period
after weaning the piglets feed is supplemented with 100 parts per million (ppm)
tiamulin and 300 ppm chlorotetracycline for one week then subsequently 25 ppm
tiamulin for the next two weeks. Research has demonstrated that provided the cohort
of pigs are moved into disinfected finishing sheds as an isolated batch the problem of
PEP within the study groups was eradicated (Miller, 1995).

There are a number of problems associated with the use of antibiotics both as a
prophylactic and a treatment measure. Antibiotic usage has more recently become
socially unacceptable and all nations now have strict regulations concerning the use of
antibiotics and the minimum residual levels that are permissible in food for human
usage. The impetus behind this social unacceptance is that consumption of low levels
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of antibiotics selects for antibiotic resistant strains of microorganisms. There are three
mechanisms which can lead to antibiotic resistance: gene mutation, acquisition of new
antibiotic resistance genes and an innate resistance already present in the strain or
species. All three mechanisms have been shown to operate in the mycoplasmas
(Roberts, 1992). Different field isolate strains of M. hyopneumoniae have different
sensitivities to a range of antimicrobials (Miller, 1995) including those antibiotics
used to treat PEP. Therefore it is feasible that the continued large scale usage of
antibiotics may lead to antibiotic resistant strains.

1.3.3

Optimal system of swine production

The conditions in which swine are housed and good animal husbandry practices can
make significant differences to losses incurred by PEP (DiFranco et al, 1989; Straw,
1991). There are a number of animal management systems each of which have
benefits for the particular sector of the pig meat industry they serve. Pig housing
facilities for all systems should be a minimum of three kilometres from other pig
housing facilities to prevent the airborne transmission of M. hyopneumoniae
(Goodwin, 1985). Continuous pig production is the predominant animal production
system used in very large scale intensive piggeries. In this system weaners through to
finishing swine are housed in the same production unit (Curtis and Backstrom, 1992).
Upon a single farm there may be a number of continuous facilities isolated by distance
and strict worker practices in use to prevent contamination between sheds. Under this
system, meeting the animals needs as well as monitoring and controlling disease is
critical. Once M. hyopneumoniae or any other pathogen is enzootic it is extremely
difficult to eradicate due to the older chronically infected animals introducing the
pathogen to the younger healthy pigs. The AI-AO production system is where all
animals at each step are treated as a batch unit and kept isolated from all other animals
on the farm. Within the AI-AO production system of housing swine, pathogens are
easier to control because all batches are isolated. Under these conditions there is no
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chronic source of disease and it is difficult to introduce new pathogens (Scheidt et al,
1990; Clark et al, 1991a; Clark et al, 1991b).

1.3.4

1.3.4.1

Environmental factors which optimise prevention of PEP

Temperature

There is no global relationship between season and the incidence of PEP. Regionally
there are patterns of PEP outbreaks corresponding to times when temperatures are the
most extreme and daily variations are greatest (Done, 1991). An optimum temperature
within a piggery is important to prevent energy from feed being expended upon the
maintenance of body temperature (Curtis and Backstrom, 1992). However, more
importantly, the temperature must be maintained constant and the animals must be
kept out of draughts. Furthermore, pigs must be well insulated from the conductive
chilling caused by floors and average variations in temperature must not be greater
than 12°C within 24 hours if the incidence of PEP is to be reduced (Done, 1991).

1.3.4.2

Humidity

Humidity can play a role in the incidence of PEP when high humidity causes damp
conditions which favour the survival of secondary respiratory pathogens which can
reduce an animals resistance to disease (Done, 1991; Curtis and Backstrom, 1992).
Because pigs within modern environmentally controlled piggeries do not rely on
evaporative heat loss to maintain temperature, humidity as a factor is not significantly
correlated to the incidence of PEP.

30

1.3.4.3

Ventilation

Adequate ventilation is vital in intensive piggeries. High stocking densities lead to
high levels of airborne pollutants all of which influence respiratory tract infections.
Animals housed in extreme winter climates have a higher prevalence of pneumonia
due to the ventilation in winter being reduced to maintain temperature. This in turn
effectively increases humidity, bioaerosol concentrations and air pollution, all of
which contribute to increasing the extent and severity of PEP (Done, 1991).
Concentrations of airborne bacteria have been shown to increase due to restrictions in
ventilation. In one study, bacterial numbers increased from 15,000 cfu/m3 in summer
to 350,000 cfu/m3 in winter (Curtis and Backstrom, 1992). Poor ventilation can also
lead to an accumulation of ammonia. Studies have demonstrated that extended
exposure to levels exceeding 100 ppm leads to the depression of pathogen clearance in
swine lungs (Curtis and Backstrom, 1992). Further studies have also indicated that
high levels of ammonia will increase the severity of PEP and correspondingly reduce
ADG in the affected swine (Diekman et al, 1993; Andreasen et al, 1994).

1.3.4.4 Floor space and pig numbers
Pig numbers confined within a single airspace should be kept between the ideal
number of 150 swine and the economically feasible upper limit of 500 swine. More
than 500 pigs in the same airspace results in a significant increase in the incidence of
PEP (Done, 1991). Weaned pigs in nurseries should be kept with between 1 2 - 2 0
penmates depending upon the weather conditions. In colder conditions pen densities
should be increased to allow for greater shared warmth (Curtis and Backstrom 1992).
If weaners are to be raised to approximately 30 kg before moving into a finishing shed
the floor space required per pig should be 0.75 - 1.0 m2 (Tubbs 1995). Finishing pigs
require 35 cm of trough space and similar floor space allowances as large weaners
(0.75 - 1.0 m2) (Curtis and Backstrom, 1992).
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Table 1.4: Summary list of physical parameters which must be maintained to ensure a
low incidence of PEP (modified from Done, 1991).

Environmental
factor

Parameter

Temperature

> 12°C range per day significantly increases PEP.

Herd size

>500 pigs housed per shed increases PEP prevalence even if all
other parameters are controlled.

Pen population

No correlation if floor space is maintained.

Floor space

Pig weight to floor space > 120 kg/m2 increases PEP.

Air space

Minimum of 3 m2/pig (if air quality is maintained).

Air quality

Ammonia, bacteria, hydrogen sulphide and dust must be
minimised.

Feeding

< 0.35 m feed trough per pig increases PEP.

1.3.4.5 Experimental vaccines
Early work using parenterally delivered whole cell M. hyopneumoniae antigens
demonstrated that without adjuvant there is no protection offered (Goodwin and
Whittlestone, 1973). Protection against the development of PEP can be elicited using
whole cell M. hyopneumoniae antigens parenterally delivered with Freund’s complete
adjuvant or a mixture of Bayol/Arlacel adjuvants (Goodwin and Whittlestone, 1973).
Due to severe adverse reactions against these adjuvants their use is unacceptable.
However, modem adjuvant mixtures such as the Auspharm adjuvant (Auspharm Int.
Ltd. Australia) do not produce such side-effects (Sheldrake et al, 1991). Studies have
shown significant protection against virulent challenge using formalin-killed M.
hyopneumoniae mixed with Auspharm adjuvant delivered parenterally (Sheldrake et
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al, 1991). Similarly, Djordjevic et al (1997) used a range of adjuvant formulations and
demonstrated significant reductions in lung damage caused by experimentally induced
PEP. These studies differ from earlier reports because the trials were carried out using
purified M. hyopneumoniae subunit antigens (in the 70-85 kDa range) that were size
fractionated using preparative SDS-PAGE column electrophoresis. This approach
facilitates the identification of antigens which are not only immunogenic in swine, but
which also confer a degree of protection against experimental challenge.

High passage number attenuated M. hyopneumoniae vaccines have been developed
(Li et al, 1992; Ding et al, 1992). These lapinized strains elicit significant protection
against experimental challenge using the parental strain. Obviously, any attenuated M.
hyopneumoniae vaccine strain must be protective against geographically diverse
strains, be cheap to produce and easy to administer. Details as to whether these
attenuated M. hyopneumoniae strains are strain specific are not published.
Furthermore, there has been no literature post-1992 which describes further
development and assessment of these vaccines.

Research into PEP vaccines has produced encouraging results. It has been
demonstrated that it is possible to provide immunological protection against virulent
M. hyopneumoniae challenge. However, commercialisation of these vaccines is slow.
Both protection from disease and economic benefits to producers must be
demonstrated before any product can be considered for marketing.

1.3.4.6 Commercial vaccines
Presently there are only two commercially available M. hyopneumoniae vaccines
available; Suvaxyn™ (Europe) also called Respifend™ (outside Europe) produced by
Solvay Animal Health and Stellamune™ (Europe) also called Respisure™ (outside
Europe) produced by SmithKline Beecham Animal Health. Both of these vaccine
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preparations consist of inactivated M. hyopneumoniae whole cells mixed with
adjuvant. The mode of delivery is intramuscular and relies on the adjuvant to
stimulate the vaccinated animals immune system to give a protective response.
Murphy and colleagues (Murphy et al, 1993) demonstrated that the systemic immune
system did not direct an immediate response against intramuscularly delivered
Respifend™ vaccine antigens, as determined by measuring serum antibody levels.
However, after challenge, serum antibody levels were significantly higher than levels
detected in control pigs and this subsequent antibody response resulted in a significant
decrease in both the incidence and severity of PEP. This study indicates that the
vaccine primed the antibody producing cells for a response. The role of these
antibodies in protection from PEP was not examined, but a correlation between serum
antibody levels and protection was observed. Field trials which examined the efficacy
of both the Respifend™ and Respisure™ vaccines in conventional piggeries have
been carried out in numerous countries under widely varying conditions (Miller et al,
1992; Bilic et al, 1992; Charlier et al, 1993; Christensen and Vraa-Anderson, 1993;
Charlier et al, 1994; Doohoo and Montgomery, 1996). Studies show the vaccine
Respifend™ is able to reduce the frequency of PEP affected pigs by greater than 50%
and significantly decrease the extent of pneumonic lesions in a majority of herds
tested (Christensen and Vraa-Anderson, 1993). Similarly, Respisure™ has also been
demonstrated to produce highly significant reductions in frequency and severity of
pneumonia (Bilic et al, 1992; Charlier et al, 1993). Because PEP outbreaks are
influenced both in severity and frequency by so many compounding factors, results
for all studies vary widely, and in no cases is there a 100% eradication of both the
disease and causal agent. Furthermore, in many studies even though the frequency and
severity of damage was significantly decreased by vaccination there was no
significant differences in average daily gains between vaccinated and control swine
(Lium et al, 1994; Morrow et al, 1994).
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Identification and
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Chapter 2

Identification and characterisation of the recombinant M.
hyopneumoniae antigen recognised by porcine immune sera

Preliminary research described within this introduction was carried out by a team
coordinated by Dr Steven P. Djordjevic at the Elizabeth Macarthur Agricultural
Institute (NSW Agriculture, EMAI, PMB 8, Camden New South Wales. 2570). The
aim of this research was to identify immunogenic antigens from M. hyopneumoniae
and to assess the protective efficacy of these proteins for use in subunit vaccines for
the protection of swine against PEP.

2.1

Preliminary research

A recombinant gene library was constructed by ligating Sau3Al digested M.
hyopneumoniae (strain J) chromosomal DNA into the BamHl site of the expression
plasmids pEXl-3 (Takeshita et al, 1987). Ligation into this site fuses the inserted
fragment to the 3' end of the lacZ gene, resulting in an open reading frame which, if in
frame, expresses a hybrid B-galactosidase fusion protein. After transformation into E.
coli MCI061 (pCI857), colonies were screened for recombinant protein expression
using porcine hyperimmune M. hyopneumoniae antiserum. A positive clone,
designated pSD9 (Fig 2.1), was identified containing DNA which encoded 11 kDa of
a M. hyopneumoniae antigen fused to B-galactosidase resulting in a 128 kDa fusion
protein. The fusion protein was purified and subsequently used to raise rabbit 128 kDa
fusion protein antisera.
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Fig 2.1:

Schematic representation of the construction of the expression plasmid

pSD9. Plasmid pEXl is an expression vector containing an ampicillin resistance gene
(Ap, open box), origin of replication (oriR, open box), lambda P r promoter

(P r ,

filled

arrow) directing the expression of the (3-galactosidase transcriptional unit (cro'-lacflacZ, open box) and stop codons in all three reading frames followed by a phage fd
terminator (stop/term, filled box). Plasmid pSD9 contains a M. hyopneumoniae
Sau3Al 0.8 kb DNA fragment (mycoplasma gene fragment, filled box) ligated into the
BamHl site of pEXl.

This 128 kDa fusion protein was subsequently used in a vaccination trial to determine
the effect on severity of PEP after immunisation. Pigs were immunised according to
the protocol described by Djordjevic et al (1997) with the following changes. Pigs
(n=12) were inoculated intramuscularly with 128 kDa fusion protein (1 mg/pig)
complexed with one of 4 different adjuvants (3 pigs/adjuvant): alhydrogel (Cyanamid
Websters), algammulin (Cooper and Steele, 1991), DEAE-Dextran/mineral oil
(Hoskinson et al, 1990) and DEAE-Dextran/Auspharm vegetable oil (Auspharm
International). After challenge with the virulent Beaufort strain (Etheridge et al, 1979)
of M. hyopneumoniae, visual appraisal of the lungs at slaughter demonstrated that pigs
vaccinated with the 128 kDa fusion protein had a significantly lower (P<0.05) mean
logistic-transformed lung score (mean lung score = 8.0) than the unvaccinated controls
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(n - 6) (mean lung score = 15.3) (Fig. 2.2) but there were no significant differences
detected among the 4 adjuvant groups.

20

15

Average
Goodwin
lungscore

10

5

0
Unvaccinated

Vaccinated

Fig 2.2: Graph showing average lung lesion scores at slaughter in 128 kDa fusion
protein vaccinated and unvaccinated pig groups after challenge with virulent M.
hyopneumoniae. The 128 kDa vaccine group represents the pooled mean of all
adjuvant groups. Standard error of the mean is indicated by vertical bars.

The significant reduction in the lung scores of vaccinated pigs led to the antigen
encoded by the plasmid pSD9 being considered as a candidate antigen for use in the
development of a live oral recombinant vaccine against M. hyopneumoniae.

37

2 .2

2.2.1

Materials and methods

Construction and identification of clones expressing a M
hyopneumoniae antigen

2.2.1. l

Bacterial strains, plasmids and media

Bacterial strains and plasmids used in the work described in this chapter are listed in
Table 2.1. All bacteria were grown in Luria Bertani broth (LB) (Sambrook et al, 1989)
or on Z agar medium (Walker et al, 1988). Antibiotics were used at the following
concentrations: chloramphenicol 50 pg/ml; ampicillin 100 pg/ml; kanamycin 50
pg/ml. For transformation experiments bacteria were grown overnight on Z agar with
appropriate antibiotic selection then subsequently seeded into 500 ml of selective LB
broth cultures, with selection, and grown at 37°C to mid log phase (ODgso = 0.5 - 0.6)
prior to harvesting by centrifugation (2000 x g for 15 min). Transformation of bacteria
was performed as described by Sambrook et al (1989).

2.2.1.2 Plasmid extraction
Plasmids were isolated by either the commercial QIAGEN 100 pg (Midi) plasmid
preparation kit or by phenol/chloroform small scale plasmid extraction. QIAGEN
extractions were carried out according to the manufacturer's instructions using the
supplied buffers. Phenol/chloroform extractions were carried out by growing a 10 ml
culture of bacteria containing plasmid overnight at 37°C in LB with selection. Cells
were pelleted at low speed in a 15 ml Falcon tube using a bench top centrifuge.
Pelleted bacteria were resuspended in 1 ml of 10 mM Tris (pH 8.5) containing 1 mM
EDTA (TE) buffer. These were then transferred to a 1.5 ml Eppendorf tube and
pelleted for 1 min at 12000 x g using an Eppendorf 5415C microfuge; all subsequent
spin steps were performed at 12000 x g using this microfuge model. The supernatant
was discarded and bacteria was resuspended in 0.4ml TE containing 15% sucrose
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Table 2.1: Plasmids and bacterial strains described within this chapter.
Bacterial Strains

Source and
Reference (where applicable)

M. hyopneumoniae strain J

A. Pointon. Adelaide, Australia.

M. hyopneumoniae strain C l735/2

Queensland Australia.
Scarman et al, 1997

M. hyopneumoniae strain YZ

M. Kobish. France.
Scarman et al, 1997

M. hyopneumoniae strain 232

T. Young. U.S.A.
Scarman et al, 1997

M hyopneumoniae Beaufort strain

Australian Mycoplasmal
Reference Collection.

M. hyopneumoniae strain Sue

If

M. hyopneumoniae strain OMZ407

It

M. hyorhinis strain GDL

ft

M. hyorhinis strain BTS7

It

M. hyorhinis field strain 1

fl

M. hyorhinis field strain 2

M

M. flocculare strain Ms42

It

Yanisch-Perron et al, 1985

E. coli JM109

Messier et al, 1987

E. coli MCI061 (pCI857)
Plasmids

Takeshita et al, 1987

pHSG398
pKFl

This study

*

Stanley and Luzio, 1984

pEXl-3

Dr Steven Djordjevic EMAI,
Camden. N.S.W. Australia.

pSD9

Janknecht et al, 1987

pQE-9-11

This study

pETEl
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(TES) and 1 mg/ml lysozyme (Sigma) then left at RT for 30 min. After incubation 0.3
ml of TE containing 0.1% Triton X-100 was added and tubes were inverted twice
prior to incubation at 65°C for 15 min. Cell debris were pelleted for 30 min at 12000 x
g. The supernatant was transferred into a new 1.5 ml tube and 0.5 ml of phenol
saturated TE was added and mixed. After centrifugation for 1 min the upper aqueous
layer was transferred to a clean Eppendorf tube and the phenol/TE step was repeated.
To the transferred aqueous layer, 1 ml of diethyl ether was added. Tubes were mixed
and centrifuged briefly prior to the transfer of the lower layer. A drop of 3 M sodium
acetate was subsequently added and the tubes vortexed prior to the addition of 2.5
volumes of chilled ethanol. The mixture was left for 5-10 min at -20°C then
centrifuged for 5 min. The ethanol was poured off and the pelleted plasmid DNA was
air dried before being resuspended in 50 pi of dH20 containing 20 pg/ml ribonuclease
A (Sigma) and incubated at 37°C for 30 min prior to use or storage at -20°C.

2.2.1.3

Bacterial chromosomal DNA isolation

Chromosomal DNA isolation from E. coli and S. typhimurium strains was performed
by phenol extraction, mycoplasma chromosomal DNA was kindly donated by A.
Scarman from EMAI. Bacteria was streaked for single colonies onto Z agar with
selection and grown at 37°C overnight, or to confluence, after which the growth was
transferred into 25 ml of 1 M NaCl in a sterile 50 ml centrifuge tube and shaken on ice
for one hour. After incubation on ice, cells were centrifuged at 12000 x g for 10 min
(Sorvall RC-5B superspeed centrifuge; SS-34 rotor). The pellet was resuspended in 25
ml of chilled TES buffer and the centrifugation step repeated. The supernatant was
poured off and the cells resuspended in 5 ml of chilled TE buffer containing lysozyme
(0.2 mg/ml) (Sigma) to degrade peptidoglycan and incubated for 15 min at 37°C.
After incubation, 0.6 ml of TE solution containing 10% sodium dodecyl sulphate
(SDS) and protease (5 mg/ml; Sigma) was added and the solution was incubated for 1
h at 37°C. Subsequently 5 ml of TE saturated phenol was added and the tube was
briefly shaken and centrifuged at 12000 x g for 10 min. The upper aqueous layer was
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transferred to a sterile 1.5 ml Eppendorf tube and a further phenol extraction step was
performed before 1 ml of diethyl ether was added to remove remaining phenol. The
tube was briefly vortexed and centrifuged at 16000 x g for 1 min in an Eppendorf
5415C microfuge after which the lower phase was transferred to a sterile 1.5 ml
Eppendorf tube and the diethyl ether step was repeated. To the transferred lower
phase, 50 pi of 3M sodium acetate was added and mixed well. The nucleic acids were
then precipitated by the addition of 2.5 volumes of ice cold ethanol followed by
centrifugation at 16000 x g in a microfuge for 5 min after which the supernatant was
poured off. The remaining pellet was air-dried then resuspended in 50 pi dH20
containing 20 pg/ml ribonuclease A.

2.2.1.4 Agarose gel electrophoresis
Agarose gel electrophoresis was used to detect and resolve DNA fragments using a
BioRad MiniSub DNA cell. A 5 pi aliquot of agarose gel loading buffer was mixed
with approximately 1 pg (5-10 pi) of DNA sample and loaded into the wells of a cast
agarose gel. The percentage of agarose was determined by the size of the fragment to
be resolved (0.7-1.5%). Electrophoresis was carried out at 50 V (constant voltage) for
an appropriate period of time. After running, the DNA was stained using 1 pg/ml
solution of ethidium bromide and visualised under ultraviolet light (UV
Transilluminator, UVP).

2.2.1.5 Electroelution of DNA from agarose gel
Prior to electroelution the restricted DNA was separated by agarose gel
electrophoresis and visualised. Agarose containing the fragment was excised and
placed in an Eppendorf tube with a small hole cut in the base. Parafilm was wrapped
around the sides of the tube, which was then secured firmly to the top of a Centricon
100 microconcentrator tube (Amicon). Both Eppendorf and Centricon tube were filled
with TAE buffer. The lower end of the Centricon was secured into a TAE buffer
reservoir containing a positive electrode, a circuit was completed by placing a
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platinum negative electrode wire into the open top of the tube. A current of 100 V was
passed through the apparatus for 30-120 min, depending on the fragment size, thereby
eluting the DNA fragment into the underlying Centricon tube. The Centricon tube was
then used according to the manufacturer’s instructions to purify and concentrate the
DNA down to a total volume of 50-100 pi in aqueous solution.

2.2.1.6 Southern hybridisation
DNA was analysed by Southern hybridisation (Southern, 1975). Restricted DNA was
resolved by agarose gel electrophoresis, visualised and photographed. The gel was
subsequently washed ( 2x10 min duration) in 0.25M HC1, to induce the breakdown of
large DNA fragments to assist in transfer, then rinsed briefly in water. The gel was
then washed (2 x 10 min) in 1.5M NaCl; 0.5M NaOH to denature DNA and
neutralised by washing ( 4x10 min) in IM Tris HCl; 1.5M NaCl. DNA was then wettransferred onto positively charged nylon membrane (Boehringer Mannheim) by
capillary transfer (Sambrook et al, 1989). Transferred DNA was bound to the
membrane by cross-linking for 3 min at 254 nm (UV Stratalinker 1800; Stratagene).
Probe DNA was a-32P dATP (Bresatec) labelled by nick translation using a nick
translation kit (Gibco BRL) following the manufacturer's instructions. The nylon
membrane was prehybridised for 6 h in prehybribisation solution at 65°C using a
mini-hybridisation oven (MK II, Hybaid). The denatured labelled DNA probe was
then added and hybridisation was carried for 6-12 h. This was followed by 2 washes
with 2x SSC containing 0.1% SDS at RT for 15 min, then 2 washes in O.lx SSC
containing 0.1% SDS at 65°C for 15 min. Membranes were subsequently exposed to
X-ray film (Kodak) at -80°C for 2-24 h prior to development.

2.2.1.8 DNA sequence analysis
The dideoxy chain termination method (Sanger et al, 1977) was performed on plasmid
pKFl using the T7 Sequenase kit (Pharmacia) following the instructions of the
manufacturer. The universal M l3 forward primer and M l3 reverse primer (Table 2.2)
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were used initially to sequence the 0.8 kb M. hyopneumoniae DNA fragment. Further
internal primers were synthesised (Table 2.2) after analysis of sequence data to allow
both strands of the M. hyopneumoniae DNA fragment to be completely sequenced.
Protein sequence comparisons were carried out using a Blast2 network service
provided by the National Center for Biotechnology Information (NCBI) accessed
through the Australian National Genomic Information Service (ANGIS, Australia).
Databases searched were the GenBank, SwissProt, PDB, EMBL and DDBJ databases.

2.2.1.9 PCR amplification
The PCR primers 5'-TTTGCCGAACCTTTTTACA-3' (primer 1469) (MUCAB,
Australia) and 5'-AATCAGCAATAAAATTTAGC-3' (primer 1470) (MUCAB,
Australia) were synthesised based upon data obtained from the cloned M.
hyopneumoniae DNA sequence spanning an internal 750 bp region. Purified plasmid
DNA, M. hyopneumoniae, M. flocculare or M. hyorhinis chromosomal DNA were
used as templates for the PCR. Amplifications were carried out in a final volume of
100 pi and contained 100 ng of template DNA; 200 pmol of primers 1469 and 1470; 6
mM MgCl2; 10 mM KC1; 20 mM Tris-HCl (pH 8.2); 0.1% Triton X-100, 6 mM
(NH4)2SC>4; dATP, dGTP, dCTP and dTTP (Boehringer Mannheim) at 2 mM each;
and 5 units of Pfu DNA polymerase (Stratagene). Parameters for amplification
consisted of 1 cycle at 96°C for 3 min (denaturation), 55°C for 1 min (primer
annealing) and 72°C for 1 min (extension) followed by 29 cycles of 96°C for 20 sec;
55°C for 20 sec; and 72°C for 30 sec with a final extension cycle at 72°C for 2 min.
Amplifications were conducted in a PCR thermal reactor (Hybaid). A 10 pi aliquot of
the reaction mixture was analysed on a 1% agarose gel and the PCR products were
stained with ethidium bromide and visualised under UV light.

43

Table 2.2: DNA primers used in the sequencing of the 0.8 kb M. hyopneumoniae
DNA fragment.

Primer

Sequence

Supplier

Forward M l3
Universal

5'-GTAAAACGACGGCCAGT-3'

Pharmacia

Reverse M l3
Universal

5'-TTCACACAGGAAACAGCTATGACC-3'

Biotech
International,
Australia

Internal reverse 1
(BamYll)

5’-GGATEG]ATCTATTATATAAACTAATIG-3’

ft

Internal forward 2
(Pstl)

5’-CIGCAGGATOCAAACDCACITnTTCAT-3 ’

tf

Internal forward 3

5’-TCGTCGATTTT GTAAAGCT G-3 ’

It

Internal reverse 4

5 ’-TTCAAAAGAGGAAACCGAA-3 ’

It

Internal reverse 5

5 ’-TGACTAAAAATTT CAGGTTC-3 ’

ft

Internal reverse 6

5’-TGTTCCTAATAATTC AAAAC-3 ’

2.2.1.10

ft

Construction of pKFl

The plasmid pKF 1 was constructed by subcloning the M. hyopneumoniae fragment of
pSD9 into the parental plasmid pHSG398 (Fig.2.3). The plasmids pHSG398 and
pSD9 were separately digested with the restriction enzymes Smal and Pstl, which cut
pHSG398 and released the M. hyopneumoniae DNA fragment from pSD9. After
ligation, the mixture was used to transform E. coli JM109 and subsequent
transformants were selected on Z agar containing chloramphenicol. A clone,
designated pKFl, expressed a recombinant 15 kDa protein, comprising the 11 kDa M.
hyopneumoniae antigen fused to 4 kDa of the LacZa protein encoded by the vector.
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fragm ent

Fig 2.3: Schematic representation of the steps involved in the construction of the
plasmid pKFl. The 0.8 kb M. hyopneumoniae DNA fragment was excised from the
plasmid pSD9 using the restriction enzymes Smal and Pstl and ligated into pHSG398
digested with Smal and Pstl. Plasmid pHSG398 is a high copy number vector
containing an origin of replication (oriR, filled box), chloramphenicol resistance gene
(Cm, open box), polylinker cloning site within the lacZa gene (LacZa, open box).
Plasmid pKFl contains the 0.8 kb M. hyopneumoniae DNA fragment (filled box)
ligated into the Smal and Pstl sites of the polylinker cloning site of pHSG398.

2.2.1.11 Construction of pETEl
To facilitate the rapid one-step purification of the recombinant antigen the M.
hyopneumoniae insert was cloned into the pQE expression vector system (Qiagen Inc,
Chatsworth, CA, USA) which allows for high level expression of histidine affinity45

tagged recombinant proteins in E. coli. Using pKFl as a template the 0.8 kb M.
hyopneumoniae insert was PCR amplified as described previously using the Internal
reverse 1 {Bam HI) and Internal forward 2 {Pst I) primers (Table 2.2) to amplify the
0.8 kb fragment. After amplification the fragment was analysed on a 1% agarose gel
and the PCR product was stained with ethidium bromide and visualised under UV
light. The fragment was electroeluted from the gel and ligated into the plasmid pCRII
using a TA cloning™ kit (Invitrogen) following the manufacturer’s instructions. One
plasmid construct containing the 0.8 kb fragment was designated pKFlO (Fig 2.4).
This TA cloning™ system was used as an intermediate step because it has been
developed to allow for the rapid and efficient cloning of PCR products into a plasmid
with lacZ colour selection. The constructed plasmid pKFlO was used to transform E.
coli JM109 which was grown either in LB or on Z agar plates with selection
(ampicillin 100 pg/ml and kanamycin 50 pg/ml) to recover large amounts of pKFlO.
No investigation was carried out to determine whether the recombinant antigen
encoded by the 0.8 kb M. hyopneumoniae insert was expressed in the E. coli JM109
(pKFlO) strain. The 0.8 kb fragment was released from isolated pKFlO DNA by a
single Bam HI restriction and ligated into the same enzyme site within the polycloning
site of the plasmid pQE9 (Qiagen Inc, Chatsworth, CA, USA). Constructed clones
were screened using colony hybridisation analysis to determine the presence of the 0.8
kb M. hyopneumoniae insert.

2.2.1.12 Colony hybridisation
Colony hybridisation was used to detect pQE9 clones containing the 0.8 kb M.
hyopneumoniae DNA fragment. Transformed colonies were replica plated onto Z agar
containing ampicillin, Z agar containing ampicillin and kanamycin and also onto
nylon membrane discs (Hybond-N+ transfer membrane discs. Amersham) laid on Z
agar containing ampicillin (100 pg/ml). Replica plates were grown overnight at 37°C.
After incubation the Z agar plates with selection were stored for future use at 4°C and
the nylon membranes were processed. The membrane was placed colony side upwards
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onto 2 sheets of filter paper saturated with 10% SDS for 3 min after which the
membrane was transferred onto filter paper saturated with denaturing solution (0.5 N
NaOH with 1.5 M NaCl) for 5 min and subsequently transferred onto filter paper
saturated with neutralising solution (0.5 M Tris (pH 7.4) with 1.5 M NaCl) for 5 min.
The nylon membrane was then placed onto filter paper saturated with dH20 for 5 min
after which the membrane was placed onto filter paper saturated with 2x SSC for 20
min, air-dried on a clean bench for at least 30 min then the membrane was baked for
10 min at 80°C. After baking, the membrane was treated as described in the Southern
hybridisation protocol, using the 0.8 kb M. hyopneumoniae fragment which was a-32P
dATP (Bresatec) labelled by nick translation using a nick translation kit (Gibco BRL)
following the manufacturer's instructions. Hybridised membranes were exposed to Xray film (Kodak) overnight and developed. Positive colonies were identified and
compared with the stored Z agar plates; if a positive was kanamycin resistant it was
ignored as a parental pKFlO plasmid. Once positive pQE derived clones (Fig 2.4)
were detected,

the

corresponding

colonies were examined using

Western

immunoblotting to detect expression of the 11 kDa recombinant protein.

2.2.1.13 Pre-absorption of 128 kDa fusion protein antiserum
To reduce the presence of antibodies against p-galactosidase, the rabbit 128 kDa
polyclonal antiserum (described in 2.1) was extensively preabsorbed against
commercially available p-galactosidase (Boehringer Mannheim). Three nitrocellulose
membranes (10 x 10 cm Transblot, BioRad) were impregnated with p-galactosidase
(100 mg/membrane) and air-dried. Rabbit 128 kDa fusion protein antiserum was
diluted 1:200 in phosphate buffered solution (PBS: pH 7.4) and exposed to the first
membrane for 1 h at room temperature (RT) followed by exposure to a second
membrane for 1 h at RT. The antiserum was then exposed to the third impregnated
membrane overnight at 4 C. The antiserum was subsequently collected and stored at o„

.

20 C prior to use.
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Fig 2.4.

Schematic representation of the steps involved in the construction of

the subclone pETEl, which encodes a recombinant histidine tagged 11 kDa protein.
The plasmid pCRII (Invitrogen) contains the lac promotor (P lac, filled arrow) which
directs expression of the lacZa gene (open arrow). This gene contains a polycloning
site in its 5’ region; the lacZa gene allows for blue/white screening of recombinant
constructs by a-complementation of (3-galactosidase. The plasmid also contains the
ampicillin resistance gene (shaded box), kanamycin resistance gene (open box) and an
origin of replication (ColEl ori, open box). The M. hyopneumoniae 0.8 kb DNA insert
(filled box) from the plasmid pKFl was PCR amplified and ligated into pCRII to
produce an intermediate plasmid pKFlO. This plasmid was recovered from E. coli
JM109 and the 0.8 kb fragment was excised with a single BamHl restriction. The
fragment was inserted into the same enzyme site of pQE9 (Qiagen) and a positive
construct was identified and designated pETEl. The parental plasmid pQE9 contains
the T5 phage promotor (Promotor, open box) and two lac operator sequences which
control expression of DNA fragments ligated into the polycloning site (open box). A 6
histidine coding sequence (6xHistidine tag, filled box) is immediately 5’ of the
polycloning site. Immediately 3’ of the poly cloning region there are translational stop
codons in all reading frames as well as a X-phage transcriptional terminator. Also
present are the amplicillin resistance gene (shaded box) and an origin of replication
(Origin, open box). The plasmid pETE contains the M. hyopneumoniae 0.8 kb DNA
insert (filled box) which is expressed as a histidine-tagged 11 kDa protein in the host
strain

coli JM109.

lacZa

M. hyopneumoniae
0.8 kb DNA insert
Amp icillin
Kanamycin

P lac

Mycoplasma DN/
fragm ent

ColEI ori

lacZa
Ampicillin

P ro motor
6xHistidine
tag
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2.3

2.3.1

Purification of expressed recombinant antigens

Preparative PAGE purification of recombinant 15 kDa antigen

Purified 15 kDa antigen was used for the preparation of rabbit antiserum. Antigen was
purified using SDS-polyacrylamide preparative column electrophoresis according to
the method described by Djordjevic et al (1994) Briefly, a 6 cm 15% polyacrylamide
matrix was used for the resolving phase which was overlaid with a 1 cm 4% stacking
gel. Bacterial culture containing the recombinant antigen was harvested, reduced with
boiling for 10 min in splitting solution (60 mM Tris-HCl, 1% SDS, 1% Pmercaptoethanol, 10% glycerol and 0.01% bromophenol blue) and fractionated using
a 491 PrepCell column (37 mm internal diameter) (BioRad). Fractions (10 ml) were
routinely monitored for the elution of the recombinant protein by Western blotting
using rabbit anti-128 kDa fusion protein serum (supplied by Dr. S.P. Djordjevic).
Samples containing the 15 kDa recombinant antigen were pooled and concentrated by
ultracentrifugation using an ultrafiltration cell according to the manufacturers
instructions (model 8050, Amicon).

2.3.2

Raising of rabbit antiserum specific for 15 kDa antigen

Rabbit antiserum was raised against the 15 kDa recombinant protein expressed by
pKFl for use in Western immunoblot and ELISA techniques. Purified 15 kDa antigen
was emulsified with Freund's complete adjuvant and subcutaneously administered at 4
sites (0.25 ml/site) into a single New Zealand white rabbit (25 pg/rabbit) after pre
immunisation bleeds indicated that no cross-reactive antibodies to the antigen were
present. A booster injection containing 15 kDaNrdF antigen (25 pg/rabbit) emulsified
with Freund's incomplete adjuvant was administered 2 weeks after the primary
vaccination and the rabbit was sacrificed two weeks post booster and serum collected.
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2.3.3

Desalting and concentration of recombinant protein

Purified recombinant proteins were concentrated and resuspended in PBS using a
Centriprep

10 concentrator tube (Amicon, USA) in accordance with the

manufacturer's instructions. Tubes containing 15 ml of sample were spun at 2000 x g
for 10 min after which the supernatant was poured off and the concentration step
repeated. Samples were reduced to a volume of less than 1 ml then made up to 15 ml
with sterile PBS. This process was repeated 2-4 times to remove detergents and salts.
Centriprep 10 concentrators have a molecular weight exclusion limit of 10 kDa
allowing for concentration of the 15 kDa and 11 kDa recombinant proteins expressed
by pKFl and pETEl respectively.

2.3.4

SDS-PAGE and Western blot analysis

Recombinant proteins were analysed by reducing SDS-PAGE (Laemmli, 1970) using
the BioRad Protean II mini gel system in accordance with the manufacturer’s
instructions. The percentage polyacrylamide in the gel varied according to the proteins
being resolved (10-20%). All gels were run at a constant 70 V until the dye front was
eluted (2-4 h). Western blotting was carried out essentially as described by Burnette
(1981). Proteins were transferred onto nitrocellulose membranes with a semi-dry
TransBlot SD transfer cell (BioRad). The gel and nitrocellulose were equilibrated for
15 min in transfer buffer. Transfer buffer was used to saturate 5 Whatman (No.l) filter
papers ( 1 0 x 7 cm) which were laid carefully to avoid air bubbles onto the negative
electrode of the transfer cell. Nitrocellulose membranes (TransBlot, BioRad) were
then placed on top of the filter papers, followed by the gel which was then covered by
another 5 Whatmann filter papers saturated in transfer buffer. The positive electrode
was installed and the transfer conducted at 15 V for 20 min. Transferred immunoblots
were blocked for 1 h at RT using PBS containing 10% powdered low fat skim milk
(Carnation) and 0.1% Tween 20. Blots were subsequently reacted for 1 h at RT with
rabbit 128 kDa fusion protein antiserum diluted 1:200 in PBS which was pre-absorbed
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against p-galactosidase as described previously. The blots were washed (3 x PBS)
prior to the addition of 1.200 diluted goat anti-rabbit horse-radish peroxidase
conjugated second antibody (BioRad) which was incubated for 1 h at RT. Blots were
then washed and developed using 4-chloro-l-napthol (BioRad).

2.3.5

Subunit ELISA profiling of M. hyopneumoniae antigens

A subunit ELISA profiling technique (Scarman et al, 1997) was used to determine the
molecular weight of the M. hyopneumoniae wild type protein from which 11 kDa
recombinant protein component was derived. Whole M. hyopneumoniae strain J cells
were centrifuged (10 000 x g for 15 min) and 10 mg of cell pellet was reduced with
boiling for 10 min in SDS-PAGE splitting buffer. To aid loading of the sample and
determine the sample collection point, bromophenol blue (0.001%) was added to the
lysate. The sample was loaded onto a 9% preparative (37 mm internal diameter) SDSPAGE resolving column (491 PrepCell, BioRad) containing a 4% stacking gel, and
electrophoresed at 40 mA constant current (150-250 V). Fractions (8.5 ml) were
collected after the bromophenol blue dye front was eluted (Djordjevic et al, 1994).

M. hyopneumoniae protein fractions were diluted 1:10 in ELISA coating carbonate
buffer. Aliquots of 100 pi were then added in duplicate to 96 well microtitre plates
(Nunc) and incubated for 1 h at 37°C. Plates were subsequently washed 5 times with
0.05% Tween 20 (Sigma) in PBS. A 100 pi sample of rabbit 128 kDa fusion protein
antiserum (pre-absorbed against B-galactosidase) diluted 1:200 in PBS containing
10% normal goat serum and 0.05% Tween 20 was added and plates were incubated
for 2 h at 37°C. After washing the plates five times with 0.05% Tween 20, 100 pi of
horse-radish peroxidase conjugated goat anti-rabbit antibodies (Bio Rad) diluted
1:2000 in PBS containing 10% goat serum and 0.05% Tween 20 was added to each
well. Plates were incubated at 37°C for 1 h then washed 5 times with 0.05% Tween 20
in PBS. ELISA plates were developed using 100 pi of 1 mM 2,2-azino-diethylbenzthiazolin-sulfonate (Sigma) diluted in carbonate buffer (0.15% sodium
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bicarbonate and 0.29% sodium carbonate pH 4.2) and absorbance was read at 405 nm
using a BioRad plate reader (model 3550, BioRad).

2.3.6

M. hyopneumoniae whole cell ELISA

The accessibility of the native antigen on the surface of intact M. hyopneumoniae
cells was examined using whole cell ELISA. Unless otherwise stated these assays
were carried out as described in the previous section (2.3.5) with the following
modifications. The primary antigen was 100 pi M. hyopneumoniae whole cell
suspension (0.03 A650 units) in 0.20 mM Tris-HCl (pH 7.2) containing 10%
methanol. Cells were coupled to 96 well microtitre plates (Linbro) by centrifugation
(2000 x g for 30 min). After coupling the supernatant was removed and wells were
blocked using 200 pi of 2% skim milk in PBS for 1 h at RT.

2.3.7

M. hyopneumoniae growth inhibition assay

Growth inhibition assays were carried out using a procedure modified from that
described by Stanbridge and Hayflick (1967). Viable M. hyopneumoniae strain J cells
were spread onto modified Friis medium containing 1.5% Noble agar (Friis, 1971)
and air-dried briefly under sterile conditions. Sterile paper discs (25 mm) were
impregnated with 40 pi of undiluted antiserum and placed onto the surface of the
seeded agar. Plates were incubated for 4 days at 37°C, with an additional 20 pi of
undiluted antiserum being added to each disc daily. After incubation the plates were
examined microscopically for zones of clearance, and subsequently stained with R250
Coomassie brilliant blue (0.1% in 40% methanol and 10% acetic acid). The period of
staining was sufficiently brief to prevent staining of the underlying agar. Excess stain
was removed by washing with destaining solution (40% methanol and 10% acetic
acid).
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2.3.8

Purification of 6xHis-tagged 11 kDa recombinant antigen

Affinity chromotography was performed using TALON™ metal affinity resin
(Clontech laboratories, CA, USA). E. coli JM109 transformed with pETEl was grown
overnight in a 500 ml LB culture with ampicillin (100 pg/ml) at 37°C. A smaller 200
ml LB culture with antibiotic selection was subsequently seeded from the overnight
culture and grown to mid logarithmic phase (OD 0.6) before cells were induced with
10 mM IPTG. Cells were grown until the end of logarithmic phase (approximately
OD 1) then cells were harvested and lysed by gentle vortexing in 45 ml of 0.01M
Tris/HCl (pH 8) containing 8M urea and 0.1 M NaH2P 04 for 10 min. Cell debris was
pelleted at 4000 x g for 10 min and the supernatant containing the His-tagged protein
was decanted into a sterile 50 ml Falcon tube. Into this supernatant, 4 ml of a 50%
Talon Ni-NTA resin slurry was added and incubated for 30 min at room temperature.
After incubation the affinity resin with bound proteins was pelleted at 4000 x g for 10
min, then resuspended in 45-50 ml of wash buffer (Tris/HCl pH 6.3 containing 8M
urea and 0.1M NaH2P 04) and subsequently pelleted (4000 x g for 10 min). This
washing step was repeated three times. After washing, the pellet was incubated in 20
ml of wash buffer containing 0.5 M imidazole for 3 min at room temperature which
released bound proteins by competitive interaction. Resin was separated from the
released protein by a brief centrifugation (4000 x g for 5 min) and eluted proteins were
then pooled and concentrated to 140 pg/ml in PBS (pH 7.2) using a Centriprep 10
concentrator (Amicon, USA).
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2.4

2-4.1

RESULTS
Expression of recombinant 128 kDa fusion protein in E. coli

After transformation of E. coli MCI061 (pCI857) with the plasmid pSD9,

the

positive recombinant clone was induced at 42°C for 2 h, lysed and screened by
Western immunoblotting for expression of the plasmid-encoded recombinant fusion
protein using porcine hyperimmune serum raised against M. hyopneumoniae (prepared
by Dr S.P. Djordjevic and G. J. Eamens).

The strain expressed a 128 kDa fusion protein which was recognised strongly by the
hyperimmune serum. This protein consisted of p-galactosidase (117 kDa) and a
recombinant M. hyopneumoniae protein (11 kDa) (Fig 2.5 A, lane 3). The E. coli
MCI061 (pCI857, pEXl) strain expressed only the P-galactosidase component (Fig
2.5 A, lane 2) which was not recognised by the porcine serum (Fig 2.5 B, lane 2). The
128 kDa fusion protein encoded by pSD9 was purified and used to generate rabbit
polyclonal antiserum for immunological analysis. The antiserum reacted strongly
against the 128 kDa protein (Fig 2.6 B, lanes 3 and 4). Immunoreactive bands
identified below the recombinant 128 kDa fusion protein in lanes 3 and 4 (Fig 2.6 B)
are most likely due to the presence of breakdown products of the recombinant fusion
protein. The pre-absorbed antiserum was used to profile the ELISA reactivity of M.
hyopneumoniae proteins separated by SDS-PAGE on a preparative 9% PrepCell
column (Fig 2.7 A and B). This antiserum was also used to probe immunoblots
containing M. hyopneumoniae whole cell extracts and fractions eluted from the
PrepCell column. In both size fractionated (Fig 2.7 C and D) and whole cell
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Fig 2.5: Expression and identification of proteins recognised by porcine M.
hyopneumoniae hyperimmune serum. A. Coomassie brilliant blue stained 11%
polyacrylamide gel. Lane 1, MC1061 (pCI857); lane 2, MC1061 (pCI857, pEXl)
(induced); lane 3, MCI061 (pCI857, pSD9) (induced); lane 4, whole cell extract of M
hyopneumoniae strain J. Positions of molecular weight standards (in kDa) are indicated
on the left of the gel. The 117 kDa (3-galactosidase and recombinant 128 kDa fusion
protein are indicated by an arrow. B. Western immunoblot analysis of equivalent protein
samples described in Fig 2.5A using porcine M. hyopneumoniae hyperimmune serum.
The sizes of molecular weight markers (in kDa) are indicated on the left.
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Fig 2.6: Expression and identification of the M. hyopneumoniae 128 kda fusion protein
encoded by the plasmid pSD9. A. Coomassie brilliant blue stained 11% polyacrylamide
gel. Lane 1, MC1061 (pCI857); lane 2, MC1061 (pCI857, pEXl) (induced); lane 3,
MC1061 (pCI857, pSD9) (induced); lane 4, purified 128 kDa fusion protein; lane 5, whole
cell extract of M. hyopneumoniae strain J. Positions of molecular weight standards (in
kDa) are indicated on the left of the gel. The recombinant 128 kDa fusion protein is
indicated by an arrow. B. Western blot analysis of equivalent protein samples described in
Fig 2.6A using rabbit 128 kDa fusion protein antiserum. The sizes of molecular weight
markers (in kDa) are indicated on the left of the blot. The 42 kDa wild type protein present
in M. hyopneumoniae whole cell extract is indicated by an arrow.
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Fig 2.7: Identification of the 42 kDa M. hyopneumoniae wild type protein using
ELISA and Western immunoblotting to detect the protein in fractionated M
hyopneumoniae strain J. A. Coomassie brilliant blue stained 15% polyacrylamide gel.
Lanes 1-6 correspond to M. hyopneumoniae strain J protein fractions 6-11 eluted after
separation using a 9% preparative SDS-PAGE polyacrylamide gel column. B. ELISA
profile of fractionated M. hyopneumoniae strain J whole cell extracts showing ELISA
positive peaks in fractions 8 and 9. C. Coomassie brilliant blue stained 11%
polyacrylamide gel. Lane 1, purified recombinant 128 kDa fusion protein; lane 2,
ELISA positive peak 8; lane 3, ELISA positive peak 9. The sizes of molecular weight
markers (in kDa) are indicated on the left of the gel. D. Western blot analysis of
equivalent protein samples described in Fig. 2.7A using rabbit 128 kDa fusion protein
antiserum. The 42 kDa wild type protein present in M. hyopneumoniae purified
fraction is indicated by an arrow on the right of the blot.
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Fig 2.8: Expression and identification of proteins recognised by rabbit P-galactosidase
antiserum.

A.

Coomassie brilliant blue stained 11% polyacrylamide gel. Lane 1, NCI061

(pCI857); lane 2, MC1061 (pCI857, pEXl) (induced); lane 3, MC1061 (pCI857, pSD9)
(induced); lane 4, whole cell extract o fM hyopneumoniae strain J. Positions of molecular
weight standards (in kDa) are indicated on the left of the gel. The recombinant 128 kDa
fusion protein is indicated by an arrow. B. Western immunoblot analysis of equivalent
protein samples described in Fig 2.8A using rabbit P-galactosidase antiserum. The sizes of
molecular weight markers (in kDa) are indicated on the left of the blot The recombinant
128 kDa fusion protein is indicated by an arrow.
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M hyopneumoniae protein preparations (Fig 2.6, lane 5) a single 42 kDa protein was
identified using both Western blot analysis and ELISA (Fig 2.7 B). The specificity of
the 42 kDa protein in the Western blot was shown to be due to the M. hyopneumoniae
component of the fusion protein as no cross reactivity was found using rabbit Pgalactosidase antiserum (prepared by Dr S.P. Djordjevic and G. J. Eamens) against
any M. hyopneumoniae protein (Fig 2.8 lane 4). The predominant protein band
recognised by the P-galactosidase antiserum is a 68 kDa protein found in all lanes
which contain E. coli MCI061 (pCI857) extracts. Cross-reactivity against Pgalactosidase was removed by extensive preabsorption with p-galactosidase
impregnated nitrocellulose (compare Fig 2.6, lane 1 and Fig 2.8, lane 1). However, the
pEXl encoded 117 kDa P-galactosidase protein (Fig 2.6 B, lane 2) was still
recognised indicating that epitopes encoded by the polycloning site are being
recognised.

2.4.2

Expression of recombinant 15 kDa protein encoded by the
plasmid pKFl

The plasmid pKFl(Fig 2.3) was constructed by excising the 0.8 kb M. hyopneumoniae
DNA fragment from pSD9 (Fig 2.1) and ligating it into pHSG398 to produce pKFl
(Fig 2.9). The recombinant DNA fragment is fused to the amino-terminal region of the
lacZa gene and consequently encodes a much smaller recombinant protein than the
128 kDa fusion protein expressed by the plasmid pSD9. After transformation of E.
coli JM109 with pKFl, a 15 kDa recombinant protein was identified by Western
immunoblotting using rabbit 128 kDa fusion protein antiserum (Fig 2.10). There are
two reactive protein bands in the 15 kDa region, these proteins were N-terminally
sequenced (results not shown) and were determined to be identical. This doublet could
be due to folding of the protein, or cleavage of COOH terminal amino acids. The
larger 15 kDa protein was purified using preparative SDS-PAGE columns and used as
antigen to raise rabbit anti-15 kDa polyclonal antibodies. This protein consists of 4
kDa
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Fig 2.9:

Southern hybridisation analysis of plasmids pKFl and pSD9 using M

hyopneumoniae 0.8 kb DNA fragment insert as a probe. A. Ethidium bromide stained 1%
agarose gel. All plasmids were double digested using the restriction enzymes Pstl and
Smal. Lane l, pKFl; lane 2, pSD9; lane 3, pEXl; lane 4, pHSG398. DNA markers (in
kb) are indicated on the left of the gel. B. Southern blot hybridisation analysis of the
equivalent plasmid digests. DNA markers (in kb) are indicated on the left of the blot.
Arrow indicates 0.8 kb fragment.
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Expression and identification of M hyopneumoniae 15 kDa recombinant

antigen in E. coli JM109. A. Coomassie brilliant blue stained 15% PAGE gel. Lane 1, E.
coli JM109; Lane 2, purified recombinant 15 kDaNrdF antigen. Lane 3, E. coli JM109
(pKFl). Positions of molecular weight standards (in kDa) are indicated on the left of the
gel. B. Western blot analysis of identical samples described above using rabbit 128 kDa
fusion protein antiserum. The recombinant 15 kDa protein is indicated by an arrow on the
right of the blot.
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encoded by the lacZa gene of pHSG398 and 11 kDa from the carboxyl terminal
region of the 42 kDa M. hyopneumoniae NrdF protein.

2*4.3

Nucleotide sequence analysis of M. hyopneumoniae DNA
fragment

The complete nucleotide sequence was obtained for both strands of the M.
hyopneumoniae 0.8 kb DNA fragment using the plasmid pKFl as a sequencing
template (Fig 2.11 A). The sequence length was found to be 819 nucleotide base pairs
with a G.C. content of 30.0% which is typical of mycoplasmal genomes (Herrmann,
1992). Translation analysis of the 0.8 kb sequence revealed the presence of three open
reading frames designated ORF1, ORF2 and ORF3 respectively (Fig 2.11 B).

The conserved 8 nucleotide sequence 5'-ATTGGGAG-3' is present 7 nucleotides
upstream of the ATG methionine start codon of ORF2 and ORF3. In both cases the
intervening sequence is composed exclusively of A and T residues indicative of
mycoplasma ribosome binding sites (Taschke, 1987). The putative ribosome binding
site of ORF2 overlaps the carboxyl-terminus of NrdF. The length of ORF2 is 150
amino acids with a region of dyad symmetry 23 nucleotides downstream of the TAA
stop codon. ORF3 is incomplete at the carboxyl-terminus, and is comprised of only 8
amino acids, however, the presence of the conserved putative ribosome binding
sequence and its relative position indicates that this is the beginning of a new open
reading frame. A putative -10 promoter sequence (5'-TATAAT-3') was also observed
33 nucleotide base pairs upstream of the ATG start codon ORF3 (Fig. 2.11 A). As for
the rrn promotor of M. hyopneumoniae, a -35 consensus sequence was not found
upstream of the ORF3 -10 sequence (Taschke, 1987). Amino acid comparisons were
made between predicted translated products for all three open reading frames and
proteins deposited in the GenBank, SwissProt, PDB, EMBL and DDBJ databases
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Fig 2.11:

DNA sequence analysis of the cloned 0.8 kb M hyopneumoniae

chromosomal DNA fragment. A. Diagrammatic representation of the strategy used to
obtain the nucleotide sequence of the 0.8 kb M. hyopneumoniae DNA fragment
(shaded). Filled arrows indicate the position of open reading frames, the first of which
contains sequence similarity to the nrdF gene of S. typhimurium. Thin arrows indicate
the extent of the sequence reaction from synthesised oligonucleotide primers. Scale is
given in kilobases. The open arrows indicate the position of putative M
hyopneumoniae ribosome binding sites whilst the keyhole symbol indicates the
presence of inverted repeats. B. Nucleotide sequence of the M. hyopneumoniae DNA
fragment. Three open reading frames are given using three letter amino acid codes.
Underlining denotes the conserved 8 nucleotide sequence which is 7 bases upstream
of the ATG start codons. Dashed arrows above sequence indicate an inverted repeat.

nrdF

0RF2

0RF3

Forward primers

Reverse primers
0

200

400

600

B

800 bp
50

GAT CTA TTA TAT AAA CTA ATT GAA TTA GAA AAA GAT TAT CTC TAT GAT TTA TAT
Asp Leu Leu Tyr Lys Leu Ile Glu Leu Glu Lys Asp Tyr Leu Tyr Asp Leu Tyr
100

•

TCT GAA GTT GGA CTT GCT GAA TCA GCA ATA AAA TTT AGC ATT TAT AAT GCC GGG
Ser Glu Val Gly Leu Ala Glu Ser Ala lie Lys Phe Ser lie Tyr Asn Ala Gly
150

•

AAA TTC TTG CAA AAT CTA GGA TAT GAT TCA CCT TTT TCA AAA GAG GAA ACC GAA
Lys Phe Leu Gin Asn Leu Gly Tyr Asp Ser Pro Phe Ser Lys Glu Glu Thr Glu
200

•

ATT GAA CCT GAA ATT TTT AGT CAA TTA TCG GCT CGA GCT GAT GAA AAT CAT GAC
He
Glu Pro Glu
He Phe Ser Gin Leu Ser Ala Arg Ala Asp Glu Asn His Asp
250

•

TTT TTT TCA GGA AAT GGC TCT TCT TAT GTA ATG GCG CTT GCT GAA GAA ACC GAA
Phe Phe Ser Gly Asn Gly Ser Ser Tyr Val Met Ala Leu Ala Glu Glu Thr Glu
300

'

GAT GAA GAT TGG GAG TTT TAA A ATG ACA AAT GAT GAA AAA TAT GAT ATA ATA
Asp Glu Asp Trp Glu Phe Stop
Met Thr Asn Asp Glu Lys Tyr Asp Ile
He
350

•

AAC AAA TCT AAA TTA AGA GGA GAA ATT TTT GTT GTT TAT TTT TCC TCA ATT TCG
Asn Lys Ser Lys Leu Arg Gly Glu He Phe Val Val Tyr Phe Ser Ser He Ser
400

•

AAT AAT ACC CAT CGG TTT GTC GAA AAA TTA AAC TTT GAA AAA GCA AGA ATT CCT
Asn Asn Thr His Arg Phe Val Glu Lys Leu Asn Phe Glu Lys Ala Arg He Pro
450

.

GTT GAG ATT GAC CAA GAA TTA GTA GTT GAT AAA GAT TAT GTA CTT TTT TGT CCA
Val Glu He Asp Gin Glu Leu Val Val Asp Lys Asp Tyr Val Leu Phe Cys Pro
500

.

ACT TAT AGT GGC GGG AAA GGT CTA AGA AGT GGG GCT GTC CCA AAA CAG GTA
Thr Tyr Ser Gly Gly Lys Gly Leu Arg
Ser Gly Ala Val Pro Lys Gin Val
550

’

"

'

’

-

.

ATA AAA TTT TTA AAC AAT GAA CAA AAT CGT CGA TTT TGT AAA GCT GTA ATC GCT
He
Lys Phe Leu Asn Asn Glu Gin Asn Arg Arg Phe Cys Lys Ala Val He Ala
600

‘

~

'

TCT GGA AAC ACT AAT TTT GGC GAT ACT TTT GCG CTT GCA GGC ACA ATT ATT TCC
Ser Gly Asn Thr Asn Phe Gly Asp Thr Phe Ala Leu Ala Gly Thr He He Ser
.

650

'

CAA AAA TTA AAA GTT CCT TTT TTA TAT AGT TTT GAA TTA TTA GGA ACA AAT GAT
Gin Lys Leu Lys Val Pro Phe Leu Tyr Ser Phe Glu Leu Leu Gly Thr Asn Asp
.

700

GAT GTA AAA AAG GTT CGG CAA ATT TTA GAA GAT TTT TGA GGA AAA TAA
Asp Val Lys Lys Val Arg Gin He Leu Glu Asp Phe Trp Gly Lys Stop
750

------------------------------- >

< -------------------------------

GCTAA AAAAT AATGA ATATA AT AGT TAGTT CGCTA ACTAA ATTGG GAGAA
800

AATAA ATG AAA AAA GTG GGT TTG GAT C
Met Lys Lys Gly Cys Asp Val
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u

189

MhyoO .8 :DLLYKLIELEKDYLYDLYSEVGLAESAIKFSIYNAGKFLQNLGYDSPFSKEETEIEPEIFSQL
Mpn RR2 :DL+Y+LIELEK.Y L .+LY...G + .E .AIKFSIYNAGKFLQNLGYDSPF++EET.I+PEIF+QL
MgenRR2 :+L+Y+LIELEKDYL.+LY...G + .+.AIKFS+YNAGKFLQNLGYDSPF+..E T .I+PEIF+QL
MtubRR2 :+LL++L.+ .E .+ Y . .D LY.EVGL.E ...K F ..Y NA.K.L.NLGY++.F .++ET++.P .I .S .L
EcoliRR2:DLL.+ L .+.E ..Y . .+LY+E...A + ....F ..Y N A .K .L .NLGY+..F..E..E+.P.I.+.L
StypRR2 :DLL.+ L .+ .E . .Y. ..LY+E.G ...... F. .Y NA.K .L .NLGY++.F ..E..++.P.I. + .L
Bsub RR2:DLL.+ L .E .E .+ Y ..D LY.+VGL+....K F ..Y NA.K .L .NLG+D..F .+E+..........
190

288

MhyoO.8 :SARADENHDFFSGNGSSYVMALAEETEDEDWEF
Mpn RR2 :SARADENHDFFSGNGSSYVM.++EETED+DW+F
MgenRR2 :SARADENHDFFSGNGSSYVM.++EET.D+DW.F
MtubRR2 :S A ..DENHDFFSG+GSSYV+..A..TED+DW+F
EcoliRR2:SA..DENHDFFSG+GSSYVM..A .ETEDEDW.F
StypRR2 :SA ..DENHDFFSG+GSSYVM....ETEDEDW.F
Bsub RR2:.... ++HDFFS..G + .Y ....A .E.+D+D+.F

Fig 2.12: Results of the predicted protein similarity search for ORF1 of the 0.8 kb M.
hyopneumoniae DNA fragment. Amino acids are given as one letter codes. Identical
amino acids are capitals, conserved amino acids are given as (+) symbols and variant
amino acids are indicated as (.) symbols. DNA sequences were compared using the
Blast 2 network service provided by the National Center for Biotechnology
information searching the GenBank, SwissProt, PDB, EMBL and DDBJ databases.
Amino acid sequence designations are as follows: MhyoO.& : M. hyopneumoniae 0.8
kb ORF1 (underlined), overlying numbers indicate the predicted position (in bases)
from the start of the 0.8 kb DNA fragment; Mpn RR2 : M. pneumoniae
ribonucleotide reductase 2; MgenKR2 : M. genitalium ribonucleoside-diphosphate
reductase (NrdF homolog); MtubKR2 : M. tuberculosis ribonucleotide reductase
(NrdF homolog); EcoliRR2 : E. coli ribonucleoside-diphosphate reductase (NrdF
homolog); ¿frypRITZ : S. typhimurium ribonucleoside-diphosphate reductase (NrdF
homolog); Bsub RR2 : B. subtilis ribonucleoside-diphosphate reductase (NrdF
homolog). Accession numbers and references for these amino acid sequences are
given in Table 2.3.
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using a Blast2 network service provided by the NCBI. The predicted ORF1
translational product shows similarity to a number of ribonucleoside-diphosphate
reductase small subunit proteins (NrdF homolog) (Fig 2.12). A summary table of the
percentage similarity for these comparisons is given in Table 2.3.
Table 2.3: Table summarising the results of a Blast2 similarity search of ORF1.
Comparisons were made between predicted translated products of ORF1 and predicted
protein sequences deposited in the databases searched.

Organism

Accession
number

Identical amino
acids

Conserved
amino acids

Reference

M. pneumoniae

AE000050

78%

90%

Himmelreich et
al, 1996

M. genitalium

U39701

73%

87%

Peterson et al,
1993

Mycobacterium
tuberculosis

z83866

56%

71%

Cole et al, 1996

E. coli

X52693

54%

63%

Gowrishankar,
1989

S. typhimurium

X73226

51%

61%

Jordan et al,
1994

B. subtilis

z68500

50%

65%

Scotti et al,
1996

The open reading frame ORF1 was subsequently designated nrdF due to the
significant predicted amino acid similarity the sequence has to a number of nrdF
homologs. The nrdF reading frame is incomplete at the 5' end, indicating that the gene
encodes the carboxyl-terminus of the NrdF protein. This open reading frame is read in
frame with the P-galactosidase protein encoded by pSD9 to produce the 128 kDa
fusion protein, now designated the 128 kDa NrdF fusion protein. This open reading
frame in the plasmid pKFl is read in frame with DNA encoding 4 kDa of the
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polycloning site to produce a recombinant 15 kDa NrdF protein. In both plasmids,
pSD9 and pKFl, this M. hyopneumoniae open reading frame is 96 amino acids in
length ending with a TAA stop codon. A region of dyad symmetry which may act as a
transcriptional terminator was not found downstream of nrdF, suggesting that nrdF
and ORF2 may be organised in an operon.

Predicted amino acid similarity comparisons (Blast2 network service. NCBI) for the
ORF2 and proteins deposited in the GenBank, SwissProt, PDB, EMBL and DDBJ
databases found similarity between predicted proteins of unknown function in a
number of organisms (Fig 2.13). A summary table of the percentage similarity for
these comparisons is given in Table 2.4.

Table 2.4. Table summarising the results of a Blast2 similarity search of ORF2.
Comparisons were made between predicted translated products of ORF2 and predicted
proteins deposited in the databases searched.
Organism

Accession
number

Identical amino
acids

Conserved
amino acids

Reference

M. pneumoniae

AE000050

64%

81%

Himmelreich et
al, 1996

M. genitalium

U39701

65%

79%

Peterson et al,
1993

Mycobacterium
tuberculosis

z83866

58%

71%

Cole et al, 1996

Escherichia
coli

D90891

51%

72%

Gowrishankar,
1989

Salmonella
typhimurium

X73226

52%

71%

Jordan et al,
1994

Bacillus
subtilis

z68500

51%

72%

Scotti et al,
1996
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Fig 2.13: Results of the predicted protein similarity search for ORF2 of the 0.8 kb M
hyopneumoniae DNA fragment. Amino acids are given as one letter codes. Identical
amino acids are capitals, conserved amino acids are given as (+) symbols and variant
amino acids are indicated as (.) symbols. DNA sequences were compared using the
Blast 2 network service provided by the National Center for Biotechnology
information searching the GenBank, SwissProt, PDB, EMBL and DDBJ databases.
Amino acid sequence designations are as follows: MhyoO.S : M. hyopneumoniae 0.8
kb ORF2 (underlined), overlying numbers indicate the predicted position (in bases)
from the start of the 0.8 kb DNA fragment; Mpne MG : M. pneumoniae MG230
homolog; Mgen MG : M. genitalium MG230; Mtub : Mycobacterium tuberculosis
unknown; StyOKFB : Salmonella typhimurium NrdEF operon ORFB; Ecoli : E. coli
ORF in the NrdEF operon; Bsubt:: Bacillus subtilis ORF in the NrdEF operon.
Accession numbers and references for these amino acid sequences are given in Table
2.4.

MhyoO .8 :MTNDEKYDMMNKSKLSGEIFWYFSSISNNTHRFVEKLNFEKASIPVEIDQELWDKDYVLFCP
Mpne M G : ............ K. .G. .+WYFSSISNNTHRF+EKL .FE ..RIPV.+D++ + .V+++YVLFCP
Mgen M G : ................G. .F+VYFSSISNNTHRF+EKL.F + ..RIPV+I.Q .+ .V . .+YVL.CP
Mtub

:..................................................................

StyORFB:..................................................................

Ecoli

:.................................................................

Bsubt

:..................... + .F .S .+ .N . .R FV.K. .F++ .R .. .E+D..............

485
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MhyoO .8 : TYSGGKGLSSGAVPKOVMKFLNNEONRRFCKAVIASGNTNFGDTFALAGTIISOKLKVPFLYS
Mpne MG : TYSGG....SGAVPKQVI.FLNN+.N R ..C + .VI +SGNTNFG+TFA+AG.I+S+KL.V P .L Y .
Mgen MG : TYSGG.... GAVPKQVI+FLNN+ .NR ..C+ .VIASGNTNFGDTF .LAGT+IS+KL .VP .L Y .
Mtub

: ......... G .VPKQVI.FLNN+.N R ...+ .VIA+GNTNFG ..F. .AG.++S+K. .VP+LY.

StyORFB:

..SGG....+GAVP+QVI+FLN+E.N R ...+.VIASGN.NFGD.+..AG.+I+QK..VP+LY.

Ecoli

: ..SGG....+GAVP+QVI+FLN+E.NR...+.VIASGN.NFG+.+..AG.+I++K..VP+LY.

Bsubt

: ................................ V .ASGN..+GD .F A .+ ...IS++ .+VP .L+ .

675

744

MhyoO .8 : FELLGTNDDVKKVRQILEDFWGK
Mpne MG: FELLGT.+DV++V+.1+.+ F .GK
Mgen MG : FELLGT.+DV++.+ + I+.+ F . ..
Mtub

: FEL+GTDDV...VR..L.+F...

StyORF : FEL+GT.D + ..V R + ..+.+F ...

Ecoli

: FEL+GT.D++.VR+..+.+F...

Bsubt

: FEL.G T + .D V + ...Q .+ E ....
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The organisms which returned significant protein sequence similarity to the second
open reading frame are the same organisms which returned similarity to the nrdF open
reading frame. In all cases the proteins homologous to the predicted nrdF protein
terminate with the same carboxy-terminal amino acid. Due to the small number of
nucleotides in ORF3 there was no significant predicted amino acid sequence similarity
between this reading frame and known sequences deposited in any of the databases
searched.

2.4.4

Southern hybridisation analysis and molecular specificity of
the 0.8 kb M. hyopneumoniae DNA fragment

Southern blot hybridisation analysis against M. hyopneumoniae (strain J), M.
flocculare (strain MS 42) and M. hyorhinis (strain GDL) chromosomal DNA was
carried out using the 0.8 kb M. hyopneumoniae DNA fragment as a probe. This DNA
probe hybridised strongly to a 2.45 kb HindlW restricted M. hyopneumoniae
chromosomal fragment, and reacted weakly against a 5.7 kb Hindlll M. flocculare
chromosomal fragment (Fig 2.14). Following overexposure of the autoradiograph, the
0.8 kb fragment hybridised with a M. hyorhinis chromosomal DNA fragment of 2.6
kb (result not shown). PCR amplification using primers specific for the 0.8 kb M.
hyopneumoniae DNA fragment resulted in an amplified PCR product of 750 bp from
M. hyopneumoniae chromosomal DNA (Fig 2.15).

At annealing temperatures below 50°C a number of low yield fragments less than 700
bp in size were amplified from M. hyorhinis chromosomal DNA; these fragments
were not amplified at annealing temperatures above 50°C. Under all conditions where
amplification of the 750 bp fragment was achieved using M. hyopneumoniae DNA, an
identically sized fragment was amplified using M. flocculare chromosomal DNA as a
template (Fig 2.15).
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Fig 2.14: Southern hybridisation analysis of M hyopneumoniae DNA, M hyorhinis
DNA, and M flocculare DNA. Lane 1, M hyopneumoniae chromosomal DNA digested
with ///«dill; lane 2, M hyorhinis chromosomal DNA digested with ///«dill; lane 3, M
flocculare chromosomal DNA digested with ///«dill. DNA markers (in kb) are indicated
on the left. A. Ethidium bromide stained 1% agarose gel. B. Southern blot analysis using
the 0.8 kb DNA fragment as a probe. Arrows indicate the 2.45 kb ///«dill M.
hyopneumoniae DNA fragment and 5.7 kb M. flocculare Hindill fragment.
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Fig 2.15: PCR amplification of porcine mycoplasma DNA using primers 1469 and 1470
which target the M hyopneumoniae 0.8 kb DNA fragment. Genomic DNA from M
hyopneumoniae, M. hyorhinis and M. flocculare (lanes 1-3 respectively) were used as
templates for the PCR. Lane 4 is a control without template. The colours of the gel have
been inverted to give the PCR product band a better contrast. The hybridisation temperature
used was 55^. DNA markers (in kb) are indicated on the left and the 0.8 kb PCR product
are indicated by an arrow.
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Fig 2.16: Detection of the 42 kDa NrdF protein in M. hyopneumoniae, M. hyorhinis and
M. flocculare strains using Western immunoblotting. Proteins were initially separated
using a 12% PAGE gel prior to transfer. Lane 1, M. hyopneumoniae J strain; lane 2, M
hyopneumoniae strain 232; lane 3, M. hyopneumoniae strain YZ; lane 4, M
hyopneumoniae Beaufort strain; lane 5, M hyopneumoniae Sue strain; lane 6, M
hyopneumoniae OMZ strain; lane 7, M. hyopneumoniae C l735/2 strain; lane 8, M
hyorhinis GDL strain; lane 9, M hyorhinis BTS7 strain; lane 10, M hyorhinis Field strain
2; lane 11, M hyorhinis Field strain 1; lane 12, M flocculare Ms42. The 42 kDa protein
is indicated by an arrow. A weakly cross-reactive antigen with a molecular mass of 49
kDa is present in all lanes. Position of molecular weight markers (in kDa) are indicated
on the right.
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2.4.5

Detection of NrdF antigen in different M. hyopneumoniae
strains

The presence of NrdF antigen in different strains was analysed by Western
immunoblotting using rabbit anti-15 kDa NrdF serum. All seven geographically
diverse strains of M. hyopneumoniae examined in this study demonstrated reactivity
(Fig. 2.16 lanes 1-7) confirming the presence of the wild type 42 kDa NrdF protein in
all seven strains tested. The 42 kDa protein is also detected in M. flocculare MS42
(Fig. 2.16 lane 12) but not in any of the M. hyorhinis strains examined (Fig. 2.16 lanes
8- 11).

2.4.6

Surface accessibility of NrdF antigen

The surface accessibility of the 42 kDa NrdF protein was examined at EMAI by Dr. J.
Chin and Mrs B. Turner using whole cell ELISA. Flow cytometric analysis of the
primary antigen, methanol-fixed M. hyopneumoniae whole cells, suggested that the
cells were intact. Rabbit antibodies raised against the recombinant 15 kDa NrdF
antigen were shown to bind to the complementary epitopes of the 42 kDa M.
hyopneumoniae protein on intact whole cells indicating that in-situ the protein is
surface accessible. A proportional increase in competitive inhibition of antibody
binding following the addition of increasing quantities of recombinant 15 kDa NrdF
antigen was demonstrated. Furthermore, the addition of antigen failed to cause any
detectable decrease in the ability of hyperimmune M. hyopneumoniae antiserum to
bind these cells confirming the specificity of the rabbit anti-15 kDa NrdF serum to a
surface accessible M. hyopneumoniae antigen (Fig. 2.17).

2.4.7

Growth inhibition of M. hyopneumoniae using NrdF anti
serum and serum from experimentally infected swine

Sterile discs impregnated with rabbit anti-15 kDa NrdF serum (Fig.2.18 B) and swine
hyperimmune anti-M. hyopneumoniae serum (Fig.2.18 A) inhibited the growth of
freshly cultured M. hyopneumoniae. A distinct clearing zone around the perimeter of
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2.5

Competing NrdF antigen
(ng/well)

Fig 2.17:

M. hyopneumoniae whole cell ELISA using rabbit anti-15 kDa NrdF serum

demonstrating the surface accessibility of the 42 kDa NrdF protein in situ. The open
circles and squares represent rabbit prebleeds prior to inoculation. Red filled squares
represent rabbit serum raised against M. hyopneumoniae whole cells. Red filled circles
show the effect of increasing the concentration of 15 kDa antigen on the ability of anti-15
kDa serum to bind to M. hyopneumoniae whole cells.
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Fig 2.18: Growth inhibition assay using sterile paper discs (25 mm) impregnated with
different serum samples overlayed onto a lawn of freshly cultured M. hyopneumoniae
strain J. Inhibition of growth can be seen as a halo-like ring (indicated by an arrow)
around the darker area where the paper disc was located. Inhibition can be seen around
the discs impregnated with hyperimmune pig serum (A) and rabbit 15 kDa NrdF
antiserum (B). No zone of clearing was detected around the rabbit prebleed serum (C).
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the disc (Fig.2.18 A and B), is in marked contrast to the absence of such zones around
the rabbit prevaccination bleed impregnated disc (Fig.2.18 C) and swine
prevaccination prebleed (result not shown).

Zones of clearance around the 6 mm

diameter disc were approximately 3 mm wide when observed by light microscopy.
The zones of inhibition are a product of the inhibited growth of M. hyopneumoniae.
Clearing increases closer to the disc presumably due to increased antibody
concentrations. Zones of clearance are reduced when stained with Coomassie brilliant
blue because the extreme regions of the zone contain small amounts of mycoplasmal
growth; however this region stains because of the sensitive visualisation technique.

2.4.8

Histidine tagging of the 15 kDa NrdF antigen

The 0.8 kb insert in the plasmid pKFlO was confirmed to be identical to the M.
hyopneumoniae DNA fragment in the plasmids pKFl and pSD9 by Southern
hybridisation (Fig. 2.19). A number of potential positive constructs were detected by
colony hybridisation after ligation of the electroeluted 0.8 kb PCR amplified DNA
fragment from pKFlO into pQE9 (Fig.2.20 A). Positive constructs derived from the
parental pQE9 vector were expected to express the recombinant 11 kDa NrdF
histidine-tagged antigen after transformation of E. coli JM109 (Fig. 2.20 C lanes 1-5).
A total of 5 clones which expressed the His-tagged 11 kDa antigen were identified and
designated pETEl-5; of these constructs pETEl was used for the affinity purification
of the NrdF antigen (Fig. 2.20 lane 6).
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Fig 2.19:

Southern hybridisation analysis of plasmids pKFlO using M hyopneumoniae

0.8 kb DNA fragment insert as a probe. A. Ethidium bromide stained 1% agarose gel. AH
plasmids were double digested using Pstl and SmdL. Lane 1, pKFlO; lane 2, pKFl; lane 3,
pSD9. DNA markers (in kb) are indicated on the left. B. Southern blot hybridisation
analysis of the equivalent plasmid digests using the 0.8 kb M hyopneumoniae DNA
fragment as a probe. Arrow indicates the 0.8 kb fragment.
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Fig 2.20: Detection of pQE9 constructs containing the 0.8 kb M. hyopneumoniae DNA
insert. A. Colony hybridisation detection of E. coli JM109 transformants containing a
plasmid construct with the 0.8 kb DNA insert This autoradiograph had 50 E. coli JM109
colonies which contained pQE9 with or without the insert. Positive colonies which contain
the insert appear as dark spots on the X-ray film. The arrow indicates a colony which was
later determined to be a positive clone which expressed the 15 kDa NrdF antigen. The
control was E. coli JM109 (pKFlO). B. Coomassie brilliant blue stained 15%
polyacrylamide gel. Lanes 1-5, E. coli JM109 (pETEl-5) respectively; Lane 6, affinity
purified histidine tagged 11 kDa NrdF protein; Lane 7, E. coli JM109. Positions of
molecular weight standards (in kDa) are indicated on the right of the gel. C. Western
immunoblot analysis of equivalent protein samples described in Fig 2.20 B using rabbit 15
kDa NrdF antigen antiserum extensively preabsorbed against E. coli JM109. The 15 kDa
histidine tagged NrdF antigen is indicated by an arrow.
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2.5

Discussion

This chapter described the characterisation of an antigen encoded by the 0.8 kb M.
hyopneumoniae DNA fragment. This insert is contained in the plasmids pSD9 and
pKFl and encodes approximately 11 kDa of the carboxy-terminal region of a 42 kDa
wild type protein. The specific function of the wild type protein was not examined
because the aim of this research is to develop a vaccine against PEP. Previous research
carried out at EMAI has demonstrated that the encoded antigen is a potential
candidate for use as a vaccine antigen. Only that part of the 42 kDa wild type protein
which confers protection is desirable. Consequently, only the recombinant antigen
which was identified as enhancing immunity against PEP was characterised and its
essential role in protection against M. hyopneumoniae examined.

The plasmid pSD9 encoded a 128 kDa fusion protein whereas the plasmid pKFl
encoded a 15 kDa protein. In both plasmids the 11 kDa M. hyopneumoniae antigen
was fused to the COOH-terminus of a highly expressed gene; in pSD9 the insert was
fused to the B-galactosidase transcriptional unit (cro’-lacT-lacZ’) which encodes a 117
kDa protein and in pKF 1 it was fused to the lacZa gene which encodes approximately
4 kDa of protein before the fusion point. Sequence analysis revealed that the cloned
M hyopneumoniae DNA fragment shows high predicted amino acid similarity
between the 11 kDa M. hyopneumoniae antigen and a carboxy-terminal region of the
NrdF protein from a number of organisms. The NrdF protein is able to detoxify
hydroxyurea in a reversible reaction where the radical is donated, thus conferring
resistance against this potent DNA synthesis inhibitor (Reichard, 1993a). The protein
also functions as a ribonucleoside-diphosphate reductase R2 subunit; this class of
enzymes is responsible for the conversion of ribonucleotides to deoxyribonucleotides
for use in DNA synthesis (Thelander and Reichhard, 1979). The 42 kDa protein
identified in this study may play a similar role in M. hyopneumoniae.
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As there are no inverted repeat structures detected at the 3' terminal of M.
hyopneumoniae nrdF and as the TAA stop codon of this gene is separated from the
ATG start codon of ORF2 by only a single nucleotide, both genes are likely to be
organised in an operon. This is consistent with the organisation of genetic information
in other Mycoplasma spp. (Herrmann, 1992). The predicted amino acid sequence of
ORF2 showed significant similarity with sequences from the same organisms which
had significant similarity to nrdF. The predicted 150 amino acid protein encoded by
ORF2 is homologous to MG230, YmaB and other predicted proteins which are found
3’ to the NrdEF operon of those organisms. The organisation of these genes within the
nrd locus appears to be conserved. In all cases the function of the predicted protein
encoded by ORF2 as well as the homologous proteins remains to be elucidated. The
conserved sequence 5'-ATTGGGAG-3' present 7 bases upstream of the start codons of
both ORF2 and ORF3 may serve as a putative ribosome binding site (Gilson et al,
1988; Taschke et al, 1987; Yogev et al, 1991). This sequence contains 4 nucleotides
which can base pair with the conserved sequence 3'-CCUCCA-5' at the 3' end of the
M. hyopneumoniae 16S rRNA. This degree of similarity is considered sufficient to
initiate translation in E. coli (Taschke et al, 1987). The position of the putative
ribosome binding site relative to the ATG start codon of ORF2 and ORF3 is identical
to the putative consensus ribosome binding site of M. hyopneumoniae (Taschke et al,
1987). A region of dyad symmetry is found 24 nucleotide base pairs downstream of
the ORF2 TAA stop codon. This inverted repeat structure may act as a transcription
termination signal. A putative -10 promoter sequence (5'-TATAAT-3') is found 33
nucleotide base pairs upstream of the ATG start codon of ORF3. As for the rrn
promoter of M. hyopneumoniae, a -35 consensus sequence was not found upstream of
the putative ORF3 -10 sequence (Taschke et al, 1987).

Using Southern blot analysis, the 0.8 kb M. hyopneumoniae DNA fragment did not
hybridise to HindIII restricted M. hyorhinis

chromosomal DNA under stringent

hybridisation conditions. This result is not surprising due to the differences previously
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described between these two species of mycoplasma at the DNA and protein levels
(Bolske et al, 1987; Herrmann, 1992). However, the 0.8 kb DNA probe did detect a
5.7 kb M. flocculare Hin<\\\\ fragment of DNA. Similarly, PCR primers based on the
DNA sequence of the 0.8 kb fragment were used to identify the presence of this DNA
fragment in other porcine mycoplasmas which inhabit the respiratory tract of pigs.
Although these primers clearly differentiated between M. hyopneumoniae and M.
hyorhinis reference strains, the usefulness of such primers for routine diagnosis is
limited by cross reaction with M. flocculare.

Western blot analysis revealed cross-reactivity between the NrdF antigen of M
hyopneumoniae and a 42 kDa M. flocculare protein. These results for the encoded
protein further support the Southern hybridisation and PCR results which indicate a
conservation of the nrd locus between these two mycoplasmas. There is, however, no
cross-reactivity between the M. hyopneumoniae antigen and a 42 kDa M. hyorhinis
protein. Antibodies raised against the 11 kDa M. hyopneumoniae component react
strongly with a 42 kDa wild type protein which is present in all of the geographically
diverse M. hyopneumoniae strains tested. Generally, antigens recognised using
hyperimmune anti-M. hyopneumoniae serum are conserved amongst geographically
diverse strains (Scarman et al, 1997) and clearly the NrdF antigen is conserved
amongst the diverse strains tested.

In the physiology of M. hyopneumoniae the absence of a cell wall and outer
membrane make this pathogen particularly vulnerable to neutralising antibodies
(Awumbila et al, 1991; Wannemueler and Galvin, 1994). Whole cell ELISA
demonstrated that the NrdF antigen is surface accessible. This feature, coupled with
the growth inhibition studies and the conservation of this antigen across the
geographically diverse M. hyopneumoniae strains tested, makes the recombinant NrdF
antigen a potential vaccine component.
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Chapter 3

Oral immunisation of mice with

S. typhimurium aroA expressing
recombinant M. hyopneumoniae NrdF
antigen

Chapter 3
Oral immunisation of mice with Salmonella typhimurium
aroA expressing recombinant M. hyopneumoniae NrdF
antigen
M. hyopneumoniae is a mucosal pathogen which does not invade the lung epithelial
cells of infected swine (Razin, 1992a), but colonises the external surfaces of these
cells (Tajima and Yagahashi, 1982; Blanchard et al, 1992; Zeilinski et al, 1993;
Zhang et al, 1995). In order to prevent microbial colonisation, an ideal vaccine
candidate should be able to trigger an efficient mucosal response. A number of
vaccine strategies can be used to achieve this desired mucosal immune response.
Within this project a live attenuated bacterial vector was chosen to express and deliver
the pSD9 128 kDa fusion protein and the pKFl encoded 15 kDa NrdF antigen. This
chapter describes the construction and characterisation of S. typhimurium aroA
SL3261 (pSD9) and S. typhimurium aroA SL3261 (pKFl) strains and the potential of
these live recombinant vaccine strains to elicit an immune response in mice.

3.1

Ribonucleotide reductase

The 15 kDa recombinant antigen encoded by pKFl had very highly conserved amino
acid similarity to a number of NrdF proteins. NrdF is the R2 subunit of a class I
ribonucleotide reductase (RR). RR is a ubiquitous enzyme which catalyses the
conversion of ribonucleotides into corresponding deoxyribonucleotides which are
used in the synthesis of deoxyribonucleic acid (DNA) (Thelander and Reichard, 1979;
Reichard, 1993a). The enzymatic reduction occurs through the replacement of the
hydroxyl group at the C-2’ position with a hydrogen (Fig. 3.1)
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Ribonucleotide

Deoxyribonucleotide

Fig. 3.1: Schematic representation of the production of deoxyribonucleotides from
ribonucleotides catalysed by RR. Circled ‘P’ represents the phosphate group. The T
hydroxyl group is replaced with a hydrogen (bold) (modified Reichard, 1993a).

There are three classes of RR which are characterised according to the type of radical
which the enzyme uses to reduce the 2’ hydroxyl group. Class I RR are aerobic
enzymes which utilise a tyrosyl radical maintained by an iron centre (Larsson and
Sjoberg, 1986). This class has been detected in eukaryotes (Chaudhuri et al, 1992;
Reichard, 1993a), prokaryotes (Jordan et al, 1994; Scotti et al, 1996) and some
viruses (Slabaugh and Mathews, 1986; Lankinen et al, 1991; Cunha and Costa, 1992).
Class II RR are found in a number of prokaryotic cells and use adenosyl cobalamin as
the

radical

generator

(Reichard,

1993a).

Finally,

class

III

RR use

S-

adenosylmethionine as the radical and are found in anaerobically grown prokaryotes
(Reichard, 1993b).

Organisms are not restricted to a single class of RR enzyme and may contain genes for
two or more of these enzymes. E. coll and S. typhimurium both have two class I
enzyme opérons, nrdAB and nrdEF. E. coli also contain an anaerobic WY/Z)-encoded
class III RR enzyme which allows it to be a facultative anaerobe (Jordan et al, 1996a).
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Lactococcus lactis also contains a class III RR encoded by a nrdDG operon and a
class I nrdEF RR (Jordan et al, 1996b).

3.1.1

Class I (iron-tyrosyl radical) ribonucleotide reductase

Class I RR enzymes have been most extensively characterised in E. coli (Fontecave et
al, 1992). However, essential features are conserved throughout all class I RR
enzymes studied (Jordan et al, 1994). This enzyme comprises two non-identical
dimeric protein subunits termed R1 and R2 (alternatively, B1 and B2 respectively)
(Fig. 3.2). The subunits vary slightly in molecular weight depending on the organism.
The R1 is the large subunit made up of two identical polypeptide chains ranging in
molecular weight from 80 - 120 kDa. R2 is the smaller subunit and is also made up of
two identical polypeptide chains which range in molecular weight from 40 - 50 kDa
(Thelander and Reichard, 1979).

R1 su b u n it

R1 binding surface
R 2 su b u n it

Fig. 3.2: Schematic representation of RR showing the two subunits consisting of
dimeric proteins (modified from Thelander and Reichard, 1979).

There are conserved essential sites in all class I enzymes. The R1 subunit contains
redox-active sulfhydryl groups which may reduce the substrate in the absence of
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external hydrogen and are, therefore, considered a part of the active site of the enzyme
(Reichard, 1993a). The R1 subunit also contains effector-binding sites for the
allosteric regulation of the enzyme by dNTPs (Thelander and Reichard, 1979). The R2
subunit contains the tyrosyl radical (Tyr*22) and conserved amino acids (Phe2^8,
Phe212 and lie234) (Jordan et al, 1994). Also bound within each R2 subunit
polypeptide is an iron (Fe(III)) centre (Asp84, Glu115, His118, Glu204, Glu238 and
His241) (Jordan et al, 1994; Reichard, 1993a) which functions in the maintenance and
generation of the tyrosyl radical. Radical scavengers such as hydroxyurea can
irreversibly alter the iron centre. This prevents the formation of the tyrosyl radical
(Thelander and Reichard, 1979; Slabaugh and Mathews, 1986) and so removes
enzymatic activity. This interaction also detoxifies hydroxyurea and consequently the
overexpression of the R2 subunit leads to hydroxyurea-resistant cell lines (Slabaugh
and Mathews, 1986; Chaudhuri et al, 1992). The R2 subunit also contains the
conserved R1 binding surface (Asp58’ Arg236 and Tyr356) (Jordan et al, 1994), a
region necessary for assembly of the enzyme which is essential for activity.

3.1.2

NrdAB ribonucleotide reductase in bacteria and viruses

The predominant class I RR in E. coli and S. typhimurium is encoded by the nrdAB
genes (Jordan et al, 1996). The transcription of E. coli nrdAB genes is temperature
regulated and cell cycle dependent (Sun et al, 1992). These genes are also regulated
by the trans-acting positive regulators Fis and DnaA proteins which operate
independently from cell cycle control (Augustin et al, 1994). Allosteric regulation of
this enzyme occurs through the binding of ATP, dATP, dGTP and dTTP at the
effector-binding sites (Thelander and Reichard, 1979).

Viral protein homologs to the E. coli and S. typhimurium NrdAB proteins are found in
the vaccinia virus, varicella-zoster virus, herpes simplex virus 1 (Jordan et al, 1994)
and equine herpes virus type 1 (Telford et al, 1990). There are also a number of RR
proteins in herpes simplex virus 2, Epstein-Barr virus (Jordan et al, 1994),
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pseudorabies virus (Lankinen et al, 1982) and African swine fever virus (Cunha and
Costa, 1992). After target cells have been invaded, the viral RR enzyme is
constitutively expressed enabling the virus to use the DNA replication machinery of
the host cell to replicate itself.

3.1.3

NrdEF ribonucleotide reductase and protein homologs

In E. coli and S. typhimurium the nrdAB gene product is preferentially expressed in
the bacteria over the nrdEF gene product under most environmental conditions
(Jordan et al, 1996a). It is known that nrdEF is under the control of the cell cycle
through the SOS regulator RecA (Scotti et al, 1996). However, the complexities of
nrdEF regulation have yet to be fully elucidated and an understanding of this operon
may provide the reasons why this second class I enzyme has evolved.

Amino acid comparisons between nrdAB gene products, viral homologs to the
products of the nrdAB and nrdEF operons demonstrate low similarity (20% - 30%)
between the nrdEF products and the other two class I enzyme R1 and R2 proteins
(Scotti et al, 1996). However, essential functional regions are conserved between both
enzymes (Jordan et al, 1994). Predicted amino acid similarity between the pKFlencoded 15 kDa NrdF recombinant antigen did not return any significant similarity to
the corresponding E. coli or S. typhimurium NrdB proteins, but did to the bacterial
NrdF protein (Fig 2.15 and 2.16).

The organisation of the nrdEF operon is conserved in those species found to contain
the NrdEF RR enzymes, S. typhimurium, E. coli (Jordan et al, 1996a), L. lactis
(Jordan et al, 1996b) B. subtilis (Scotti et al, 1996) and M. genitalium (Peterson et al,
1993). In B. subtilis, a putative promotor and ribosome binding site is immediately
upstream of an open reading frame (ymaA) which encodes a predicted 130 amino acid
polypeptide of unknown function (Scotti et al, 1996). Downstream of the first open
reading frame is a ribosome binding site which precedes the nrdE gene. No stem and
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loop structures are found between the nrdE and nrdF genes or the subsequent open
reading frame. The fourth open reading frame (YmaB), like the first, encodes a
hypothetical peptide of unknown function (Scotti et al, 1996). All open reading
frames contain adjacent putative ribosome binding sites. There are no promotors
found in the operon after the first open reading frame and the operon is terminated by
a stem and loop structure immediately downstream of the final open reading frame
(Fig 3.3).

Y m aA
(130aa)

NrdF
(329aa)

N rdE
(700aa)

YmaB
(206aa)

Pr
(96aa)

(150aa)
ir

~ ~ it

M. hyopneumoniae
DNA fragment
Fig. 3.3:

Diagrammatic representation of the nrdEF operon. Gene products and sizes

in amino acids (aa) are given using B. subtilis designations. Keyhole symbol indicates
the presence of inverted repeats. Arrow indicates the direction of transcription. Pr
indicates the presence of a promotor sequence. The region of the nrdEF operon
encoded by the 0.8 kb M. hyopneumoniae fragment inserted into the plasmids pKFl
and pSD9 is given below the main map. The size of the gene product is given as
amino acids (aa).

3.1.4

Blocking of subunit assembly to inhibit enzymatic activity

Association of the RR subunits can be prevented by a nonapeptide which blocks the
conserved R1 protein binding with the carboxy terminal 9-11 residues of the R2
subunit proteins (Telford et al, 1990; Climent et al, 1991). Inhibition studies of the
herpes simplex virus type 1 (Telford et al, 1990) and E. coli RR (Climent et al, 1991)
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targeting this carboxy terminal region demonstrated that prevention of the assembly of
the enzyme abolishes activity. It is this same carboxy-terminal region of the M.
hyopneumoniae NrdF 42 kDa protein which is expressed as the 15 kDa NrdF antigen
in the E. coli JM109 (pKFl) construct.

3.2

3.2.1

Mucosal immune system

Immune defences at mucosal surfaces

The lack of a cell wall in mycoplasmas makes these organisms vulnerable to
neutralising antibodies against essential proteins (Awumbila and Rosenbusch, 1991;
Wannamuehler and Galvin, 1994). If M. hyopneumoniae has only a single class I RR
(NrdEF) then the 42 kDa wild type NrdF protein may be essential to metabolic
function. Consequently, antibodies against the 15 kDa NrdF antigen may inhibit DNA
synthesis and provide protection from the development of PEP. Because M
hyopneumoniae is a mucosal pathogen, the immune response elicited by a vaccine
against this organism must be localised to the respiratory mucosae. The immune
defences at mucosal surfaces consist of mucin barriers, CMI and humoral responses.
The importance of each mechanism differs depending on the organism and differences
between responses in mammalian species can be large.

3.2.1.1

Mucins

Mucins are hydrophilic gels made up of glycoproteins that are secreted from epithelial
goblet cells (McNabb and Tomasi, 1981). This gel forms a confluent barrier against
colonisation by pathogens of the intestinal tract and regions of the respiratory tract.
This layer is moved by the mechanical action of cilia which facilitate clearance from
these surfaces. Mucins form a physical barrier preventing pathogens coming into
contact with the underlying epithelial surfaces. Furthermore, secretory antibodies are
able to cross-link with cysteine residues in the mucin layer. Bound antigen is thus
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trapped and may subsequently be removed by ciliary action (McNabb and Tomasi,
1981).

3.2.1.2

Cell mediated immunity

The extent of the role played by CMI on mucosal surfaces is yet to be fully elucidated.
CMI has been demonstrated at mucosal surfaces. Those responses identified include
MHC restricted cellular cytotoxicity, natural killer cell activity and antibody
dependent T-cell mediated cytotoxicity (Holmgren, 1991). The predominant response
to oral ingestion of antigen is a type 2 Thelpermediated response, which regulates the
humoral B-cell responses (McGhee et al, 1992; McGhee and Kiyono, 1993).
However, significant type 1 Thelper responses, which mediate CMI, are elicited by
intracellular pathogens such as S. typhimurium. The type 1 Thelper1secreted INF-y is a
significant mediating cytokine in the immune defences (Holmgren, 1991) that
enhances IgA production, inhibits viral replication, increases the activity of
macrophages, inhibits the proliferation of type 2 Thelper cells and facilitates the
secretion of IgA (Holmgren, 1991). However, down-regulation of pro-inflammatory
cytokines, including INF-y, does not affect IgA production and secretion (Shalaby,
1995) demonstrating the complexity of the secretory IgA response.

3.2.1.3

Humoral immunity

Secretory IgA is the predominant immunoglobulin of mucosal surfaces (Mestecky,
1987; Brandtzaeg, 1989; Holmgren, 1991; Bernstein, 1992). The most common
protective mechanism by which secretory IgA functions is via immune exclusion of
antigens (Childers et al, 1989; Holmgren, 1991). This mechanism can prevent the
adherence and uptake of bacteria, viruses, toxins, carcinogens and allergens (McNabb
and Tomasi, 1981; Underdown and Schiff, 1986). Secretory IgA also increases
antigen uptake by the M cells overlying the Peyer’s patch regions of the gut, which is
critical for antigen presentation in the mucosal immune system (Holmgren, 1991).
This isotype cannot act as a macrophage opsinin, nor can it fix complement
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efficiently. As a consequence secretory IgA does not initiate inflammatory reactions
(Conley and Delacroix, 1987).

In mucosal secretions of the lower respiratory tract, IgG is the predominant isotype
detected (Daniele, 1990). The mechanism by which this immunoglobulin transverses
the epithelium is unclear; it is hypothesised that this isotype is secreted into the
interstitial space and the immunoglobulin is carried by transudation into the mucosal
secretions (Bernstein, 1992). In the broncheoalveolar mucosa, IgG fixes complement
and opsinises antigen which, in cases of chronic infection, may lead to persistence of
inflammation and an increase in epithelial permeability allowing colonisation by
secondary invaders (Bernstein, 1992). However, under normal conditions IgG plays a
major defensive role in the distal regions of the airways (Daniele, 1990).

Secretory IgM has been detected in mucosal secretions of humans which have an IgA
deficiency (Brandtzaeg et al, 1968; Daniele, 1990). Helper T-cell clones in the
mucosal inductive sites preferentially cause the class switching of IgM B-cells into
IgA B-cells (James et al, 1986). Consequently, in healthy individuals secretory IgM is
rarely detected.

3.2.2

Compartmentalisation of the common mucosal immune
system

The predominant defence of the common mucosal immune system is the eliciting of a
secretory IgA response against antigen which is processed at sites which lie within the
mucosal surfaces. This system is compartmentalised into inductive sites, where
antigen is processed and remote effector sites, where primed immune cells actually
function (for reviews see Brandtzaeg, 1984; Mestecky, 1987; Bergmann and
Waldman, 1988; Brandtzaeg, 1989; Lintermans and Greve, 1995). The common
mucosal immune system has been investigated primarily in humans, however, it has
been identified as ubiquitous in mammals (Bergmann and Waldman, 1988). There are
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two separate inductive sites: the gut-associated lymphoid tissue and bronchusassociated lymphoid tissue (GALT and BALT respectively).

The GALT is represented almost exclusively by the Peyer’s patches, which are
discrete regions enriched for macrophages, lymphocytes and some plasma cells found
throughout the gastrointestinal tract (McGhee et al, 1992). Overlying the Peyer’s
patches are specialised follicle-associated epithelial cells (also referred to as microfold
(M) cells). These cells are specialised to uptake antigen without degradation and
deliver the intact antigen to the underlying lymphoid tissue (McGhee et al, 1992).
Distinct B-cell sites are present in this underlying region which serve as germinal
centres where IgA class switching and affinity maturation occurs. Adjacent to these
areas are T-cell sites, which contain all the major T-cell populations, and discrete
accessory cell sites containing macrophages and dendritic cells. Following antigen
stimulation and presentation in the Peyer’s patches the antigen-induced B- and T-cells
migrate to distal effector sites via the lymphatic and circulatory system.

Similar structures analogous to the GALT Peyer’s patches have been identified in the
proximal airways and less defined lymphoid aggregates have been identified in the
more distal airways (Daniele, 1990; Bernstein, 1992). Morphological studies
demonstrate that BALT regions are dynamic and undergo functional and structural
changes depending upon antigenic stimulation (Daniele, 1990). In animals such as
rabbits and mice, regions of BALT can be identified from birth in all individuals. In
humans and pigs, however, the production of BALT is stimulated by antigen (Pabst
andBinns, 1994).
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Fig 3.4:

Schematic showing distribution of known IgA isotypes at different regions

of the human body (modified from McGhee and Kiyono, 1993).

In higher mammals the predominant IgA subclass elicited by the GALT is IgA2 and
the predominant subclass elicited by the BALT is IgAl. Although immune cells from
both inductive sites can migrate to all effector sites, there are mucosal surfaces which
have a predominant IgA subclass (Fig 3.4). This is taken as evidence that the GALT
and BALT sites are compartmentalised and preferentially defend specific mucosal
sites throughout an animal.

3.3

M u c o s a l im m u n isa tio n as a ro u te to p ro tect a g a in st
m u c o sa l p a th o g e n s

The mucosal immunisation route is advantageous in eliciting responses against
mucosal pathogens because it provides a defence that can act at the point of entry,
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effectively providing a “first line of defence”. Furthermore, a number of methods of
mucosal antigen delivery have been developed which are capable of stimulating
mucosal, cell-mediated and humoral immune responses (Staats et al, 1994). Oral
tolerance, which immunosuppresses the systemic immune response, is a well
documented phenomenon which develops after repeated exposure to low oral doses of
protein antigen (Challacombe and Tomasi, 1980). Whilst oral tolerance is beneficial
under certain circumstances, such as allergies and autoimmune diseases, it can limit
the otherwise effective CMI and humoral immune responses against pathogens (Ruedl
and Wolf, 1995) (Table 3.1).

Table 3.1:

Table demonstrating the range of immune responses which provide

protection from various mucosal pathogens (modified from Staats et al, 1994).

Site of
Challenge

Infectious agent or product

Protective mechanism

Lung

Respiratory syncytial virus

Anti-RSV IgG

Nasal mucosa

Influenza

Anti-influenza IgA
Possibly Anti-Hemagglutinin IgG
Cytotoxic T lymphocytes

Gastro
intestinal tract

Vibrio cholerae
Salmonella typhimurium
Toxoplasma gondi

Antigen specific polymeric secretory IgA
and specific CMI responses

Subcutaneous

Tetanus toxin

IgG

3.3.1

Adjuvants

Antigens delivered parenterally with adjuvants such as cholera toxin and heat labile
enterotoxin target the mucosal immune system and do not elicit oral tolerance (Staats
et al, 1994). Although efficacious delivery of vaccine antigens can be achieved by this
route, the required needle delivery is time consuming, labour intensive and requires
trained personnel. Furthermore, some adjuvants such as cholera toxin produce
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detrimental side effects making the routine use of this adjuvant unacceptable
(Husband, 1993).

3.3.2

Microspheres, liposomes and ISCOMS

Although the technology involved in the development of microspheres, liposomes and
ISCOMS as mucosal delivery vehicles is different, all three rely upon encapsulation of
the antigen to prevent degradation. Mucosal delivery of antigen using these methods
delivers antigen to the Peyer’s patch regions and will elicit strong CMI, systemic IgG
and secretory IgA responses (Staats et al, 1994). The use of this novel technology to
deliver antigen is receiving considerable attention and may in the future provide
efficacious vaccines against mucosal pathogens.

3.3.3

Attenuated viral and bacterial vectors

Live attenuated viral and bacterial vectors have been developed to be used as vaccines
against the virulent parental strains (Attenuated viral vaccines are reviewed in
Melnick, 1989 and Connell et al, 1992. Attenuated bacterial vaccines are reviewed in
Dougan et al, 1989; Connell et al, 1992 and Lintermans and Greve, 1995). These
attenuated organisms are capable of invading, causing limited infection in the host and
stimulating a specific immune response analogous to that elicited by natural infection.
These strains, however, are not capable of surviving without supplementation and
consequently cannot cause disease, furthermore these strains will not result in
potentially deleterious oral tolerance due to the invasive mode of antigen delivery.
Attenuated Salmonella bacterial vectors are the most widely used vaccine delivery
vehicles. These strains are well characterised and have been used to deliver
heterologous antigen (reviewed in Curtiss et al, 1993). Consequently,

attenuated

Salmonella typhimurium aroA mutant (SL3261) was chosen within this study to
deliver the candidate M. hyopneumoniae NrdF antigen.
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3.4

Salmonella typhimurium as a vaccine carrier

3.4.1

Salmonella typhimurium pathogenesis

Salmonella spp. are facultative intracellular pathogens which are capable of invading a
variety of mammalian epithelial cells. Although rarely fatal, mortality is often
associated with infection of young, aged or immunocompromised individuals. S.
typhimurium causes acute enterocolitis, a disease with high morbidity but low
mortality (Reed et al, 1986). This bacterium attaches to and invades intestinal
enterocytes and the M cells overlying the Peyer’s patches of the GALT (Carter and
Collins, 1974). It is able to avoid the host’s immune defence mechanisms (Galan,
1996) and can reach deep-lying cells. The pathogen may even transverse the intestinal
barrier to reach the lymphoreticular organs (Curtiss et al, 1993). S. typhimurium can
induce immune suppression which facilitates the establishment of the carrier state and
may lead to complications associated with secondary infection (Curtiss et al, 1993).
Primary infection with Salmonella stimulates both antibody and CMI responses
(Flynn et al, 1990). Protection appears to be due to CMI, specifically a macrophage
mediated inflammatory response (Al-Ramadi et al, 1991a) and a S. typhimurium
specific cytotoxic T-lymphocyte response (Dougan et al, 1989; Flynn et al, 1990).
The role of serum antibody responses is not clear. Infection elicits serum antibody
responses, however, no correlation between immunoglobulin levels and protection has
been demonstrated (Eisenstein et al, 1984).

3.4.2

Attenuated Salmonella mutants

Ideal live attenuated vaccine strains would need to contain well characterised stable
mutations in more than one essential pathway (Roberts et al, 1994). The first
attenuated vaccine was a S. typhi Ty21a, which contained a single mutation in the
galE gene (Germanier and Fiirer, 1975). This strain was licensed as an oral typhoid
vaccine and has been used successfully for a number of years (Roberts et al, 1994).
Ty21a has proved to be stable, with no revertants being detected (Hone and Hackett,
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1989). This strain demonstrates that attenuated oral vaccines are achievable.
Development of attenuated strains has lead to the construction of auxotrophic and
regulatory mutants, which are used as vaccines against virulent parental strains as well
as carriers for heterologous antigens (Table 3.2). The most widely characterised
auxotrophic mutants are those with deletions in the aromatic amino acid biosynthesis
pathway genes (aroA, aroC and aroD) (see next section) (Roberts et al, 1994) or the
purine biosynthesis pathway genes (purA and purE) (McFarland and Stocker, 1987;
O’Callaghan et al, 1988). The most common regulatory mutants contain deletions in
the adenylate cyclase gene (cya), cAMP receptor protein gene (crp), or the genes
involved in phosphate regulation (phoP and phoQ) (Roberts et al, 1994).
Table 3.2:

Attenuated bacterial strains used as oral vaccines or delivery vectors.

Bacterial strain
S. typhimurium

S. typhimurium

Mutation

Reference

aroA, aroD, aroC, galE,

Hoiseth and Stocker, 1981;

cya, crp, asd

Roberts et al, 1994

aroA or pur A or pur A,

O’Callaghan et al, 1988

aroA or purE, aroA

Bordetella pertussis

aroA

Roberts et al, 1990

P. multocida

aroA

Homchampa et al, 1992

Yersinia enterocolitica

aroA

Bowe et al, 1989

Salmonella choleraesuis

cyal2( crp-cdt)

Stabei et al, 1993

Salmonella typhi

aroA

Dougan et al, 1987a

Salmonella dublin

aroA

Roberts et al, 1994

Salmonella enteridis

aroA

Roberts et al, 1994

3 .4.3

Salmonella typhimurium aroA mutants

Aromatic-dependent S. typhimurium aroA gene mutants were developed, using
transposon mutagenesis, as non-virulent live vaccine strains against typhoid (Hoiseth
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and Stocker, 1981). These strains are non-reverting mutants which carry a deletion in
the

aroA

gene

(Cardenas

and

Clements,

1992).

The

aroA

encodes

3-

enolpyruvylshikimate-5-phosphate synthetase which catalyses the conversion of
shikimic acid into chorismic acid. The product of this reaction is an intermediate in
the synthesis of the essential compounds PAB-folate and enterochelin, which are not
present in mammalian cells (Fig. 3.5).

Essential but
available in
mammalian cells
Shikimic
acid

Essential and not
available in
mammalian cells
Not Essential

Figure 3.5:

Diagrammatic representation of the role of the AroA enzyme in S.

typhimurium (modified from Cardenas and Clements, 1992).

S. typhimurium aroA mutants have been demonstrated to be invasive yet non-virulent
strains capable of eliciting immune responses which protect against subsequent
virulent challenge (Hoiseth and Stocker, 1981; Cardenas and Clements, 1992;
Lumsden and Wilkie, 1992; Mukkur, 1992; Curtiss et al, 1993; Dougan, 1994).
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3.4.4

Attenuated S. typhimurium mutants as delivery vectors for
heterologous antigen

Attenuated Salmonella strains are capable of carrying and presenting heterologous
antigen to the mucosal immune system and eliciting humoral, mucosal and cell
mediated immune responses (Table 3.3) (Dougan et al, 1987b; Dougan et al, 1989).
The DNA encoding the heterologous antigens may be present in the attenuated strain
on a plasmid or alternatively the DNA may be inserted into the vector’s chromosomal
DNA (Cardenas and Clements, 1992). Plasmids can be unstable and require genes
which allow for selection, usually antibiotics, so that the plasmid is maintained within
the attenuated strain (Cardenas and Clements, 1992). Multicopy recombinant plasmids
allow for over-expression orheterologous antigen within attenuated carrier vectors.
Delivery of a large antigen load is critical if a mucosal antibody response is to be
elicited (Cardenas et al, 1994). Insertion of the heterologous antigen DNA into the
chromosome of the host is more stable and does not require the use of selective
antibiotics. Studies have demonstrated that if the antigen can be inserted under the
control of a /«-vz'vo-activated promotor, such as nirB, large amounts of antigen can be
produced and these recombinant strains can be effective in eliciting protective
immune responses (Chatfield et al, 1992). The immune responses elicited by oral
delivery of antigen using attenuated Salmonella spp. vectors is varied (Table 3.3).
Even within a species, the immunogenicity of attenuated strains is variable (Roberts et
al, 1994). The dose of delivered antigen and the vaccination regime appear to be the
predominant factors affecting host immune responses (Killar and Eisenstein, 1986;
Stabel et al, 1991; Cardenas and Clements, 1992; Stabel et al, 1993). Persistence of
the attenuated organism in host cells and intracellular location of cloned antigens do
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not appear to be major contributing factors in the immunogenicity of a number of
reported strains (Brown et al, 1987; Cardenas et al, 1994).

Table 3.3: Examples of types of heterologous antigens expressed in attenuated
Salmonella spp. Elicited host immune responses and protective efficacy of vaccine
strain are indicated (modified from Roberts et al, 1994).

Antigen

C-fragment

Organism

C lo strid iu m
te ta n i

Salmonella

Ab

CMI CT

Protectio

L

n

S. typh im u riu m
a ro A ,

Yes

ND

ND

Yes

P.69

B o rd e te lla

S. typh im u riu m

No

Yes

ND

Yes

0 antigen

p e r tu s s is
S h ig e lla

aroA a ro C , a r o D
S. ty p h i Ty21a

Yes

ND

ND

Yes

Yes

ND

ND

ND

Yes

ND

ND

Yes

No

ND

ND

Yes

fle x n e r i

8kDa OMP

N e s s e r ia

S. typh im u riu m

m e n in g itid is

aroA

S tre p to c o c c u s

S. typh im u riu m

pyogenes

aroA

E sc h e ric h ia
c o li

S. typh im u riu m

E sc h e ric h ia
c o li

S. typh im u riu m
aroA

Yes

Yes

ND

N/A

31 kDa

B ru c e lla

S. c h o le ra su is c y a
c rp c d t

No

Yes

ND

ND

31 kDa

a b o rtu s
B ru c e lla

S. typh im u riu m
aroA

Yes

No

ND

ND

a b o rtu s

Influenza A

S. typh im u riu m

Yes

Yes

Yes

Yes

M protein
K1 capsule
ßgalactosidase

Nucleoprotein

aroA

aroA

gpD

Herpes
Simplex

S. typh im u riu m
aro A

ND

ND

ND

Yes

gp63

P la sm o d iu m

»S', typh im u riu m
WR4024

No

Yes

ND

Yes

Dengue virus 4

S. typh im u riu m
aroA

ND

ND

ND

ND

Murine

S. typh im u riu m

ND

ND

ND

N/A

Yes

ND

ND

N/A

S. d u b lin aroA

Yes

ND

ND

Yes

S. d u b lin aroA

Yes

Yes

ND

ND

fa lc ip a r u m

Envelope
antigen
IL-6

aroA

IL -lß

Human

S. typh im u riu m
aroA

Flagellin-M

S tre p to c o c c u s
pyogenes

LTB-HBsAg

Hepatitis B

Ab = antibody responses detected; CMI = cell mediated response detected; CTL

Reference

Fairweather e t
a l, 1990
Strugnell e t al,
1992
Baron e t al,
1987
Tarkka e t al,
1989
Poirier e t al,
1988
O’Callaghan e t
al, 1988
Brown e t al,
1987
Stabe 1 e t al,
1993
Stabel e t al,
1991
Bao and
Clements, 1991
Bowen e t al,
1990
Aggarwal e t al,
1990
Roberts e t al,
1994
Dunstan e t al,
1996
Carrier e t al,
1992
Newton e t al,
1991
Schodel e t al,
1990
= cytotoxic T-

lymphocytes detected; Protection = protection from virulent challenge; ND = not determined; N/A =
not applicable.
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3.5

^•5*1

Materials and methods

Bacterial strains and plasmids

Plasmid DNA isolation and transformation were performed as described in Chapter 2.
All plasmids used to transform S. typhimurium SL3261 aroA (Hoiseth and Stocker,
1981) were modified to prevent host restriction by transforming initially into S.
typhimurium SL5283 (Hoiseth and Stocker, 1981) prior to isolation and subsequent
transformation into S. typhimurium SL3261.

Antibiotics were used at the following concentrations: chloramphenicol 50 pg/ml;
ampicillin 100 pg/ml. All bacteria were grown overnight on Z agar with appropriate
antibiotic selection then seeded into 250 ml LB with selection and grown at 37°C
overnight in a shaking incubator. For vaccine studies, overnight LB cultures were
used, seeded into 500 ml LB broth with selection and grown at 37°C to mid log phase
(OD650 0.5 - 0.6) prior to harvesting by centrifugation (2000 x g for 15 min).

Growth curves were performed to determine if the recombinant antigens being
produced by the strains containing the plasmids pKFl or pSD9 were deleterious to the
viability of those strains. Two growth curve experiments were carried out using either
S. typhimurium SL3261 (pKFl) or S. typhimurium SL3261 (pSD9). In both
experiments, S. typhimurium SL3261 and S. typhimurium SL3261 containing the
parental plasmid were grown as controls. All strains were grown overnight on Z agar
with appropriate antibiotic selection then subsequently seeded into 300 ml LB with
selection and grown at 37°C overnight in a shaking incubator. This overnight LB
culture was subsequently used to seed a 300 ml LB culture with selection and grown
at 37°C. Absorbance readings (OD 560 nm) were taken at time zero and at 30 minute
intervals until the absorbance reached a plateau.
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Viable numbers of bacterial cells for all Salmonella strains were determined by taking
duplicate samples in early, mid and late log phase. These samples were pelleted (2000
x g for 15 min) and resuspended to an optical density of 1. The samples were serially
diluted in sterile PBS and aliquots (100 pi) of each diluted sample were plated in
duplicate onto Z agar with the appropriate selection and incubated overnight at 37°C
prior to determining the number of viable bacterial cells grown.

3.5.2

Mice immunisation

Three independent mouse trials were carried out. Two trials were identical for
treatments and controls, these were pooled and labelled Trial 1 (Table 3.4). The other
trial had different treatment groups and is labelled Trial 2 (Table 3.5). Immunisation
was performed essentially as described by Guzman et al (1991). Six to eight week old
female BALB/c mice were caged separately according to treatment groups (Tables 3.4
and 3.5). For live oral vector and vaccine groups, cultures were grown to mid
logarithmic phase and subsequently pelleted by centrifugation (2000 x g for 15 min).
Bacteria were resuspended in ice cold PBS to an optical density corresponding to 2 x
109 viable bacteria per 100 pi. Immediately prior to immunisation an equal volume of
3% sodium bicarbonate in PBS was added to give the final working dilution of 1 x
109 viable bacteria per 100 pi. Mice in all oral groups were deprived of water 2 to 3
hours before delivery of the vaccine (100 pi of the bacterial suspension) through an
oesophageal cannula. For intraperitoneal (IP) immunisation a total of either 100 pg of
128 kDa fusion protein or 50 pg of 15 kDa NrdF protein was diluted in 50 pi then
subsequently emulsified in an equal volume of Freund’s complete adjuvant to give the
final 100 pi volume for the primary immunisation. In subsequent immunisations
Freund’s incomplete adjuvant was used, while the volume and antigen dose remained
identical to the primary immunisation.
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Table 3.4:

Mice immunisation protocol for trial 1

Trial 1
Group

Treatment

Number of

Dose

Route

mice
a

PBS

8

100 pi

Oral

b

SL3261

9

109 bacteria

Live oral

c

SL3261(pSD9)

7

109 bacteria

Live oral

d

128 kDa fusion
protein

8

100 pg in
adjuvant

Intraperitoneal

Primary immunisation at day 0, boosters at day 30 and day 40 and sacrificed at day 50

Table 3.5:

Mice immunisation protocol for trial 2.

Trial 2
Group

Treatment

Number of
mice

Dose

Route

e

PBS

5

100 pi

Oral

f

SL3261

5

109 bacteria

Live oral

g

SL3261(pKFl)

10

109 bacteria

Live oral

15 kDa NrdF
protein

5

50 pg in
adjuvant

Intraperitoneal

h

Primary immunisation at day 0, boosters at day 30 and day 40 and sacrificed at day 50.

All mice received primary immunisation at day 0, boosters at days 30 and 40 and were
sacrificed at day 50. Mice were killed by cervical dislocation prior to exsanguination
by the severing of the brachial artery. Sera were collected and stored at -20°C. Lung
lavages were collected by pertracheal cannulation by instilling 0.8 ml of PBS
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containing 2 mM phenylmethylsulfonylfloride. Lung lavages were centrifuged briefly
at 3000 x g to remove debris then stored at -20°C.

3.5.3

Enzyme linked immunosorbant assay

An enzyme linked immunosorbant assay (ELISA) was used to determine mouse
antibody responses for IgA, IgM and IgG isotypes in sera and lung lavage samples.
Primary antigen was either 15 kDa NrdF protein diluted to a final concentration of 1
pg/ml in carbonate buffer (30 mM sodium carbonate, 20 mM sodium hydrogen
carbonate, pH 9.6), or S. typhimurium aroA SL3261 whole cell lysate, prepared by
boiling 10 mg of cell pellet for 10 min in 0.5 M Tris-HCl (pH 6.8) containing 1%
glycerol, 0.2% SDS and 0.5% (3-mercaptoethanol. Whole cell lysate was then pelleted
(16000 x g 3 min RT) to remove debris and the protein concentration adjusted to 1
pg/ml in carbonate buffer prior to use. Aliquots (100 pi) of the primary antigen were
coated to 96 well microtitre plates (Nunc) by incubation for 1 h at 37°C. Plates were
subsequently washed 5 times with 0.05% Tween 20 (Sigma) in PBS (pH 7.4). First
antibody was mouse sera diluted 1 in 200, or lung lavage samples diluted 1 in 20; in
both cases diluent was PBS containing 10% foetal bovine serum and 0.05% Tween
20. Aliquots (100 pi) of the first antibody were added in triplicate and incubated for 1
hr at 37°C. Following incubation, plates were washed as previously described and 100
pi aliquots of horseradish peroxidase conjugated rabbit anti-mouse immunoglobulin
antibodies (Bio Rad) diluted in PBS (pH 7.4) containing 10% foetal bovine serum and
0.05% Tween 20 were added to each well. Rabbit anti-IgG (KPL) and anti-IgM (KPL)
second antibodies were diluted 1 in 2000, whereas anti-IgA (KPL) was diluted 1 in
400. Plates were incubated at 37°C for 1 h then washed as described above. ELISA
plates were developed using 100 pi aliquots of tetramethylbenzidine dihydrochloride
(Sigma). Development was stopped after 3 min by the addition of 50 pi 0.1 M
phosphoric acid and the absorbance was read at 450 nm. Plates were blanked against a
PBS control and variation between plates was standardised using positive control sera
allowing isotype comparisons between groups.
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The surface accessibility of the NrdF antigen to the mouse immune response on intact
M. hyopneumoniae cells was examined using whole cell ELISA. Coating of the plates
with whole cells is described in section 2.3.6. Mouse primary antibodies were
processed as described above.

ELISA was also used to determine the immunogenicity of the NrdF protein in infected
swine sera (n = 6) from a previously described M. hyopneumoniae challenge trial
(section 2.1). Primary antigen was 15 kDa NrdF protein prepared as described above.
Primary antibody was swine serum diluted 1 in 100 in PBS (pH 7.4) with 2% skim
milk powder (w/v) and 0.05% Tween 20. Secondary antibody (horseradish peroxidase
conjugated goat anti-swine IgG (KPL) diluted 1 in 500 in PBS (pH 7.4) with 2% skim
milk powder (w/v) and 0.05% Tween 20. All incubation conditions, plate washes
between incubations and the development of ELISA plates were carried out as
described above.

3.5.4

Statistical analysis

Treatment group antibody responses determined by ELISA results were compared
against the oral PBS control treatment group using a Tukey multiple comparison test
for unequal sample sizes as described by Zar (1984).
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3.6

Results

3.6.1

Expression of recombinant proteins in Salmonella
typhimurium aroA strains

In attenuated S. typhimurium aroA SL3261 (pSD9), a recombinant 128 kDa fusion
protein, analogous to the E. coli (pSD9) protein, was expressed. This protein
comprised 11 kDa of a 42 kDa M. hyopneumoniae NrdF protein fused to the carboxyterminus of the 117 kDa fi-galactosidase protein (Fig 3.6, lane 1). The S. typhimurium
aroA SL3261 (pKFl) strain expressed a 15 kDa non-fusion protein (Fig 3.7, lane 3),
consisting of 11 kDa from the carboxyl-terminus of the 42 kDa M. hyopneumoniae
NrdF protein and the remainder being the polycloning region of pHSG398 (Stanley
andLuzio, 1984).

3.6.2

Viable counts and growth curves

There were no significant differences between strains in the number of viable bacteria
after samples were standardised to an optical density of 1.0 (Table 3.6)

Table 3.6:

Salmonella strain viable numbers after standardisation to an
optical density of 1.0.
Viable number per 100 pi

Standard deviation

S. typh im u riu m SL3261

1.83 x 1010

1.0 x 109

S. typh im u riu m SL3261 (pE X l)

1.03 xlO 10

0.3 xlO 9

S. typh im u riu m SL3261 (pSD9)

1.30 x 1010

0.2 x 109

S. typh im u riu m SL3261 (pHSG398)

1.43 xlO 10

0.6 x 109

S. typh im u riu m SL3261 (pK Fl)

1.20 x 1010

0.3 x 109

Bacterial Strain
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Fig 3.6:
SL3261.

Expression and identification of 128 kDa fusion protein in S. typhimurium
A.

Coomassie brilliant blue stained 11% PAGE gel. Lane l, S. typhimurium

SL3261 (pSD9); Lane 2, S. typhimurium SL3261; Lane 3, S. typhimurium SL3261
(pEXl); Lane 4, R coli MC1061 (pSD9). Positions of molecular weight markers (in kDa)
are indicated on the left of the gel. B. Western blot analysis of identical samples described
above using rabbit 128 kDa fusion protein antiserum. The recombinant fusion protein is
indicated with an arrow on the right of the blot
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A

B
1 2 3 4

1 2 3 4
49

33
28.6
19.4

Fig 3.7:
Expression and identification of 15 kDa NrdF antigen in S. typhimurium
SL3261. A. Coomassie brilliant blue stained 15% PAGE gel. Lane 1, S. typhimurium
SL3261; Lane 2, purified recombinant 15 kDa NrdF antigen; Lane 3, S. typhimurium
SL3261 (pKFl); Lane 4, S. typhimurium SL3261 (pHSG398). Positions of molecular
weight markers (in kDa) are indicated on the right of the gel. B. Western blot analysis of
identical samples described above using rabbit 15 kDa NrdF antigen antiserum. The
recombinant NrdF antigen is indicated with an arrow on the left of the gel.
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Fig 3.8:

Growth of S. typhimurium SL3261 (pSD9) overtime. Immunisation

groups are indicated as follows: S. typhimurium SL3261 (open box); S. typhimurium
SL3261(pEXl) (half filled box); S. typhimurium SL3261 (pSD9) (filled box).
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Time (hours)

Fig 3.9:

Growth of S. typhimurium SL3261 (pKFl) overtime. Immunisation

groups are indicated as follows: S. typhimurium SL3261 (open box); S. typhimurium
SL3261(pHSG398) (half filled box); S. typhimurium SL3261 (pKFl) (filled box).
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S. typhimurium SL3261 containing either pSD9 or the parental pEXl plasmids do not
grow as well as the same strain without the plasmid burden. Growth curves
demonstrate that the overproduction of the pEXl-encoded 117 [3-galactosidase protein
or the pSD9-encoded 128 kDa recombinant NrdF fusion protein causes the strain to
grow at a slower rate (Fig 3.8). S. typhimurium SL3261 containing either pKFl or the
parental pHSG398 plasmids are not burdened by the expression of the respective
recombinant antigens (Fig 3.9).

3.6.3

Assessment of antibody responses in immunised mice

In both trials the absence of IgM antibody in lung lavage samples precludes the
possibility of serum contamination of the mucosal washes. Consequently, the isotypes
detected in the mouse lung lavage samples can be considered an accurate indication of
immunoglobulin isotypes present.

Oral delivery of the live S. typhimurium SL3261(pSD9) and S. typhimurium
SL3261(pKFl) vaccine strains elicited significant (P < 0.05) NrdF IgA antibody
responses in the lungs of vaccinated mice (Fig 3.10 A and C, groups c and g
respectively). This delivery route in Trial 1 elicited significant IgG in the lungs,
however, in Trial 2 the observed increase in IgG was not significant (P < 0.05)
(compare Fig 3.10 A, group g against group f). Similarly, oral immunisation with S.
typhimurium SL3261(pSD9) elicited a significant 15 kDa NrdF serum IgG response
(Fig 3.11 A group c), whereas in Trial 2 the increase in serum IgG for the
corresponding treatment was detected but was not significant (Fig 3.11 C, group g). In
both trials oral immunisation with the vaccine strains did not elicit significant IgM
responses in the lungs or serum (Fig 3.10 A and C, groups c and g, and Fig 3.11 A and
C, groups c and g).
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Fig 3.10:

Levels of recombinant 15 kDa NrdF specific IgG, IgM and IgA

antibodies in mouse lung lavage samples after vaccination. A. Lung antibody levels
from trial 1 specific for 15 kDa NrdF protein. B. Lung antibody levels from trial 1
specific for S. typhimurium SL3261 whole cell proteins. C. Lung lavage antibody
levels from trial 2 specific for 15 kDa NrdF protein. D. Lung lavage antibody levels
from trial 2 specific for S. typhimurium aroA SL3261 whole cell proteins.
Designations under the graphs correspond to treatment groups outlined in the
immunisation protocol (Table 3.4 and 3.5). Standard error of the mean is indicated by
vertical lines. Statistical significance (P < 0.05) comparing treatments against the PBS
oral control group is indicated by an asterisk (*).
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h

Fig 3.11:

Levels of recombinant 15 kDa NrdF specific IgG, IgM and IgA

antibodies in mouse serum samples after vaccination. A. Serum antibody levels from
trial 1 specific for 15 kDa NrdF protein. B. Serum antibody levels from trial 1 specific
for S. typhimurium SL3261 whole cell proteins. C. Serum antibody levels from trial 2
specific for 15 kDa NrdF protein. D. Serum antibody levels from trial 2 specific for S.
typhimurium aroA SL3261 whole cell proteins. Designations under the graphs
correspond to treatment groups outlined in the immunisation protocol (Table 3.4 and
3.5). Standard error of the mean is indicated by vertical lines. Statistical significance
(P < 0.05) comparing treatments against the PBS oral control group is indicated by an
asterisk (*).
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Fig 3.12:
Levels of recombinant 15 kDa NrdF specific IgG and IgA antibodies
detected in whole cell M. hyopneumoniae ELISA. A. mouse serum from trial 2. B. lung
lavage samples from trial 2. Standard error of the mean is indicated by vertical lines.
Designations under the graphs correspond to treatment groups outlined in the
immunisation protocol (Table 3.5). Statistical significance (P < 0.05) comparing
treatments against the PBS oral control group is indicated by an asterisk (*).
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All mice orally immunised with S. typhimurium aroA SL3261 and S. typhimurium
aroA SL3261 vaccine strains had significant (P < 0.05) Salmonella IgG and IgM
antibody responses in serum (Fig 3.11 B and D, groups b, c, f and g) and IgA
responses in lung lavage samples (Fig 3.10 B and D, groups b, c, f and g). These
results indicate that the Salmonella vector is being recognised and processed by the
hosts immune system and subsequently elicits a response. However, the
intraperitoneal delivery of the M. hyopneumoniae NrdF protein also induced
significant serum IgG, IgM (Fig 3.11 B and D, groups d and h) and lung IgG
Salmonella antibody responses (Fig 3.10 B and D, groups d and h) indicating cross
reactivity between the recombinant NrdF protein and epitopes found in the S.
typhimurium SL3261.

Intraperitoneal delivery of the 15 kDa NrdF antigen in Trial 2 (Fig 3.11 C, group h)
elicited significant (P < 0.05) serum IgG, IgM and lung IgG responses (Fig 3.10 C,
group h). This delivery route in Trial 1, using the 128 kDa fusion protein, elicited a
significant IgG response in the serum (Fig 3.11 A, group d), however, all other isotype
responses in the lungs and serum within this treatment group were not significant.

In mice orally immunised with the 15 kDa antigen (Trial 2) there were significant
secretory IgA levels (P < 0.05) which recognise the cell surface of M. hyopneumoniae
in whole cell ELISA (Fig.3.12 B, group c). Significant serum IgG in the
intraperitoneally immunised 15 kDa treatment group (Fig.3.12 A, group d) was also
observed.
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3.6

Discussion

The burden of expressing the 128 kDa fusion protein in S. typhimurium SL3261
(pSD9) appears to stress the vaccine strain, resulting in slower growth and decreased
tolerance to higher bacterial numbers in culture. S. typhimurium SL3261 (pKFl)
strain, which expresses the 15 kDa NrdF antigen, grew at the same rate as the control
SL3261

The recombinant 15 kDa antigen encoded by the plasmid pKFl has no carrier
molecule that would direct the protein to a particular cellular location. Interestingly
there is no requirement to use strategies to express the NrdF antigen on the bacterial
surface in order to promote a lung mucosal IgA response after oral vaccination. Due to
a demonstrated 51% identical amino acid similarity, 61% similarity if conserved
amino acids are considered (Table 2.3), some degree of cross reactivity is expected
between the NrdF M. hyopneumoniae antigen and the NrdF protein of S. typhimurium.
This does present a problem in the detection of NrdF specific antibody responses.
Antibodies raised against the M. hyopneumoniae NrdF antigen recognise cross
reactive epitopes in the S. typhimurium aroA SL3261 ELISA, resulting in high
absorbance values in this ELISA due to the excess of S. typhimurium coating antigen
in the assay wells. The lack of antibody response in the S. typhimurium aroA SL3261
oral control groups against M. hyopneumoniae NrdF protein (Fig.3.12 A and C,
groups b and f) indicates that the bacterial cross-reactive antigen is not immunogenic.
This could be due to either the S. typhimurium protein not being expressed in
sufficiently large quantities to induce a humoral immune response, or the bacterial
antigen may not be processed and presented to the host immune system.

Results unique to Trial 2 were the presence of significant serum NrdF IgA in the oral
vaccine (compare Fig 3.11 A, group c to Fig 3.11 C, group g), significant serum
SL3261 IgA in the oral control groups (compare Fig 3.11 B, group b to Fig 3.11 D,
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group f), and significant serum NrdF IgM in the IP group (compare Fig 3.11 A, group
d to Fig 3.11 C, group h). It is feasible that the 128 kDa fusion protein does not elicit
the same serum immunoglobulin responses that are stimulated by the 15 kDa NrdF
antigen.

The results described in this chapter demonstrate that, in mice, the recombinant
vaccine strains are able to stimulate M. hyopneumoniae NrdF specific secretory IgA
antibody in lungs and IgG in the serum after oral delivery. Furthermore, whole cell
ELISA demonstrates the surface accessibility of the in-situ NrdF protein in M.
hyopneumoniae to these mouse antibodies elicited against the pKFl-encoded 15 kDa
NrdF antigen. Whole cell ELISA examination of the surface accessibility of the wild
type NrdF subunit by mouse antibodies raised against the pSD9 encoded 128 kDa
fusion protein was not undertaken. Due to the reduced growth rate demonstrated in
growth curves and potential problems associated with the 117 kDa P-galactosidase
fusion protein component, the S. typhimurium SL3261 (pSD9) vaccine strain was not
chosen as the candidate vaccine strain for use in pig trials.

The successful oral immunisation against a heterologous mycoplasmal antigen in a
Salmonella vector is unique not only because it demonstrates that there are no
problems associated with the adenosine-tyrosine bias and different codon usage
between the selected mycoplasma antigen and Salmonella vector, but also because an
immune response specific for this antigen can reduce the severity of PEP in swine
(Chapter 2). Although there are differences between the mucosal immune physiology
of mice and swine, the induction of a secretory response, in mice, against a
metabolically essential ribonucleotide reductase from a swine respiratory pathogen
provides evidence that this vaccine strain may prove to be efficacious in protecting
swine from M. hyopneumoniae infection.
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Chapter 4
Assessment of Immune Protection of Swine Orally Vaccinated with
Attenuated Salmonella typhimurium SL3261 aroA Expressing the
Recombinant 15 kDa M. hyopneumoniae NrdF Antigen.

Studies examining the complex interactions between the swine host and colonising M.
hyopneumoniae have not as yet demonstrated a correlation between any single
specific immune response and protection from PEP. In a recent study, pigs
parenterally immunised with a pool of M. hyopneumoniae antigens were shown to
have reduced lung pathology

compared to unvaccinated controls. Serum and

respiratory tract washing IgG and IgA concentrations in this study were demonstrated
to be a poor prognostic indicator of protection against enzootic pneumonia (Djordjevic
et al, 1997). However, resolution of the disease has been correlated with both the
presence of serum antibodies (Messier et al, 1990) and an increase in cell-mediated
immunity (CMI) during the later stages of infection (Adegboye, 1978a; Messier et al,
1990). Current commercial vaccines comprise bacterin formulations which reduce the
severity of PEP (Bilic et al, 1992; Christensen & Vraa-Andersen, 1993; Charlier et al,
1993; Murphy et al, 1993; Dohoo and Montgomery, 1996). Whilst most of the studies
have reported reductions in lung damage caused by PEP after bacterin immunisation,
some studies failed to demonstrate economic improvement to pig production such as
increases in average daily gains (Murphy et al, 1993; Morrow et al, 1994).
Furthermore, the labour intensive mode of delivery and the cost of purchasing such
vaccines may not justify their widespread commercial use. The purpose of the work
described within this chapter was to evaluate whether oral immunisation of swine with
the S. typhimurium SL3261 (pKFl) vaccine strain (described in Chapter 3) can elicit
a mucosal immune response in the lungs and stimulate cellular and humoral immune

116

responses in the serum. Furthermore, the effectiveness of this vaccine strain to protect
swine from challenge with virulent M. hyopneumoniae was assessed.

4.1

4.1.1

Salmonellae in swine

Natural infections caused by Salmonellae

Swine are naturally infected with a number of Salmonellae serotypes. The resulting
disease, porcine salmonellosis, manifests itself predominantly as septicemia or
enterocolitis although pneumonia, encephalitis, meningitis, rectal stricture and
lymphadenitis have also been reported as symptoms of this condition (Reed et al,
1986). Salmonella choleraesuis is the predominant organism associated with porcine
salmonellosis (Minev et al, 1984; Minev et al, 1987) and is usually associated with
septicaemic disease (Wilcock et al, 1976). S. typhimurium is the second most
frequently isolated pathogen in salmonellosis and is associated with the enteric form
of the disease (Wilcock et al, 1976; Reed et al, 1986). A large number of other
serotypes are associated to a lesser degree. A comprehensive study of porcine
salmonellosis in Bulgaria between 1970 and 1985 reported S. choleraesuis and S.
typhimurium as the predominant causal serotypes but also detected Salmonella agona,
Salmonella jerusalem,

Salmonella

tennessee,

Salmonella

bovis-morbificans,

Salmonella derby, Salmonella thompson and other undefined exotic serotypes (Minev
et al, 1984; Minev et al, 1987).

4.1.2

Attenuated S. typhimurium strains in swine

Infection of swine with virulent Salmonella spp. occurs by the same route as described
in section 3.5 (Salmonella typhimurium pathogenesis). The organism invades the
Peyer’s patch regions of pigs and colonises the intestine and mesenteric lymph nodes
(Stabel et al, 1991) stimulating secretory, humoral and CMI responses (Reed et al,
1986). In swine, aroA mutants of S. typhimurium have been demonstrated to be both
safe and efficacious in protecting immunised swine from infection with the virulent
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parental strain (Lumsden and Wilkie, 1992). Both attenuated S. typhimurium and S.
choleraesuis have been used to deliver a 31 kDa Brucella abortis antigen to the
mucosal immune system of swine (Stabel et al, 1991; Stabel et al, 1993). Delivery of
the 31 kDa antigen using attenuated S. typhimurium stimulated mucosal (intestinal)
and systemic antibody responses, however, no DTH or lymphoproliferative responses
were detected (Stabel et al, 1991). Conversely, delivery of the 31 kDa antigen using
attenuated S. choleraesuis stimulated DTH responses but no mucosal or systemic
antibody responses (Stabel et al, 1993). These results indicate that the elicited immune
response varies with the delivery vector strain and possibly with the amount of
antigen delivered. To date there has been no study into the use of an attenuated
Salmonella to deliver antigen for the stimulation of immunity against a mucosal lung
pathogen of swine.
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4.2

4.2.1

Materials and methods

Bacterial strains, plasmids and media

Bacterial strains used in this work are described in Table 2.1. For vaccination, S.
typhimurium SL3261 containing either the plasmid pKFl encoding the 15 kDa NrdF
antigen or the parental plasmid pHSG398 (Takeshita et al, 1987) were grown to mid
logarithmic phase in an orbital incubator at 37°C and subsequently pelleted by
centrifugation (2000 x g for 10 min). Bacteria were then resuspended in ice cold PBS
(pH 7.2) to an optical density corresponding to 2 x 109 viable bacteria per ml and
stored on ice. Immediately prior to immunisation, an equal volume of 3% sodium
bicarbonate in PBS (pH 7.2) was added to give the final working dilution of 1 x 109
viable bacteria per ml in a final volume of 20 ml. For delayed type hypersensitivity
(DTH) and lymphoprolifération assays, S. typhimurium SL3261 (pHSG398) cells
were similarly grown and pelleted then placed in a boiling water bath for

10 min to

heat kill the bacteria prior to use.

4.2.2

Viability of vaccine strain after storage on ice

The viability of the S. typhimurium SL3261 and S. typhimurium SL3261 (pKFl)
strains after storage on ice was determined by preparing the strains for oral
immunisation (section 3.5: Mice immunisation). At hourly intervals, samples were
taken and a serial dilution series was made. Aliquots (100 pi) of each diluted sample
was plated in duplicate onto Z agar with the appropriate selection and incubated
overnight at 37°C prior to determining the number of viable bacterial colonies.

4.2.3

Experimental animal procedures

Pigs were anaesthetised for the collection of respiratory tract washings (RTW),
challenge with virulent M. hyopneumoniae (Beaufort strain) and for DTH testing. Pigs
between the ages of 6 to

10 weeks old were restrained in a bleeding cradle in dorsal

recumbency and anaesthetised with a mixture of xylazine
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(100 mg/ml) and ketamine

(100 mg/ml) formulated at 0.25 ml and 1 ml per 10 kg weight. Older pigs were
restrained with a nose snare and anaesthetised with a similar mixture of xylazine and
ketamine formulated at 0.28 and 1.12 ml per 10 kg weight. Blood samples were
collected by venipuncture of the precava and RTW were collected by intubation.
Following the introduction of an endotracheal tube a 10 ml aliquot of PBS was
instilled and immediately removed by aspiration under vacuum using a fine

(2 mm)

silicon tube within the endotracheal tube. Pigs were challenged using infected lung
filtrate. Consolidated infected lung tissue from pigs previously infected with the
virulent M hyopneumoniae Beaufort strain and stored at -70°C was thawed,
macerated in PBS (pH 7.2) and filtered through cheese cloth. Aliquots of 20 ml
(equivalent to 9.2 g wet weight of infected lung) were administered to anaesthetised
pigs through a silicon tube (4 mm) located within the endotracheal tube. For DTH and
mitogenicity assays, inoculation of antigen or mitogen was given in triplicate in the
ventral skin 2-3 cm lateral to the nipple line using 100 pi of 50 pg/ml antigen at each
test site. Antigens used in the DTH tests during weeks 0 and 5 were purified 15 kDa
NrdF antigen, heat killed whole cells of S. typhimurium SL3261 (pHSG398) and PBS.
Phytohaemaggluttinin (PHA) was used as the mitogen. Only the mitogenicity assay,
using PHA and PBS, was carried out at week 12. Tests were read as skin thickening
(mm) at 48 h using a micrometer calliper.

Pig trials were carried out to assess the ability of the S. typhimurium SL3261 (pKFl)
vaccine strain to elicit immune responses in immunised swine and to determine the
protective efficacy against subsequent challenge. Five to six week-old pigs sourced
from a M. hyopneumoniae-frQQ piggery were allocated to 4 treatment groups as
indicated in Table 4.1. Pigs were double ear-tagged and individually weighed 5 days
before the start of the trial, with groups and pens balanced by weight. Pigs allocated to
the oral salmonella vector and oral salmonella vaccine groups were housed separately
in one of two air-conditioned high security rooms each containing 5 pigs. Pigs in the
control and NrdF intramuscular groups were housed in an experimental piggery with
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3-4 pigs per pen, as mixed treatment groups. The number of pigs per treatment was
also balanced on both sides of the piggery, to reduce pen effects. The pigs were fed an
antibiotic-free grower ration twice daily (at approximately 80% ad libita until
slaughter at 19 weeks of age. All pig handling was performed with pigs in the lower
security area before any movement of personnel to the high security area. Pigs in the
oral salmonella vector group were always handled before those in the oral salmonella
vaccine group. Personnel working in the high security facility used separate work
clothes and waterproof overgarments which were disinfected on exit from each pen.

The time course of procedures used in the live oral vaccination and challenge trial are
outlined in Table 4.2. At week 12, pigs were weighed and the average daily weight
gain was calculated. Pigs were slaughtered at the end of week 12 and the lungs were
collected to determine the extent of damage. Lung damage was determined both by
Goodwin lung score (GLS) (Goodwin, 1969) and by the weighing of excised affected
tissue and comparison with the average weight of all lungs in the trial. This value was
then expressed as a percentage.

Table 4.1. Pig immunisation treatment groups.
Treatment

Number of Pigs

Dose

Route

15 kDa NrdF
intramuscular (IM)

6

1 ml containing 1.8
mg/ml mixed 1:1

Intramuscular

with alhydrogel
Control

6

-

-

Oral Salmonella
vector

5

20 ml containing 1 x
109cfu/ml

Live oral

5

20 ml containing 1 x
109cfu/ml

Live oral

S. typ h im u riu m SL3261

(pHSG398)

Oral Salmonella
vaccine
S. typ h im u riu m SL3261

(pKF 1)
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Table 4.2:

M. hyopneumoniae live oral vaccine trial protocol.

Procedure

WeekO

Week 3

Immunisation
*

All groups

All
groups

Week 5

Challenge

Week 10

Week 12#

All
groups

All groups

All groups

Bleed

All groups

RTW

All groups

All
groups

All groups

All groups

All groups

All groups

All groups

All groups
except NrdF
IM

All groups
except NrdF
IM

DTH
Lympho
prolifération

All groups
except NrdF
IM

Weigh

All groups

All groups

control pigs did not receive any immunisation.
^Pigs were slaughtered and the lungs assessed for PEP damage after week 12.

4.2.4

Lymphocyte proliferation assays

Lymphoprolifération assays were carried out by B. Turner at EMAI. These assays
were performed on separated lymphocytes derived from blood collected from control,
oral salmonella vector and oral salmonella vaccine groups at pre-vaccination (week.O),
post-vaccination (week.5), and post-challenge (week. 12). Blood was collected in
heparinised vacuum tubes and processed within 4 hours from the time of collection.
Blood (3 ml) was diluted with an equal volume of saline (0.85% w/v NaCl) and
layered onto 3 ml of Nycoprep (density 1.077 g/cm3) then centrifuged at 2200 rpm
(1200 x g) for 20 min at room temperature. Lymphocytes partitioning at the interface
were aspirated into PBS containing 1% w/v glucose. The cells were pelleted by
centrifugation at 1200 rpm (700 x g) for 10 min. Erythrocyte contaminants in the
preparation were lysed by brief resuspension of the cell pellet in 5 ml AMCO [0.85%
(w/v) NH4CI, 0.1% (w/v) KHC03, 10 mM EDTA]. The erythrocyte-free cell pellet
was recovered by centrifugation and washed twice in
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8 ml of PBS containing 1% w/v

glucose. The washed cell pellet was then dispersed gently in Complete Medium (CM)
(RPMI 1640 containing 5% foetal calf serum, 2 mM L-glutamine, 2 mM sodium
pyruvate, 50 pM 2-mercapto-ethanol, 50 pg/ml penicillin and 50 I.U./ml
streptomycin) at a cell density of 4 x

106/ml. Lymphoprolifération was carried out in

triplicate by delivering 2 x 105 cells in 50 pi CM to each well of a flat-bottomed 96well plate containing 200 pi of CM supplemented either with heat-killed M.
hyopneumoniae (J strain) or S. typhimurium (pHSG398) (107 colony forming units
per well) or purified M. hyopneumoniae 15 kDa NrdF antigen (20 pg per well).
Lymphocyte cultures were incubated at 37°C in 10% CO2 for 6 days and then pulsed
for 18 h with 0.5 pCi -^H-thymidine (925 Gbq/mmol, 25 Ci/mmol, Amersham). The
cells in each well were then harvested onto glass fibre discs using a PHD cell
harvester (Cambridge Technology), transferred into Pony vials (Packard) containing
2.5 ml of scintillant (Ultima Gold, Packard) and counted in a LKB scintillation
counter. Stimulation indices were expressed as a ratio of counts per minute for each
triplicate culture containing antigen to an equivalent replicate set without antigen.

4.2.4

Enzyme linked immunosorbant assay (ELISA) and Western
blot analysis

The Auspharm™ M. hyopneumoniae ELISA was used to determine the serological
status of swine according to the method described by Sheldrake and Romalis (1992).
Other ELISA methods based on 15 kDa NrdF antigen or whole cell S. typhimurium
SL3261 antigens were performed as described in Chapter 2 with the following
modifications. Primary antibody was pig serum or RTW diluted according to the
immunoglobulin isotype being tested. ELISA detection of serum IgG used pig serum
diluted 1 in 100 in PBS (pH 7.4) containing 2% skim milk powder and 0.05% Tween
20 (Sigma) (PST). In the determination of all other isotypes a blocking step of 200 pL
PST incubated for 1.5 h at room temperature was carried out prior to the addition of
the primary antibody. Primary antibody was diluted 1 in 2 with PST in the RTW IgG
ELISA. The primary antibody for all IgA ELISA was neat serum or RTW. Secondary
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antibodies were horseradish peroxidase conjugated goat anti-swine IgG (Bethyl
Laboratories) diluted 1 in 500 using PBS (pH 7.4) or horseradish peroxidase
conjugated goat anti-swine IgA (Bethyl Laboratories) diluted 1 in 400 using PBS (pH
7.4).

Plates

were

developed

using

100

pi

of

1

mM

2,2’-

azinodiethylbenzthiazolinsulfonate (KPL) and read at 405 nm. Positive and negative
control swine sera was used to allow comparisons of the same isotype between plates.
A pooled swine prebleed serum was used as a negative control to determine
background.

Western blot analysis was performed according to the modified method of Burnette
(1981) in Chapter 2 (Section 2.2. SDS-PAGE and Western blot analysis). Rabbit anti15 kDa NrdF serum was used as the primary antibody in Western immunoblots. Pig
sera used to investigate the immunological recognition of the NrdF protein in swine
were raised as described in Chapter 2 (Section 2.1: Preliminary research).

4.2.5

Statistical analysis

The effects of vaccination on lung scores, ELISA values and lymphocyte proliferation
results were analysed within the same treatment group over time (if applicable) and
between all treatment groups at the same time point. Values were initially assessed
using analysis of variance (Zar, 1984) to indicate whether two or more of the samples
displayed significant treatment effects. If a significant difference (P < 0.05) was
obtained, a Tukey multiple comparison test for unequal sample sizes (Zar, 1984) was
used to determine significance.
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4.3
4.3.1

Results
Strain viability after storage on ice

Both strains used for the oral immunisation of swine, S. typhimurium SL3261 and S.
typhimurium SL3261 (pKFl), remained viable on ice until the end of monitoring at

6

h (Fig 4.1). This indicates that variability between pig responses is due to differences
in the swine and not due to the strain losing viability over time.

4.3.2

Antibody response against NrdF protein in swine after
experimental M. hyopneumoniae infection

The sera of the pigs experimentally infected with a virulent strain of M.
hyopneumoniae (section 2.1: Preliminary research) produced an antibody response
against the 15 kDa NrdF antigen. Whilst pre-challenge serological responses against
NrdF were consistently low, experimentally infected pigs developed significant (P <
0.05) levels of serum IgG against the NrdF antigen. These significant antibody levels
remained elevated for at least 3 weeks post-challenge (Fig. 4.2).

4.3.3

Swine morbidity associated with vaccination and challenge

Swine given two oral doses of S. typhimurium SL3261 showed no signs of morbidity,
diarrhoea or lethargy, associated with oral immunisation using live attenuated
bacteria. Four weeks after challenge, one pig from the control group died from severe
pneumonia, indicated by a Goodwin lung score of 55, complicated by secondary
Actinomyces pyogenes infection which was confirmed by culture. One pig from the
NrdF intramuscular group and one from the control group died during week 12 from
mesenteric torsion possibly associated with handling during anaesthesia (Noyes et al,
1988). Two pigs from the oral salmonella vector group had lesions characteristic of A.
pleuropneumoniae
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Fig 4.1

Viability o f immunisation strains, S. typhimurium SL3261(open squares) and

S. typhimurium SL3261 (pK Fl) (red filled squares), after storage on ice.
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Fig. 4.2.

ELISA detection o f antibodies specific for the 15 kDa NrdF antigen in

experimentally challenged swine. Pigs from a M hyopneumoniae-frQQ piggery were bled
at weekly intervals and the animals were challenged with virulent Beaufort strain o f M

hyopneumoniae at week 10 (indicated by an arrow). ELISA absorbance results are not
blanked against a prebleed. Vertical bars represent standard deviation o f the mean.
Statistical significance (P < 0.05) comparing bleeds against week 0 bleed is indicated by
an asterisk (*).
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which were confirmed by culture and one of these pigs also had severe fibrinous
pleuritis and concurrent infection with P. multocida and A. pyogenes. There were no
other complicating factors or secondary infections identified in this vaccine trial.

4.3.4

Incidence and extent of PEP disease in challenged swine

Seven weeks following endotracheal challenge, M. hyopneumoniae specific antibodies
were detected in all animals using the Auspharm ELISA (Fig. 4.3). All groups, except
for the NrdF intramuscular group, when compared with a stock PEP negative control
serum had a mean ELISA ratio greater than the positive cut off point of 3 indicating
positive PEP status. The NrdF intramuscular group had an average ELISA ratio of
2.92 (± 0.53) which is in the high inconclusive range (2 to 3). At necropsy, pigs from
the oral salmonella vaccine group had visibly healthier lungs. This oral salmonella
vaccine group had the lowest incidence of lung damage when measured by the
percentage weight of affected lung with a mean of 6.4% ± 6.8, and the second lowest
GLS with a mean of 16 ± 5.6 (Fig. 4.4). The NrdF intramuscular group also had a
relatively low incidence of lung damage, when compared to the control groups, as
measured by weight of tissue affected 7.5% ± 4.0 and the lowest incidence of damage
when measured by GLS with a mean score of 15.3 ± 4.1. The control and oral
salmonella vector groups had percentage lung affected values of 11.9% ± 5.65 and
14.24% ± 9.27 respectively and GLS of 24.2 ± 6.4 and 26.2 ± 6.8 (Fig. 4.4).

4.3.5

Lymphoproliférative responses in pigs

The CMI response of pigs was determined by lymphoprolifération utilising
lymphocytes purified from blood collected before vaccination (week 0), at post
vaccination but before experimental challenge with M. hyopneumoniae (week 5), and
also at post-challenge (week 12). Three different antigens were used in these
lymphoprolifération assays. Fig. 4.5 shows that unvaccinated pigs and pigs in the oral
salmonella vector and vaccine groups had stimulation indices below 2.5 at week. 0,
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Fig. 4.3.
M. hyopneumoniae specific Auspharm™ antigen ELISA representing the
average antibody ratio for each treatment group at different time points during the pig
trial. An ELISA ratio below 2 is characteristic of a PEP negative sample group, 2-3 is
inconclusive and above 3 is indicative of PEP infection. Treatment groups are indicated
as follows: NrdF intramuscular (red filled box); control (open box); oral salmonella
vector group (cross hatched box); oral salmonella vaccine group (black filled box). Error
bars indicate standard deviation of the treatment groups. Arrow indicates time of M.
hyopneumoniae challenge.
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Fig. 4.4.
Percentage lung affected by lesions in individual pigs at slaughter as
determined by the weight of affected damaged tissue compared to an average weight of
all pig lungs in the trial. Immunisation groups were: (A) NrdF intramuscular (average
7.5%); (B) control (average 11.9%); (C) oral salmonella vector group (average 14.2%);
(D) oral salmonella vaccine group (average 6.4%). Swine treatment group averages are
represented by a horizontal bar.
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Fig. 4.5.

Lymphocyte proliferation responses of pig treatment groups at week 0

(Wk 0; prebleed), week 5 (Wk 5; postvaccination/prechallenge) and week 12 (Wk 12;
post challenge). Antigens used as immunostimulants were (A) M. hyopneumoniae
whole cell proteins; (B) S. typhimurium whole cell proteins; and (C) 15 kDa NrdF
antigen. Immunisation groups are indicated as follows: control (red filled box); oral
salmonella vector group (cross hatched box); oral salmonella vaccine group (black
filled box). Error bars represent the standard error of the mean. Asterisk denotes
statistical significance (P < 0.05) between all values.
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Wk 12

irrespective of the assay antigen. Following vaccination (week. 5) only animals in the
oral salmonella vaccine group exhibited a significant lymphoproliférative response
against S. typhimurium SL3261 whole cell proteins and also NrdF antigen.
Lymphoprolifération response was subdued following experimental challenge (week.

12) in all groups of pigs tested.
4.3.6

Delayed type hypersensitivity responses

The CMI response of pigs was also assessed by skin testing using S. typhimurium
SL3261 cell proteins and also NrdF antigen (Table 4.3). A wheal and flare response at
24 hours was not observed in any pig from each of the four groups post-vaccination or
post-challenge. Intradermal inoculation with the mitogen PHA, however, elicited a
significant immediate hypersensitivity response in all pigs at weeks 5 and 12
compared to saline control inoculation sites on the same pig. There was no significant
difference in the PHA response between treatment groups.
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Table 4.3:

Average skin thickness of treatment groups following DTH and

mitogenic testing with indicated antigens at week 5 and

Week

5

12

Antigen

12

Treatment group
NrdF IM

control

Oral
Salmonella
vector

Salmonella
whole cell

2.59 ±0.07

2.74 ±0.11

2.56 ±0.09

2.68 ± 0.09

15 kDa
NrdF
antigen

2.94 ±0.11

2.72 ± 0.09

2.64 ±0.12

2.61 ± 0.10

PHA*

3.57 ± 0.13

3.53 ±0.17

3.36 ±0.19

3.54 ±0.14

PBS

2.51 ±0.07

2.63 ± 0.09

2.47 ± 0.09

2.59 ±0.08

PHA*

5.33 ±0.14

5.33 ±0.11

5.47 ±0.32

5.14 ± 0.17

PBS

3.75 ± 0.09

3.92 ±0.09

3.46 ±0.18

3.84 ±0.07

Oral
Salmonella
vaccine

PHA: phytohemmagglutinin; PBS: phosphate buffered saline (pH 7.4).
All treatment groups in week 5 and 12 had significant (P < 0.05) skin thickening indicative o f a
positive mitogenic response to the PHA antigen.

4.3.7

Assessment of antibody responses

Intramuscular immunisation using the recombinant 15 kDa NrdF antigen elicited a
NrdF specific IgG antibody response in the serum of swine detectable at week 5 and
maintained at a level significantly greater (P < 0.05) than the swine prebleed (week 0)
and all other treatment groups until slaughter (Fig. 4.6 C). After endotracheal
challenge (week 5) a 15 kDa NrdF specific IgG response was also elicited in the oral
Salmonella vaccine, control and oral salmonella vector groups (Fig. 4.6 C). There
were no significant IgG NrdF antibodies detected in the respiratory tract washings of
pigs from any of the treatment groups either after immunisation or after challenge
with M. hyopneumoniae (Fig. 4.6 A). Similarly there were no NrdF specific IgA
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antibody responses elicited in the serum of swine during the course of the trial (Fig.
4.6 B). After immunisation (week 5) there was no significant NrdF specific secretory
IgA detected in the lungs of any groups (Fig. 4.6 B). At seven weeks post challenge
(week 12) there was a significant secretory NrdF IgA response detected in the lungs of
pigs in the oral salmonella vaccine group (Fig. 4.6 B). The oral delivery of live S.
typhimurium aroA SL3261 in either live oral treatment groups did not elicit
Salmonella specific serum IgG or lung IgA antibody responses after vaccination
(week 5) (Fig. 4.7). After challenge there was significant (P < 0.05) serum IgG
Salmonella specific antibodies for all groups including the NrdF IP and control groups
(Fig. 4.7). Challenge also elicited significant (P < 0.05) lung IgA Salmonella specific
antibodies for the oral salmonella vaccine group (Fig. 4.7 B) and also significant (P <
0.05) lung IgG in the oral salmonella vaccine group oral salmonella control
groups(Fig 4.7 A).

4.3.8

Average daily weight gains

Due to the controlled rations fed daily to pigs, the average daily gain is a measure of
feed conversion efficiency. The fastest growing swine group was the NrdF
intramuscular group with an average daily increase of 747 g (Fig. 4.8). The control
swine group had the lowest average daily gains at 671 g, the Salmonella vector
treatment had an average gain of 707 g per day and the Salmonella vaccine group had
an average gains of 716 g per day. Due to the small sample sizes and large variation
within groups there were no statistical significance between groups.
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Fig.4.6.

Levels of recombinant 15 kDa NrdF specific IgG and IgA antibodies in

swine lung lavage and serum samples at week 0 (Wk 0; prebleed), week 5 (Wk 5;
postvaccination/ prechallenge) and week 12 (Wk 12; post challenge). (A) lung lavage
IgG antibody levels (B) lung lavage IgA antibody levels (C) serum IgG antibody
levels (D) serum IgA antibody levels. Immunisation groups are indicated as follows:
NrdF intramuscular (red filled box); control (open box); oral salmonella vector group
(cross hatched box); oral salmonella vaccine group (filled box). Error bars represent
the standard error of the mean. Statistical significance (P < 0.05) comparing the same
treatment group to the corresponding prebleed is indicated by a small asterisk (*). A
large asterisk (* ) denotes statistical significance (P < 0.05) to all other treatments at
the same time period and to the corresponding prebleed. Vaccinations were carried out
at week 0 and week 3; challenge was carried out at week 5 and is denoted by an
arrow.
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Fig.4.7.

Levels of S. typhimurium SL3261 specific IgG and IgA antibodies in

swine lung lavage and serum samples at week 0 (Wk 0; prebleed), week 5 (Wk 5;
postvaccination/ prechallenge) and week 12 (Wk 12; post challenge). (A) lung lavage
IgG antibody levels (B) lung lavage IgA antibody levels (C) serum IgG antibody
levels (D) serum IgA antibody levels. Immunisation groups are indicated as follows:
NrdF intramuscular (red filled box); control (open box); oral salmonella vector group
(cross hatched box); oral salmonella vaccine group (filled box). Error bars represent
the standard error of the mean. Statistical significance (P < 0.05) comparing the same
treatment group to the corresponding prebleed is indicated by a small asterisk (*). A
large asterisk ( ) denotes statistical significance (P < 0.05) to all other treatments at
the same time period and to the corresponding prebleed. Vaccinations were carried out
at week 0 and week 3; challenge was carried out at week 5 and is denoted by an
arrow.
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t
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Average daily
gain (g)

Treatment group

Fig. 4.8.
Average daily weight gain (g) of individual pigs at slaughter. Treatment
groups were: (A) NrdF intramuscular (average 747g); (B) control (average 671g); (C) oral
salmonella vector group (average 707g); (D) oral salmonella vaccine group (average 716g).
Swine treatment group averages are represented by a horizontal bar.
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4.4

Discussion

Cell mediated immune responses were examined in vaccinated pigs by
lymphoprolifération and DTH using S. typhimurium and M. hyopneumoniae antigens
including NrdF. The data in Fig. 4.5 demonstrate that oral immunisation with a live
recombinant vector expressing heterologous antigen is able to elicit CMI responses.
CMI was demonstrated by significant increases in the stimulation index of pigs orally
dosed with S. typhimurium expressing the recombinant NrdF antigen. These animals
responded not only against S. typhimurium proteins but also against M
hyopneumoniae and the NrdF antigen. The surprising observation was a complete
absence of lymphoprolifération in pigs in the oral salmonella vector group. It is
conceivable that epitopes of NrdF antigen, which are conserved in the bacterial vector
may be responsible for the lymphoproliférative responses against S. typhimurium
proteins. As previously reported in orally immunised mice (Chapter 3), the analogous
S. typhimurium NrdF antigen was not immunogenic. Antibodies elicited by oral
immunisation using the Salmonella vector did not cross react with the recombinant M.
hyopneumoniae NrdF antigen. However, antibodies raised against the 15 kDa NrdF
antigen did cross react with Salmonella epitopes. Similarly, within this pig trial the
lack of demonstrable lymphoproliférative responses in the oral salmonella vector
group may also be due to the bacterial vector being poorly immunogenic.
Alternatively, the bacterial vector unencumbered by recombinant NrdF expression
may be better able to evade the swine immune response. Further studies are required
to clarify these possibilities.

The inability to detect lymphoproliférative responses after M. hyopneumoniae
challenge has been previously reported (Adegboye, 1978; Messier et al, 1990). Within
this study, there is a strong humoral antibody response prevailing in all pigs post
challenge. Recent reports indicate that diseased animals biased towards a T^eiper tyPe
2 response produce high levels of IL-10 which suppress CMI responses (Li et al,
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1994). However, the presence of the cell-mediated PHA mitogenic response post
challenge would discount complete immunosuppression of CMI (Adegboye, 1978).
Furthermore, researchers have demonstrated that M. hyopneumoniae-specific
lymphocyte populations are localised to the bronchial lymph close to the site of
infection (Adegboye, 1978; Messier et al, 1990). Within this study only the
circulating lymphocyte populations were sampled. As a consequence, the reported
values may not indicate the extent of sensitisation of the lymphocyte populations in
the lungs and peripheral lymph nodes.

Failure to observe DTH responses in pigs orally immunised with S. typhimurium
SL3261(pKFl) could be due to a number of reasons. Widely variable DTH
responses against heterologous antigen delivered across the mucosae by attenuated
Salmonella have been reported for a number of animals including swine (Killar and
Eisenstein, 1986; Stabel et al, 1991; Stabel et al, 1993; Roberts et al, 1994).
Studies in pigs immunised with attenuated S. typhimurium or S. choleraesuis
expressing heterologous Brucella abortus antigen demonstrate that DTH response
is dependent upon strain immunogenicity, route, frequency and dosage of antigen
delivery (Stabel et al, 1991; Stabel et al, 1993).

All pigs at slaughter exhibited lung damage characteristic of PEP indicating that
protection was incomplete in all vaccine groups. There was no correlation between
the extent of lung damage and the Auspharm™ ELISA ratio. This agrees with
previous findings confirming that serology cannot be used to accurately predict
disease severity when using this Auspharm™ ELISA (Djordjevic et al, 1994). The
mean weighed lung tissue affected value (11.9%) for the control group, in this
instance, does not accurately indicate the severity of damage within this group. The
weight of tissue affected would have been higher except that two pigs were not
included as both died before slaughter, one of which died from severe pneumonia.
The Goodwin lung score (24.2) includes the lungs from pigs which died. The two
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methods of measuring the extent of lung damage was carried out to allow for
comparison of the methods. The GLS is an excellent method to examine large
numbers of lungs rapidly, however, resolved lesions have the same weighting.
Subsequently, the GLS method when compared to weighing affected tissue, may
overestimate the severity of tissue damage.

The intramuscularly immunised pigs had significant serum anti-NrdF IgG levels after
vaccination which were maintained after challenge when compared to pre-vaccination
IgG levels. The post-challenge level of serum IgG in all pigs was significantly greater
than pre-challenge IgG levels. However, serum IgG levels in the intramuscularly
immunised pigs during this post-challenge period was significantly greater than all
other treatment pigs. This indicates that the intramuscular route preferentially
stimulates a serum antibody response. The production of significant secretory IgA
post-challenge in the oral salmonella vaccine treatment pigs demonstrates that this
route preferentially stimulates the mucosal immune system to respond against M.
hyopneumoniae following challenge. Both of these routes when used to deliver the 15
kDa NrdF antigen resulted in reduced lung pathology and increased average daily
gains.
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Chapter 5

General discussion

C hapter 5
General discussion
The results of this study confirm that S. typhimurium SL3261 (pKFl), when used as a
live oral vaccine strain, is safe to use with pigs with no associated morbidity being
detected. Pig trial results demonstrate that immunisation with M. hyopneumoniae
NrdF antigen, either parenterally or using S. typhimurium as a delivery vector, resulted
in reduced lung pathology and an increase in average daily gains indicating the
recombinant NrdF antigen would be a beneficial component in a M. hyopneumoniae
vaccine. Parenteral delivery of antigen, although reducing lung pathology and
increasing daily gains, is a comparatively expensive mode of immunisation. Needle
delivery is time consuming, labour intensive and expensive due to the costs involved
in antigen preparation and in the purchase of adjuvants. Alternatively, live attenuated
oral vaccines could be developed that are easy to administer and cheap to produce in
large quantities. It is clear, however, that a number of modifications must be made to
the S. typhimurium SL3261 (pKFl) live oral vaccine strain before the minimum
requirements for use of genetically modified organisms in the field are met. Presently,
the plasmid is maintained by antibiotic selection. This form of selection is easily
controlled in vitro under laboratory conditions, however, once the strain is
administered this selection is removed and the plasmid places a disadvantage on the
recombinant strain due to the burden of expressing heterologous antigen. Antibiotic
selection is also undesirable because it introduces the potential for transfer of bacterial
antibiotic resistance into other bacterial gut flora. In the case of S. typhimurium
SL3261 (pKFl) the plasmid is not mobile through conjugation. However,
maintenance of the plasmids encoding the heterologous M. hyopneumoniae antigen
must be ensured through other means to make this strain acceptable. The technology
is available to stably incorporate the heterologous antigen DNA into the host
chromosome. A potential promotor to direct chromosomal expression of the NrdF
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antigen would be the anaerobically inducible nirB promotor (Roberts et al, 1994).
This genetic element has been used to stably express and deliver an antigen dose
sufficient to elicit protective cellular and humoral immune responses against a
mucosal pathogen after a single oral dose (Chatfield et al, 1992). Currently, host
integration is a priority for future attenuated vaccine strains expressing NrdF antigen
to overcome potential antibiotic resistance gene transfer, and plasmid stability
problems.

The nrdF gene encodes the small subunit of a ribonucleotide reductase. This enzyme
catalyses the conversion of ribonucleoside diphosphates to deoxyribonucleoside
diphosphates, an essential step in DNA replication (Thelander and Reichard, 1979).
In the physiology of M. hyopneumoniae, the absence of a cell wall and outer
membrane makes this pathogen particularly vulnerable to neutralising antibodies
(Awumbila and Rosenbusch, 1991; Wannemeuler and Galvin, 1994). Antibodies
raised against the recombinant NrdF antigen reacted with a 42 kDa wild type NrdF
protein in all 7 geographically diverse strains of M. hyopneumoniae tested. The
presence of reactive epitopes in French, American and Australian strains indicates that
this protein is conserved. Whole cell ELISA demonstrated the surface accessibility of
the in-situ NrdF protein in M. hyopneumoniae. Furthermore growth inhibition studies
demonstrate that serum antibodies specific for the NrdF antigen inhibit mycoplasmal
growth. In inhibition studies of the herpes simplex virus type 1 (Telford et al, 1990)
and E. coli (Climent et al, 1991) ribonucleotide reductase enzymes inhibition is the
result of targeting of the carboxy-terminal region of the NrdF protein. This is the same
carboxy-terminal region that is expressed in the S. typhimurium aroA SL3261 (pKFl)
oral vaccine strain. No investigation was carried out to determine the mechanism by
which these antibodies inhibited growth of the organism. It may be possible that the
antibodies involved in inhibition within this study are preventing the assembly, and
subsequent functioning of this enzyme.
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The colonisation of swine lung epithelium by M. hyopneumoniae elicits a damaging
inflammatory response which results in lung lesion development. The immunomodulating effect of this pathogen is clearly demonstrated in studies with
thymectomised pigs (Tajima et al, 1984). Within this study, swine with compromised
T cell and macrophage mediated immune responses after experimental M.
hyopneumoniae infection had significantly reduced lung pathology. However, M.
hyopneumoniae numbers in the lungs increased, highlighting the pathogen’s ability
under natural conditions to elicit cellular, humoral and inflammatory responses which
are both detrimental to the host yet also play a major role in pathogen clearance.

There are a number of diseases in which pathogenesis has been determined to be due
to the eliciting of an immune response which subsequently results in more damage
than if a response was not mounted against the colonising pathogen. The eliciting of a
severe macrophage type-1 Thelper (Th I) mediated inflammatory response in sheep
against Corynebacterium pseudotuberculosis results in chronic pneumonia and
cachexia (Ellis et al, 1995). The eliciting of a dominant type-2 Thelper (Th2) mediated
humoral response against cytomegalovirus in bone marrow transplant recipients
frequently leads to severe and often fatal pneumonia (Sparrelid et al, 1997). The
diseases seborrhoeic dermatitis (Nueber et al, 1996), Castlemans disease and systemic
lupus erythematosus (Emilie et al, 1997) are all the result of a similar unregulated Th2
mediated humoral response. Other diseases such as acute respiratory distress
syndrome (ARDS) as well as AIDS-related wasting and pneumonia are both
complicated by the a lack of immuno-modulation between effector arms of the
immune system (Cohen et al, 1997; Headley et al, 1997).

As a M. hyopneumoniae vaccine, the use of attenuated Salmonella to deliver vaccine
antigens can feasibly result in the immune regulation between the cellular and
humoral immune responses. Studies have confirmed that orally administered
Salmonella expressing recombinant antigen can elicit antigen specific Th I and Th2
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responses at distal mucosal sites (VanCott et al, 1996). Consequently, attenuated
strains can ameliorate the immune bias towards macrophage-mediated inflammatory
responses by priming both the cellular and humoral immune responses at the mucosal
site of M. hyopneumoniae colonisation. This priming of immune responses is similar
to the establishment of the natural BALT immune defences present in adult pigs, but
not in newly weaned pigs (Pabst and Binns 1994). The predominant lymphocyte
subset in the mucocilliary epithelium of weaned pigs are naive cytotoxic T cells
(Pabst and Tschemig, 1995). In contrast, naive T helper cells are dominant in the
respiratory lamina propria (Pabst and Tschemig, 1995) and in the same region only a
small proportion of cells present are memory cells (Sheldrake, 1990; Pabst and
Tschemig, 1995). In the bronchoalveolar space, macrophages represent almost all
immune cells (Pabst and Binns, 1994). In natural infections, M. hyopneumoniae is
dealt with initially by bronchoalveolar macrophages. The activation of macrophages
leads to secretion of cytokines, which at a local level increase vascular permeability
and upregulate the expression of epithelial adhesion molecules (Arai et al, 1990;
Akira et al, 1993). These changes allow circulating monocytes, lymphocytes and
neutrophils to bind to adhesion receptors and subsequently move from the vascular
system into the tissue space causing margination of these cells and characteristic
hyperplasia. In the lungs of infected pigs, macrophages are stimulated by M.
hyopneumoniae colonisation and produce significantly higher levels of the cytokines
IL-1, TNF-a, IL-6 (Asai et al, 1993; Asai et al 1994) and IFNy (Nishimoto, 1993).
This cytokine profile is the same as the profile of mice infected with the human
pathogen M. pneumoniae (Pietsch et al, 1994). However, in this mouse study the role
of the inflammatory mediators was further demonstrated after re-infection which
resulted in an exacerbation of pneumonic lung lesions corresponding to an increase in
pro-inflammatory cytokines (Pietsch et al, 1994).

Examination of the cytokine responses during the progression of pneumonia raises the
question of the role of TNF-a in PEP. This cytokine is identical at the protein level to
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cachectin which is a molecule named for its ability in mice and other experimental
animals to induce drastic weight loss, fever and acute inflammatory reactions
(cachexia) (Beutler et al, 1985; Arai et al, 1990; Tracey and Cerami, 1993, Ling et al,
1997). It is unlikely that the significant high levels of this molecule observed in pigs
during PEP does not contribute to a large degree to the economic losses incurred by
the disease.

The use of the S. typhimurium aroA SL3261 (pKFl) oral vaccine strain can be
beneficial in the immuno-modulation of the macrophage mediated inflammatory
response. Data from the pig trial described in Chapter 4 confirm that the predominant
immune response observed is a mucosal IgA response. This secretory antibody
response is mediated by the Th 2 cytokine IL-10 (Yamamoto et al, 1996; Fayette et al,
1997). This cytokine is multifunctional and serves to maintain IgA responses while
also down-regulating macrophage mediated THl inflammatory responses, including
TNF-a (Mulligan et al, 1993; Burdin et al, 1997).

Within the pig trial described in Chapter 4 of this thesis no actual CMI responses were
experimentally demonstrated. However, this immune response was not specifically
examined, and consequently, the role of CMI within this study cannot be commented
upon. The significant lymphoproliférative responses in the orally immunised group
may not have necessarily been from THl lymphocyte populations. Further
investigation using cell sorting should be used to resolve the contribution of the
various lymphocyte subsets. Similarly, a lack of DTH response is not indicative of
CMI immunosuppression by the oral salmonella vaccine strain. As described in
Chapter 4.3 (Discussion) the lack of a demonstrable DTH response can be due to a
number of possibilities including antigen dose, Salmonella strain immunogenicity or
immuno-modulation

of the

various

lymphocyte populations.

Alternately,

immunosuppression of the DTH response may be due to the responsive lymphocytes
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congregating due to chemotactic attraction at the site of localised infection
(Adegboye, 1978a; Messier e/ al, 1990).

Pigs in this study were vaccinated by intratracheal inoculation with a large dose of M.
hyopneumoniae derived from the maceration of diseased lung. This dose does not
represent the usual mode of pathogen transfer yet it results in PEP with the same
severity as found in commercial piggery environments (Jericho, 1986). However, even
though the severity is similar, the use of this inoculation may initially overwhelm a
primed immune system and give higher lung scores than would be achieved under a
typical low level frequent exposure scenario common in piggeries with M.
hyopneumoniae (Jericho 1986). To overcome this problem, cohort studies using the
vaccines described in this study must be organised so that the effect of natural, low
level exposure can be elucidated. Furthermore, during these cohort trials, cytokines
profiles could be monitored to give a clearer picture of which effector arms of the pigs
immune system are being stimulated.

Currently, a cohort trial is being planned using the affinity purified His-tagged 11
kDa recombinant antigen expressed by the plasmid pETEl. It would be very useful
if during this pig trial cytokine profiles could be examined, especially for IL-10 and
TNFa. Presently it is not possible to carry out large scale cohort trials using live
attenuated recombinant vectors for the delivery of heterologous antigen. However,
recent reports indicate a series of phase 2 clinical human trials using live attenuated
S. typhi based vaccines are being planned in North America (Hone et al, 1992;
Gonzalez et al, 1994; Levine et al, 1996; Tacket et al, 1997). If these attenuated
vaccines are approved for use in humans it should not be long before this approval
is extended for veterinary vaccine cohort trials.
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Appendix 1

General solutions and buffers

Appendix 1.

General solutions and buffers

Phosphate buffered saline (PBS)
NaCl

137.0 mM
2.7 mM
8.0 mM
1.5 mM

KC1
Na2H P0 4
KH2P 0 4

Diluted with dH20 up to volume
and pH checked to be 7.4
SDS-PAGE and Western transfer
Splitting Buffer
Tris. HCl (pH 6.8)
Bromophenol blue
Glycerol
SDS
B-mercaptoethanol

60 mM
0.01% (w/v)
10% (v/v)
1% (w/v)
1% (w/v)

Running Buffer
Tris.Base
Glycine

15 g/1
72 g/1
5 g/1
made up to volume with d ^ O

SDS

and pH checked at 8.3
Acrylamide Stock Solution (35:0.8)
87.5 g
2.0 g
made up to 250 ml with d ^ O

Acrylamide
Bis-acrylamide

Resolving Gel
Acrylamide stock (35: 0.8)

12.5%
3.56

10%
2.85
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15%
4.25

20%
5.7 ml

1.5 M Tris.HCl (pH 8.8)
10% SDS
dH20

2.5

2.5

2.5

0.1

0.1

0.1

4.5

3.80

3.4

10% APS

50

50

50

TEMED

50

25

10

Stacking Gel

2.5 ml
0.1 ml
1.65 ml
50 pi
10 pi

4%

1.1 ml

Acrylamide stock (35: 0.8)
0.5 M Tris.HCl (pH 6.8)
10% SDS
dH20

2.5 ml
0.1 ml
6.3 ml

10% APS
TEMED

50 pi
50 pi
Coomassie Stain

Coomassie Brilliant Blue R250
Methanol
Acetic acid

Destain

lg/1
50% (v/v)
10% (v/v)

Western transfer buffer
SDS
Tris.Base
Glycine
Methanol

50% (v/v)
10% (v/v)

0.037% (w/v)
48 mM
39 mM
20% (v/v)
made up to volume with dK^O

Development buffer (4 chloro-l-napthol)
Solution A
20 pi H2O2in 30 ml dt^O
Solution B

30 mg 4 chloro-l-napthol in 10 ml

methanol
Add solutions A and B immediately
prior to

use-

SDS PAGE preperative column gel
Resolving Gel

7.5%

9%

15%

Acrylamide stock (35: 0.8)
1.5 M Tris.HCl (pH 8.8)
10% SDS
dH20

22.5 ml
22.5 ml

27.0 ml

45.0 ml

22.5 ml

22.5 ml

0.9 ml
43.5 ml

0.9 ml
39.0 ml

0.9 ml
21.0 ml

10% APS

450 pi

450 pi

450 pi

TEMED

30 pi

30 pi

30 pi

Total volume:

90 ml

Stacking Gel

4%

Acrylamide stock (35: 0.8)
0.5 M Tris.HCl (pH 6.8)
10% SDS
dH20
10% APS
TEMED

1.33 ml
1.3 ml
0.1 ml
6.1 ml

50 pi
5 pi
A 1 cm staking gel was cast over a 6-7 cm resolving gel.

Southern hybridisation
20x SSC Buffer
175.3 g/1
88.2 g/1
pH to 7.0

NaCl
Sodium citrate

Prehybridisation solution
6XSSC
Denhardts lOOx salts
Salmon sperm DNA
dH20

10% v/v
200 pg/ml
20 pg/ml (boiled immediately prior to addition)
Make up to 50 ml

SDS

0.5% w/v add last

ELISA coating carbonate buffer
30 mM sodium carbonate
20 mM sodium hydrogen carbonate
Make up to with sterile dH20 and check pH at 9.6
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Appendix 2

Publications and abstracts

Publications and abstracts associated with work described within
this thesis.

Articles in books or journals

Eamens, G.J., S.P. Djordjevic, J. Chin, P. Fagan, M.J. Walker and A. Scarman.
(1995): Strategies for Developing a Subunit Mycoplasmal Vaccine for Enzootic
Pneumonia. Manipulating Pig Production (v). Proceedings in the Fifth Biennial
Conference of the Australasian Pig Science Association (APSA). Canberra, Australia
November 1995. 229.
Fagan, P.K., S.P. Djordjevic, G.J. Eamens, J. Chin and M.J. Walker. (1996):
Molecular Characterisation of the Ribonucleotide Reductase (NrdF) Gene of
Mycoplasma hyopneumoniae and Assessment of the Recombinant Gene Product as an
Experimental Vaccine for Enzootic pneumonia. Infection and Immunity. 64 (3): 1060
1064.
Fagan, P.K., S.P. Djordjevic, J. Chin, and M.J. Walker. (1997): Oral immunisation of
mice with attenuated Salmonella typhimurium aroA strains expressing a recombinant
Mycoplasma hyopneumoniae antigen (NrdF). Infection and Immunity. 65 (6): 2502
2507.
Fagan, P.K., M.J. Walker, J. Chin, G.J. Eamens and S.P. Djordjevic. (1997):
Assessment of immune protection of swine orally vaccinated with attenuated
Salmonella typhimurium SL3261 aroA expressing a recombinant Mycoplasma
hyopneumoniae antigen (NrdF). Manuscript submitted to ‘Vaccine’ in June 1997.
Published Contributions to Academic Conferences
Fagan, P.K., S.P. Djordjevic, S. Wilson, M.J. Walker. (1993): Development of a
Recombinant Oral Vaccine Delivery System For the Stimulation of Immunity Against
Mycoplasma hyopneumoniae. Vaccines 93. Conference at Erskine House, Lome,
Victoria (Australia), March 1993. D31.
Fagan, P.K., S.P. Djordjevic, G.J. Eamens, J. Chin and M.J. Walker. (1994):
Expression and Characterisation of a Recombinant 42 kDa Antigen from Mycoplasma
hyopneumoniae Which Confers Enhanced Protection in Experimentally Challenged
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Pigs. Australian Microbiologist 15 (4). Australian Society for Microbiology,
Melbourne, Australia, September 1994. A-108.
Fagan, P.K., S.P. Djordjevic, G.J. Eamens, J. Chin and M.J. Walker. (1995): Antibody
Responses in the Lungs of Mice Following Oral Immunisation with Salmonella
typhimurium aroA Expressing an 11 kDa Mycoplasma hyopneumoniae Antigen.
Australian Microbiologist 16 (4). Australian Society for Microbiology, Canberra,
Australia, September 1995.
Djordjevic, S.P., P.K. Fagan, J.L. Wilton, A.L. Scarman, R. Towers, M.J. Walker, J.
Chin, and G.J. Eamens. (1997). Characterisation and assessment of recombinant
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